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The identification and development of cancer biomarkers and targets have greatly accelerated
progress towards precision medicine in oncology. Studies of tumor biology have not only provided
insights into the mechanisms underlying carcinogenesis, but have also led to discovery of molecules
that have been developed into cancer biomarkers and targets. Multi-platforms for molecular
characterization of tumors and blood-based biopsies have greatly expanded the portfolio of potential
biomarkers and targets. These cancer biomarkers have been developed for diagnosis, early detection,
prognosis, and prediction of treatment response. The molecular targets have been exploited for
anti-cancer therapy with proven benefits in improving treatment response and survival. However,
plenty of research opportunity exists for discovering, developing, and validating cancer biomarkers
and targets for improving the clinical outcomes of patients with malignant diseases, particularly those
in the digestive system.
2. Cancer Biomarkers and Targets in Digestive System
Pancreatic-hepato-biliary and gastrointestinal carcinoma are among the most lethal human
malignant diseases [1]. With the advance in developing tumor biomarkers and targets, progress
has been made to improve treatment response and survival for patients with cancer of the digestive
system [2–7]. In clinical practice, a few biomarkers and targets have been utilized for patients
with cancers of digestive organs. Serum levels of carcinoembryonic antigen (CEA), carbohydrate
antigen 19-9 (CA 19-9), and alpha-fetoprotein (AFP) have been clinically used as tumor markers of
gastrointestinal and hepato-pancreatic-biliary malignancies [8–10]. Yet the sensitivity and specificity of
these biomarkers for disease diagnosis and prognosis are somewhat limited. However, there are several
clinically developed predictive biomarkers of treatment response. For instance, the cell-surface human
epidermal growth factor receptor 2 (HER2) when amplified or over-expressed, has been targeted
for treatment using the anti-HER2 antibody, trastuzumab, with proven survival benefit in gastric
carcinoma [11]. Expression of programmed death-ligand 1 (PD-L1) in gastric carcinoma predicts
therapeutic responsiveness of the anti-PD-1 antibody, pembrolizumab [12]. Wild-type K-RAS in
colorectal carcinoma predicts clinical benefits of the anti-epidermal growth factor receptor antibodies,
cetuximab [13] or panitumumab [14]. Deficiency in mismatch repair protein, or a high level of
microsatellite instability in colorectal carcinoma, suggest treatment response using anti-PD-1 antibody,
pembrolizumab [15], or nivolumab [16]. In recent years, studies have been conducted to explore and
develop molecular biomarkers and targets in gastrointestinal cancers. Intense research for clinical
translation is ongoing, with the goal of attaining the goal of precision care for patients with cancers in
digestive organs.
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3. Recent Advances in Gastrointestinal Oncology
This Special Issue of Biomedicines comprises a variety of articles about recent advances in the
discovery, characterization, translation, and clinical application of cancer biomarkers and targets in
the digestive system. These articles include original research, reviews, case studies, and conference
papers. At the Multi-Disciplinary Patient Care in Gastrointestinal Oncology conference in Hershey,
Pennsylvania, the new frontiers in various aspects of digestive organ cancers were presented [17].
In this meeting report, Yee et al. provide updates and discuss advances in the epidemiology
and genetics, diagnostic and screening evaluation, treatment modalities, and supportive care for
patients with gastrointestinal cancers. In a critical review, Zhang et al. present new perspectives
of the development of biomarkers for gastrointestinal cancers [18]. The biomarkers, including those
derived from tumor genome, tumor-associated microenvironment, and liquid biopsies, are discussed.
Complementary to the review on biomarkers, Yee presents an up-to-date report of the systemic
treatment of gastrointestinal malignancies [19]. In this conference paper, results and implications
of the recent clinical trials that investigated the efficacy of chemotherapy, targeted therapeutics,
and immunotherapy in pancreatic, gastroesophageal, biliary tract, hepatocellular, and colorectal
carcinoma are discussed. In addition to this, Tchelebi et al. provide an overview of the role of
stereotactic body radiation therapy (SBRT) in the management of malignant diseases in the upper
gastrointestinal tract [20]. Moreover, the emerging data on biomarkers of immunotherapy and SBRT
are evaluated, with a focus on pancreatic and hepatocellular carcinoma.
4. Biomarkers and Targets in Cancer of Digestive Organs
A number of articles in this Special Issue examine the biomarkers and targets with a focus on
cancer in individual organs, including liver. While liver transplantation is a potentially curative
treatment of hepatocellular carcinoma, liver graft injury has been identified as an acute phase event
that leads to post-transplant tumor recurrence. Lee et al. examined this acute phase event at the
molecular level by transcriptomic analysis of liver grafts from recipients with or without tumor
recurrence following liver transplantation [21]. This study reveals the altered genetic expression
in liver grafts, and paves the way to identify key molecular pathways that may be involved in
post-transplant tumor recurrence. On the other hand, Posadas et al. demonstrate the potential value of
tumor molecular profiling for individualized therapy in hepatocellular carcinoma [22]. In this patient
case study, the treatment response as determined by progression-free survival appears to correlate
with the differential expression of biochemical markers and genetic mutations of the tumors.
Besides hepatocellular carcinoma, several articles focus on cancer biomarkers and targets in the
gastrointestinal tract. Fonkoua and Yee present a critical review of the molecular characterization
of gastric carcinoma by the Cancer Genome Atlas Research Network, the Asian Cancer Research
Group, and tumor molecular profiling through expression analysis and genomic sequencing of tumor
DNA [23]. These molecular analyses have generated a number of potential biomarkers and targets
that may be translated into clinical use. Moreover, patient cases of gastroesophageal carcinoma
are reported to demonstrate survival advantage of molecular profile-based treatment, suggesting
the potential value of tumor molecular profiling in guiding selection of therapy tailored to the
individual patient. For colorectal carcinoma, Zhang et al. evaluate circulating tumor cells and their
expressed genes as biomarkers, along with assessment of the clinical outcomes [24]. Results of this
study show that circulating tumor cells and their expression of both endothelial and tumor progenitor
cell biomarkers are potential prognostic biomarkers in colorectal cancer. Complementary to clinical
investigation in humans, Lu et al. described the zebrafish model to study human intestinal disorders
and tumors [25]. In this review article, mutant and transgenic zebrafish as well as xenograft models as
an in vivo platform for understanding the pathogenesis of gastrointestinal diseases and for evaluation
of anti-cancer drugs are discussed.
Despite advances in developing clinically useful biomarkers and targets in gastrointestinal cancers,
relatively little progress has been made for patients with pancreatic carcinoma. While early detection of
2
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pancreatic carcinoma is critical for improving patient survival, agents that selectively target pancreatic
tumor are expected to enhance therapeutic efficacy. In this Special Issue, Matters and Harms present
a detailed review of G protein-coupled receptors, which are key target proteins for drug discovery.
They further discuss the potential of GPCRs as biomarkers for tumor imaging and targeted treatment
of pancreatic carcinoma [26].
5. Conclusions and Future Perspectives
Research on discovery and development of cancer biomarkers and targets has been steadily
progressing. Rigorous investigation for identification and validation of biomarkers and targets in
both preclinical models and clinical studies are expected to generate new opportunities for making
a positive impact on survival and quality of life in the patients. The articles in this Special Issue provide
an update on the frontiers in gastrointestinal oncology, with a focus on biomarkers and targets in
cancers of the digestive system. We hope this Special Issue will help stimulate research collaboration on
developing strategies for prevention, early detection, diagnosis, and screening of cancers in digestive
organs, as well as improving treatment outcomes and psychosocial support in patients with these
malignant diseases. In particular, liquid biopsy for cancer biomarkers and targets has been a major
focus of research with translation into clinical applications.
Recent advances in plasma-derived extracellular vesicles (EVs) have demonstrated the potential
of making a clinically meaningful impact in the field of cancer biomarkers and targets. Analysis of
EV-derived molecular markers is complementary to the conventional diagnostic modalities. By application
of nano-, micro-, digital-, and microarray-based technologies, multiplex analysis of disease-specific markers
is expected to improve the sensitivity and specificity of bodily fluid-based biopsies for diagnosis of
cancer. These minimally invasive diagnostic tools that utilize ultra-low sample volume may prove to be
economically cost effective for screening of cancer in the high-risk population and even in the general
population. In addition to this, increasing evidence has indicated the potential value of blood-based
biopsies in combination with tumor molecular profiling for developing predictive biomarkers of treatment
response, as well as personalized targets of therapy. Further development, optimization, and clinical
validation of these cancer biomarkers and targets will hopefully enable us to attain the goal of precision
medicine in cancer of digestive organs.
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Abstract: Colorectal carcinoma (CRC) is the second leading cause of cancer-related mortality. The goals
of this study are to evaluate the association between levels of invasive circulating tumor cells (iCTCs)
with CRC outcomes and to explore the molecular characteristics of iCTCs. Peripheral blood from
93 patients with Stage I–IV CRC was obtained and assessed for the detection and characterization of
iCTCs using a functional collagen-based adhesion matrix (CAM) invasion assay. Patients were followed
and assessed for overall survival. Tumor cells isolated by CAM were characterized using cell culture
and microarray analyses. Of 93 patients, 88 (95%) had detectable iCTCs, ranging over 0–470 iCTCs/mL.
Patients with Stage I–IV disease exhibited median counts of 0.0 iCTCs/mL (n = 6), 13.0 iCTCs/mL (n = 12),
41.0 iCTCs/mL (n = 12), and 133.0 iCTCs/mL (n = 58), respectively (p < 0.001). Kaplan–Meier curve
analysis demonstrated a significant survival benefit in patients with low iCTC counts compared with
in patients with high iCTC counts (log-rank p < 0.001). Multivariable Cox model analysis revealed that
iCTC count was an independent prognostic factor of overall survival (p = 0.009). Disease stage (p = 0.01,
hazard ratio 1.66; 95% confidence interval: 1.12–2.47) and surgical intervention (p = 0.03, HR 0.37; 95%
CI: 0.15–0.92) were also independent prognostic factors. Gene expression analysis demonstrated the
expression of both endothelial and tumor progenitor cell biomarkers in iCTCs. CAM-based invasion
assay shows a high detection sensitivity of iCTCs that inversely correlated with overall survival in CRC
patients. Functional and gene expression analyses showed the phenotypic mosaics of iCTCs, mimicking
the survival capability of circulating endothelial cells in the blood stream.
Keywords: circulating tumor cells; colorectal carcinoma; CAM invasion assay; phenotypic mosaics;
tumor progenitor
1. Introduction
Colorectal carcinoma (CRC) is the second leading cause of cancer-related mortality in the United
States with an incidence rate of 135,430 new cases and an estimated 50,260 deaths in 2017 [1].
Patients with Stage IV disease have a 5-year survival rate under 10% [2]. Of patients with Stage
II or III disease, 25–50% suffer from relapse, likely as a consequence of undetected spread of malignant
cells, even after radical surgery and adjuvant therapy [3,4]. A prospective biomarker is needed to
better predict disease recurrence, treatment response, and drug resistance, and to better understand
the molecular mechanism of tumor cell invasion [5].
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Circulating tumor cells (CTCs) have been isolated and have proven prognostic value in CRC
patients [6–8]. We have developed a functional collagen-based adhesion matrix (CAM) enrichment
assay for identifying CTCs that are positively expressing epithelial markers EpCAM and ESA/CD24
(Epi+), and for detecting the subpopulation that also expresses CAM uptake (CAM+) or invasion marker
seprase and stem cell marker CD44, termed invasive CTCs (iCTCs) [9,10]. Detection, enrichment, and
clinical utilities have been demonstrated in both metastatic and nonmetastatic cancers of the breast,
ovary, and prostate [9–15]. Here, we utilized the CAM invasion assay to detect iCTCs from the
blood of patients with colorectal carcinoma. Patients with biopsy-proven colorectal carcinoma were
recruited. Peripheral blood samples (2 mL each assay) were collected from patients with Stage
I–IV disease and were applied to the CAM system. iCTCs were quantified and the patients were
followed with routine clinic exams. Herein, we have shown that iCTCs have prognosticative value in
patients with CRC. Specifically, we assess the association between overall survival and the level of
iCTCs. This study supports the paradigm that assessment for iCTCs may be utilized by clinicians in
identifying individuals with CRC who are at high risk for aggressive disease [16]. Furthermore, we
evaluated the clinical significance of iCTCs in patients receiving surgery, chemotherapy, and radiation.
Microarray and cell culture analyses further demonstrated the possibility for iCTCs to be potentially
used as a prognostic biomarker in CRC patients.
2. Materials and Methods
2.1. Patient and Clinical Samples
This study was performed through Stony Brook University Medical Center and the Department
of Veterans Affairs Medical Center, Northport, NY, USA. The study was performed with the approval
of the Institutional Review Board and the Committee on Research in Human Subjects (ID code 100593,
renewed 7 November 2016). Specimens were collected from 19 October 1999 to 24 November 2015.
Patients were followed and monitored for disease recurrence and mortality. The patients were staged
according to the American Joint Committee on Cancer TNM system. Samples were obtained via three
to twenty milliliter (mL) collections of peripheral blood (n = 93). Blood was collected in VacutainerTM
tubes (Becton Dickinson, Franklin Lakes, NJ, USA; green top, lithium heparin as anticoagulant)
and processed within four hours of collection. Two milliliter aliquots of blood were employed for
quantification of iCTCs. Blood was collected in the clinic and processed in the laboratory according to
the workflow below; detailed steps were described in a previous paper [14].
2.2. Clinical Data Collection
All clinical data and end points were collected and documented in a de-identified fashion. All data
was entered and stored in a Microsoft Excel worksheet. Data was extracted from the electronic medical
record of the patient’s medical charts and collected through 1 November 2016. Overall survival
length was calculated from the date of blood sample collection to the date of death or most recent
documented contact.
2.3. Cell Culture, Identification of CTCs and iCTCs, and Functional Proliferation/Invasion Assays
Cell culture, identification of CTCs and iCTCs, and proliferation/invasion assays using the
functional CAM enrichment platform have been described previously [9,14]. Briefly, nuclear cells from
2 mL whole blood aliquots were seeded onto one well of a CAM-coated 6-well plate (Vita-Assay™,
Vitatex Inc., Stony Brook, NY, USA) with the complete cell culture (CCC) medium and incubated
in a CO2 incubator for 12–18 h for capture of CTCs, iCTCs, and approximately 0.1% leukocytes,
collectively called CAM-avid cells. Using the experimental tumor-cell-spiked-in blood, the Vita-Assay™
enrichment platform functionally captured and enriched (up to one-million-fold) 98% of tumor
cells spiked in blood—CTCs—with 0.01–1.0% purity (most co-isolating cells were leukocytes).
Furthermore, the platform exhibited the unique advantage that CAM-avid cells could be identified
6
Biomedicines 2018, 6, 69
as iCTCs after subsequent ingestion of fluorescent CAM (CAM+). Since the functional proclivities to
degrade and ingest the extracellular matrix are major acquired capabilities of invasive and metastatic
cells, CAM+ cells represent a unique way to identify iCTCs.
To culture iCTCs ex vivo, old media and nonadherent cells in the same plate were removed and
replaced with fresh media every three days for continued culture. Proliferative and differentiative
activities of iCTCs were determined by their capability to duplicate and form stem-cell-like colonies
and epithelial morphology.
To identify CTCs and iCTCs, cells adhered on CAM-coated plates were collected, fixed, and
stained for microscopy using anti-hematopoietic lineage (HL) antibody against CD45 (clone T29/33,
DakoCytomation, Carpinteria, CA, USA); anti-epithelial pan-cytokeratins 4, 5, 6, 8, 10, 13, and 18
(CK) (clone C11, Sigma, St. Louis, MO, USA); or anti-endothelial CD31 (Clone JC/70A, NeoMarkers,
Fremont, CA, USA); this was followed by red or blue color alkaline-phosphatase-anti-alkaline-phosphatase
(APAAP) secondary antibodies (DakoCytomation), then by staining with fluorescein isothiocyanate (FITC)-
or tetramethylrhodamine (TRITC)-conjugated anti-tumor progenitor (TP) antibodies (anti-CD44 and
anti-seprase, Vitatex) or anti-epithelia (EPI) antibodies (ESA clone B29.1, Biomeda; EPCAM clone Ber-Ep4).
Stained cells in suspension were mounted using a Cytospin device (StatSpin cytofuge and Filter
Concentrators). Microscopic analyses were performed on a Nikon Eclipse E400 inverted fluorescence
microscope equipped with a Microfire digital camera system and Image Pro Plus software. EPI + CD45-
cells were identified as CTCs; EPI + CD45-CAM+ or TP+ cells were iCTCs. Microscopic counting of
cells was performed by trained personnel and confirmed by a second observer.
The invasive activity of iCTCs was determined by the CAM uptake assay using fluorescently
labeled CAM-coated 6-well plates, as described [14]. Cells exhibiting CAM uptake (CAM+) were
identified as a functional label for iCTCs. To demonstrate the acquired endothelial function by iCTCs,
CAM-adherent cells were incubated with fluorescein-acetylated low-density lipoprotein (acLDL,
Invitrogen, Carlsbad, CA, USA) at 37 ◦C in a CO2 incubator for three hours. Cells exhibiting acLDL
uptake were identified as either circulating endothelial cells or iCTCs in CRC blood (Figure 1).
2.4. Microarray Data Analysis
CAM-adherent cells that were directly isolated from 1 mL of whole blood using a CAM-coated
tube (Vita-Cap™, Vitatex Inc., Stony Brook, NY, USA) were used in DNA microarray analysis, as
described [9]. Briefly, generation of cRNA, labeling, hybridization, and scanning of the Affymetrix
high-density oligonucleotide microarray HG_U133_Plus_2 chip (containing 54,675 gene probes)
were performed according to the manufacturer’s specifications (Affymetrix, Santa Clara, CA, USA).
Analysis of each chip was performed using the Affymetrix Microarray Suite 5.1 Software to generate
raw expression data. GeneSpring 7.2 software (Silicon Genetics, Redwood City, CA, USA) was used to
assist in the statistical analysis and the selection of genes specific for CAM-enriched circulating cells.
2.5. Statistical Analysis
Patient data was stratified as continuous or categorical variables. Continuous variables, such as
patient age and iCTC counts, were analyzed by way of medians, means, and standard errors. Due to
the fact the data distribution was not normal, nonparametric statistics (Kruskal–Wallis test for multiple
groups and Mann–Whitney U test for two groups) were employed. Categorical variables, such as
patient gender, race, disease stage, and history of chemotherapy/radiation therapy/surgery were
listed as frequencies and percentages. Categorical data was analyzed with chi-square tests.
Effects of iCTC counts on overall survival were evaluated using the Cox proportional hazards models.
For multivariable analyses, iCTC and other characteristics (e.g., gender, race, chemotherapy, stage, surgery,
and radiation) and their interactions were all included in the Cox model. For univariable analyses, iCTC
counts were included as a sole predictor in the Cox model. To determine an optimal cutoff point of
iCTCs, which can best differentiate the survival curve by high- and low-iCTC groups, the Cox model was
fitted iteratively using all possible cutoff points. The cutoff point with the best model fitting index akaike
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information criterion (AIC) (lowest value) was selected as the optimal point. The patients were categorized
into the high- and low-iCTC groups using the optimal cutoff point. The survival curve for each group
was estimated using the Kaplan–Meier method. Log-rank tests were used to assess survival differences
between patients who had high iCTC counts versus low iCTC counts. iCTC detection was defined as the
presence of at least one detectable iCTC. Results with two-tailed p-values less than 0.05 were considered
statistically significant. All analyses were performed using SAS v9.4 (the SAS Institute, Cary, NC, USA).
3. Results
3.1. Patient Characteristics
Ninety-three patients (M/F: 63/30; median age: 62.0 years, range: 35–82 years) with colon
and rectal cancers had samples collected and were analyzed in this study. Of the 93 total patients,
88 patients (95%) had detectable iCTCs and iCTC positives correlated with disease status: Stage I,
6 patients (7%); Stage II, 12 patients (14%); Stage III, 12 patients (14%); and Stage IV, 58 patients (65%)
(Table 1). A total of 64 (69%) patients were undergoing treatment for tumors in the colon and 29 (31%)
for tumors in the rectum. Patients received various treatments: chemotherapy, 71 (81%); surgical
resection, 74 (84%); and radiation therapy, 30 (34%). There was no significant correlation between
iCTCs and patient gender, race, disease stage, or age.
Table 1. Characteristics by cancer type.
















Patient baseline clinical–pathological characteristics. * Of 93 total patients, 88 patients had detectable iCTCs.
3.2. Clinical Characteristics of iCTCs: Stage and Survival
A baseline of 5.0 iCTCs/mL was used as a predetermined cutoff for iCTC positivity with readings
below 5.0 iCTCs/mL considered undetectable levels (Table 2). Data comparing iCTCs and CTCs were
available for 31 patients, in which 38% to 72% of CTCs overlapped with iCTCs. However, CTCs as
identified using Epi+ markers were high in patients with benign disease (85%, n = 30), suggesting low
specificity. Analyses were performed to establish a correlation between iCTC measurements and clinical
staging. Overall, 95% (n = 88) of patients had detectable iCTCs at the time of evaluation. There is a
significant correlation between disease stage and iCTCs: 92% (n = 12) of patients with Stage III disease
and 97% (n = 58) of patients with Stage IV disease had detectable iCTCs. This is opposed to only 17%
(n = 6) and 50% (n = 12) of patients with Stages I and II disease, respectively (Figure 2, p-value < 0.001).
Analysis of the median iCTC count as a function of disease stage demonstrated significance (Figure 3;
Table 3). Median iCTC counts of 0.0 iCTCs/mL (n = 6), 13.0 iCTCs/mL (n = 12), 41.0 iCTCs/mL (n = 12),
and 133.0 iCTCs/mL (n = 58) were observed for Stages I, II, III, and IV disease, respectively (Figure 3;
p-value < 0.001); mean iCTC counts of 8.3 iCTCs/mL (n = 6), 35.8 iCTCs/mL (n = 12), 65.9 iCTCs/mL
(n = 12), and 144.8 iCTCs/mL (n = 58) were observed for Stages I, II, III, and IV disease, respectively.
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Figure 1. Flow chart representing the procedural steps of invasive circulating tumor cell (iCTC)





















Figure 2. iCTC detection rate by disease stage. Percentage of patients within each stage group and
their detectable iCTC rates. iCTC detection varied considerably between Stage III/IV disease and Stage

























p-value < 0.001 
Figure 3. Mean iCTC counts. Median iCTCs by stage with SD. Median iCTC counts differ significantly
between Stage IV disease and Stage I–III disease (p-value < 0.001).
Table 2. CTC detectability by stage.
Stage CTC < 5 CTC ≥ 5 CTC ≥ 5%
I (n = 6) 5 1 17%
II (n = 12) 6 6 50%
III (n = 12) 1 11 92%
IV (n = 58) 2 56 97%
Distribution of iCTC counts over different stage groups.
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Table 3. iCTC median, mean and SD.
Stage iCTC Median iCTC Mean iCTC Standard Error
I (n = 6) 0.0 8.3 8.3
II (n = 12) 13.0 35.8 13.5
III (n = 12) 41.0 65.9 23.1
IV (n = 58) 133.0 144.8 13.8
Patients were followed to assess the correlation of iCTC counts and patient survival.
Mean follow-up time was 71.7 months (range 1.0–143.2 months). At the conclusion of the study,
28% (n = 26) of patients were living and 72% of patients (n = 67) were deceased. Patients were stratified
by an arbitrary cutoff of 30 iCTCs/mL for survival analysis and survival times were compared
between patients with high iCTC counts (>30 iCTCs/mL) and low iCTC counts (≤30 iCTCs/mL;
lowest AIC = 506.8). A significant decrease in survival time was observed in patients who had
iCTC counts greater than 30 iCTCs/mL (Figure 4; log-rank p-value < 0.001). The hazard ratio of
survival increases by 5% for every 10 iCTCs/mL (hazard ratio 1.05, 95% CI: 1.03–1.07, p < 0.001).
When evaluated by cancer type, iCTC counts correlate significantly with survival in colon cancer
(hazard ratio: 1.06, 95% CI: 1.03–1.09, p < 0.0001) but with a trend toward significance in rectal cancer
(hazard ratio: 1.03, 96% CI: 1.00–1.07, p = 0.06).
Figure 4. Kaplan–Meier curve analysis for disease outcome according to high-iCTC-count groups and
low-iCTC-count groups using optimal iCTC cutoff point (≤30 iCTCs/mL vs. >30 iCTCs/mL). The two
survival curves are significantly different (log-rank p-value < 0.001). The red line indicates the high
iCTC count group; blue line indicates the low iCTC count group.
A multivariable analysis of the survival data from this patient cohort was performed to establish
correlations between iCTC counts and patient characteristics (e.g., cancer type, stage, gender,
chemotherapy, surgery, radiation, and age); iCTC counts, stage, and surgical treatment remained
significant with adjustments for other covariates (Table 4). These results indicate that iCTC count is an
independent prognostic factor for distant metastases (hazard ratio = 1.66, 95% CI: 1.12–2.47, p = 0.01).
As expected, surgical intervention as assessed by iCTC count was associated with improved outcome
(hazard ratio = 0.37, 95% CI: 0.15–0.92, p = 0.03). As iCTC counts increase by 10 units, the hazard ratio
increases by 4% (Table 4; 95% CI 1.12–2.47, p = 0.01). If the disease status increases by one stage, the
hazard ratio increases by 66% (95% CI: 1.12–2.47, p = 0.01). For patients who had undergone surgery,
the hazard ratio is reduced by 63% (p = 0.03).
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Table 4. Hazard ratio (HR) for stage and surgery.
Factor Univariable Model Multivariable Model
Hazard Ratio (95% CI) p Value Hazard Ratio (95% CI) p Value
iCTCs 1.05 (1.03–1.07) <0.0001 1.04 (1.01–1.06) 0.009
Stage 1.89 (1.37–2.61) 0.0001 1.66 (1.12–2.47) 0.01
Surgery 0.17 (0.08–0.36) <0.0001 0.37 (0.15–0.92) 0.03
Cox regression multivariate analysis of prognostic factors for colorectal carcinoma.
3.3. Molecular and Functional Phenotyping of iCTCs in CRC Patients
iCTCs represent a subpopulation of CTCs that exhibit the phenotype of a metastasis-initiating cell
in blood [17], including proliferation and tumor differentiation, invasion, progenitor cell potency, and
survival capability in the blood stream.
To determine the proliferative and functional activities of iCTCs, we captured iCTCs in CRC blood
using Vita-Assay™ plates and cultured the cells on the same CAM substrata. We successfully cultured
iCTCs for up to four weeks in blood of 56 out of 61 CRC patients (92%), a result similar to those in both
metastatic and nonmetastatic cancers of the breast, ovary, and prostate [9–15]. The number and size of cells
increased over time in culture, resulting in sizeable colonies within 10 days (Figure 5a) and large-spread
cells with epithelial morphology after 20 days (Figure 5a), whereas co-purified hematopoietic cells were
observed in reduced number over time (Figure 5a). The growth rate of iCTCs was estimated by counting
numbers of cells in colonies formed in Day 5 cultures, which were composed of 16–32 iCTCs, suggesting a
doubling time of about 34–42 h for iCTCs. These ex vivo results indicate that the iCTC phenotype includes
the ability to propagate and progress to tumor cell morphology.
To examine whether iCTCs surviving in the blood stream acquire the phenotype of circulating
endothelial cells, cells captured in the CAM-coated wells were immuno-stained with antibodies against
epithelial CK and endothelial CD31, and underwent functional analyses using CAM uptake for invasive
tumor cells as described [14] and acLDL uptake for circulating endothelial cells as described [18].
iCTCs showed tumor-cell-like morphology, were CK+ and CD31+, and showed both acLDL and CAM
uptakes (Figure 5b). This finding shows that iCTCs acquire the phenotypic characteristics of circulating
endothelial cells, such as the expression of the endothelial lineage marker and the endothelial function
to adopt for their survival in the blood stream and extravasation.
Based on the assumption that subsets of endothelial cell genes are upregulated in iCTCs, global
gene expression profiling of cells isolated by CAM from the blood of healthy subjects and of CRC and
breast cancer patients were conducted using Affymetrix HG_U133_Plus_2 chips containing 54,675 gene
probes (Figure 6). Genes related to multiple cell lineage–progenitor potency (DTR, SOX1, FGFR2, NOTCH1,
FOLH1, NEUROG2, FLT3LG, TEKT3, CDH5, FLT4, TEK) and tumor immune response (DPP4/CD26) were
upregulated in 9 CRC samples and 20 breast cancer samples, but other endothelial genes (FGF4, SOX2,
NRG1, FLT1, CDC2, MCAM, EGFR, FGFR1, BMP1, PECAM1, FGF6, FGF5, VWF) were not (Figure 5).
In addition, four cytokeratin genes (KRT8, KRT16, KRT17, and KRT19) and eight tumor-associated genes
(TERT, MUC16/M17S2/CA125, CD44, TWIST1, TACSTD1/EpCAM/CD326/ESA/HEA125/GA733, DPP4/CD26,
ESR1, and PGR), were upregulated in CRC and breast cancer samples, as described previously [9].
The expression data strongly suggest that iCTCs express a subset of endothelial markers, in addition
to their own tumor progenitor markers.
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Figure 5. Proliferative and invasive activities and expression of multiple cell lineage markers of iCTCs
in blood of CRC patients. (a) Proliferation and differentiation of iCTCs into epithelial colonies ex vivo.
CAM-enriched cells were cultured on the CAM scaffold for ten days and twenty days. Live cells were
photographed under phase contrast microscopy. Tumor cells grew in clusters with large epithelioid
cells but hematologic cells (solitary small cells and platelet-like cell fragments seen in the lower image)
decreased in number and became not evident; (b) iCTCs express epithelial and endothelial biomarkers
as well as display epithelial and endothelial functions. Cell multipotency of iCTCs was verified in
single cells using expression of epithelial cytokeratins (CK) and endothelial CD31, acLDL uptake of
endothelial function, and CAM uptake of tumor progenitor cell function. Background cells that were
not labeled with antibody staining were leukocytes and platelets co-isolated with iCTCs. (Upper) panel:
circulating endothelial cells in normal blood were seen to be CD31+ acLDL uptake+ but CAM uptake−.
(Middle) panel: iCTCs in blood of a Stage IV CRC patient were seen to show CD31+ acLDL uptake+
CAM uptake+ (indicated by small arrows and double small arrows). However, circulating endothelial
cells and platelets were seen to be CD31+ acLDL uptake± CAM uptake− (indicated by large solid and
open arrows). (Lower) panel: iCTCs in blood of a Stage IV CRC patient were seen to show CK+ acLDL
uptake+ CAM uptake+ (indicated by small arrows and double small arrows).
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Figure 6. Expression of tumor-progenitor-associated genes in iCTCs isolated by CAM from blood
of patients with CRC and breast cancer. Global gene expression profiling of circulating cells
isolated by Vita-Cap™ from 9 healthy subjects, 9 CRC patients, and 20 patients with breast cancer.
Columns represent catalogues of cell samples analyzed: circulating Normal (N) cells isolated from
healthy donors with suffix M for Male and F for Female; CCa are circulating Colorectal Cancer (CCa)
cells and BCa are circulating Breast Cancer (BCa) cells with suffixes I–IV being stages of the disease.
Colorgram depicts high (red) and low (blue) relative levels of gene expression. Red arrows indicate the
three internal control genes that exhibited no difference between normal and cancer cell samples.
4. Discussion
CTCs have been demonstrated to have potential clinical validity in a variety of different
cancers [19]. CTC enumeration is a potential method for early detection, treatment monitoring,
and response assessment in colorectal cancer patients [20,21]. Unfortunately, the relationship between
CTC counts and clinicopathological parameters remains unknown [22]. There is a paucity of data
regarding CTC counts and clinical outcomes. It has not been used in clinical practice to date [23].
In this study, we utilized an iCTC detection system, which assesses for CAM adhesive and invasive
properties in conjunction with tumor progenitor marker expression in patients with colorectal cancer.
We showed that microscopic examination of CAM-avid cells detected iCTCs with a high sensitivity, i.e.,
88 of 93 patients (95%) had detectable iCTCs, ranging over 0–470 iCTCs/mL. In addition, we found that
patients with Stages I, II, III, and IV disease exhibited median iCTC counts of 0.0 iCTCs/mL, 13.0 iCTCs/mL,
41.0 iCTCs/mL, and 133.0 iCTCs/mL, respectively (p-value < 0.001), suggesting that our iCTC detection
method may have the highest sensitivity compared with previous methods [20–23], which detected
1 CTC/7.5 mL blood from fractions of patients with Stage IV disease. A possible explanation for the more
than 10-fold detection sensitivity and specific detection in early stages of disease from our method is that
CAM is an artificial extracellular matrix mimic that exerts powerful attractive force for solid-tissue-derived
cells themselves including CTCs and iCTCs circulating in blood. Other methods rely on devices with
specific filtration, microfluidic dynamics, or antibody-coated microcarriers to extract CTCs from whole
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blood. Other methods, therefore, might miss a portion of CTCs that are small in size, lack specified physical
properties, or are low in expression of needed cell surface antigens.
Our data supports the paradigm whereby iCTC count is a promising biomarker with diagnostic
and prognostic value. In our cohort of 93 patients, those with advanced disease harbored significantly
higher iCTCs. We found that surgical intervention affected iCTCs in colorectal cancer (HR 0.37), in
contrast to previous studies that focused on CTC count correlation with chemotherapy [24]. Analysis of
our patients revealed a significant survival benefit in those with low iCTC counts. iCTC counts were
not significantly associated with gender, age, or race. Due to limitations in sample size, data was not
stratified to account for differences in patients with colon or rectal cancers.
CTCs provide a unique source of tumor-derived material for molecular analysis [24]. The majority
of the genes identified were involved in cell motility, cell adhesion, chemokine activity, signal
transduction, and cell proliferation in a previous study using cDNA from CTCs [25]. We performed
global gene expression profiling from the isolated iCTCs and found upregulation of multiple
cell lineage–progenitor potency (DTR, SOX1, FGFR2, NOTCH1, FOLH1, NEUROG2, FLT3LG,
TEKT3, CDH5, FLT4, TEK), tumor immune response (DPP4/CD26), cytokeratin genes (KRT8, KRT16,
KRT17, and KRT19), and tumor-associated genes (TERT, MUC16/M17S2/CA125, CD44, TWIST1,
TACSTD1/EpCAM/CD326/ESA/HEA125/GA733, DPP4/CD26, ESR1, and PGR). In this study, gene
expression profiling supports the hypothesis that iCTCs are a subpopulation of CTCs that exhibit the
phenotype of a metastasis-initiating cell in blood [17], including proliferation and tumor differentiation,
invasion, progenitor cell potency, and tumor immune response. This pattern is consistent with a
previous report of cDNA from CTCs in CRC using microarray analysis [25].
In this study, the detected iCTC counts correlated with tumor burden and disease staging,
suggesting that iCTCs have the potential to be a monitoring and prognostic biomarker in CRC.
Also, we have validated use of the CAM method in detection of iCTCs in patients with CRC and
provided groundwork for future prospective studies. For example, treatment monitoring for early
recurrence of disease has yet to be evaluated using iCTCs in the CRC patient cohort. Pearl et al. has
reported that increases in iCTCs predated relapse of epithelial ovarian cancer earlier than cancer
antigen 125 (CA-125) monitoring [12]. Wang et al. demonstrated that postoperative detection of
CTCs detects disease relapse early while carcinoembryonic antigen (CEA) levels are within normal
limits. CTC levels were found to have a six-month lead time over CEA levels with relation to disease
recurrence [26]. These studies exemplify the promising role of CTCs as a surrogate tumor marker.
However, while the small sample size of 93 patients only in this study allowed for proof-of-principle
demonstrations and hypothesis generation of iCTCs in colorectal cancer, a larger cohort study is
warranted to determine the prognostic relevance of iCTCs in CRC patients. Moreover, that there are
no studies to date investigating a head-to-head comparison between CAM assay and the traditional
anti-EpCAM approach, although such studies may be technically challenging [27].
In summary, we provide data on iCTCs enriched through a functional CAM assay in the CRC
patient cohort. iCTCs are readily enriched and detectable with the approach. We found that iCTC
levels correlate clinically with disease stage and tumor burden, providing promising evidence for
the prognosticative value of iCTCs. iCTCs may serve as a surrogate biomarker for colorectal tumors.
Further studies are warranted to determine if iCTCs may have a role in early detection of disease
recurrence, drug response testing, and genomic studies. Our findings highlight the clinical significance
of iCTCs in CRC and suggest a role for iCTC quantification in disease diagnosis, treatment monitoring,
and post-treatment surveillance.
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Abstract: Background: Liver transplantation remains the treatment of choice for a selected group of
hepatocellular carcinoma (HCC) patients. However, the long-term benefit is greatly hampered by
post-transplant HCC recurrence. Our previous studies have identified liver graft injury as an acute
phase event leading to post-transplant tumor recurrence. Methods: To re-examine this acute phase
event at the molecular level and in an unbiased way, RNA sequencing (RNA-Seq) was performed on
liver graft biopsies obtained from the transplant recipients two hours after portal vein reperfusion
with an aim to capture frequently altered pathways that account for post-transplant tumor recurrence.
Liver grafts from recurrent recipients (n = 6) were sequenced and compared with those from
recipients without recurrence (n = 5). Results: RNA expression profiles comparison pointed to
several frequently altered pathways, among which pathways related to cell adhesion molecules were
the most involved. Subsequent validation using quantitative polymerase chain reaction confirmed
the differential involvement of two cell adhesion molecules HFE (hemochromatosis) and CD274 and
their related molecules in the acute phase event. Conclusion: This whole transcriptome strategy
unravels the molecular landscape of liver graft gene expression alterations, which can identify key
pathways and genes that are involved in acute phase liver graft injury that may lead to post-transplant
tumor recurrence.
Keywords: Liver transplantation; liver graft injury; intragraft gene expression profiles; cell adhesion
molecules; CD274; HFE
1. Introduction
Hepatocellular carcinoma (HCC) is a clinically challenging liver malignancy with a nearly equal
worldwide incidence and death. Among various treatments, liver transplant results in a favorable
survival in a well selected patient subgroup [1]. However, this treatment unavoidably accompanies
ischemia and reperfusion injury that can trigger acute phase graft injury, or even rejection [2]. Acute phase
liver graft injury is a hallmark event leading to late phase HCC recurrence in liver transplantation.
Our previous studies using a liver transplant animal model have revealed a deregulation of signaling
pathways related to inflammation, invasion and migration in the acute phase event and their associations
with late phase tumor recurrence [3,4]. Besides, various molecules, e.g., CXCL10 (C-X-C motif chemokine
ligand 10), and certain cells, e.g., endothelial progenitor cells, were found capable of promoting tumor
recurrence after liver transplantation in studies using relevant animal models and clinical specimens [5,6].
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These studies have unequivocally demonstrated that acute phase liver graft injury is an early event
leading to post-transplant tumor recurrence. A better understanding of the acute phase event is important
for developing new or prophylactic treatments for post-transplant tumor recurrence.
Despite the efforts that have been devoted to the study of acute phase liver graft injury and late
phase HCC recurrence in liver transplantation, the molecular mechanisms underlying these events were
not fully uncovered. Here, we revisited this theme by using RNA sequencing to capture intragraft gene
expression changes in acute phase liver graft injury that account for post-transplant tumor recurrence,
for which some of them are known for their effects on recipient outcomes. In a liver transplant animal
study, cDNA microarray results revealed a number of genes, especially those inflammatory genes,
were up-regulated in liver grafts that are more prone to develop tumors [4]. On the other hand, certain
genes, such as GPx3 (glutathione peroxidase 3), experienced down-regulation [7]. Apart from the
above effects, intragraft gene expression changes can also influence other post-transplant outcomes,
such as graft rejection. A preferential expression of genes related to signal transduction, inflammation,
and immune response was detected in liver grafts undergoing acute cellular rejection, which is
a common situation leading to graft loss in a specific recipient group [8]. Overall, these prior studies
have put forth the importance of studying intragraft gene expression patterns in acute phase liver
graft injury and their correlation with post-transplant outcomes. The derived results can enhance
the understanding of acute phase liver graft injury, for which the knowledge can improve patient
management in terms of risk stratification, prophylaxis and treatment of post-transplant tumor
recurrence. Our long-term goal is to improve the recipient outcomes after liver transplantation.
2. Experimental Section
2.1. Clinical specimens
HCC patients that were included in this study received their liver transplant in Queen Mary
Hospital, Pokfulam, Hong Kong (March 2004 to April 2010). Written patient consents were obtained.
The last follow-up date was September 2013. The clinicopathological information between HCC
patients with and without HCC recurrence after liver transplantation including sex, age, type of liver
transplant, Milan criteria, vascular permeation, HBsAg before liver transplantation, new TNM stage,
AST level (24 h after liver transplantation), and ALT level (24 h after liver transplantation) were listed
in Supplementary Table S1. Among them, both the AST and ALT level in recurrence group were
significantly higher than the non-recurrence group (Supplementary Table S1). The recurrence period
and recurrence sites are listed in Supplementary Table S2. Liver graft biopsies collected 2 h after portal
vein reperfusion during liver transplantation were frozen immediately and stored at −80 ◦C. The use
of clinical specimens for research was approved by the Institutional Review Board of The University of
Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB).
2.2. RNA sequencing (RNA-Seq) and data processing
RNA-Seq was performed on liver grafts from recipients with (n = 6) or without (n = 5)
post-transplant HCC recurrence. The 5 patients without post-transplant HCC recurrence are patients
treated with deceased donor liver transplant (DDLT). Total RNA was extracted from liver grafts using
TRIzol reagent (Life Technologies, Waltham, MA, USA) as before [9,10]. RNA quality was analyzed
in an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). RNA sequencing was
performed in a HiSeq 2500 System sequencer (Illumina, San Diego, CA, USA) in BGI, Hong Kong.
A total of eight billion bases of sequencing data (quality control passed) was produced. The data were
preprocessed using cutadapt version 1.1 to remove sequencing adapters. Then the data were mapped to
the human reference genome GRCh37 (hg19) using aligner BWA version 0.6.2 with default options and
then converted into BAM file format using SAMtools version 0.1.19. The gene expression level of each
sample was calculated using the method introduced by Mortazavi et al. [11]. More specifically, the gene
expression level difference between any given two samples was gauged by the number of sequencing
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data mapped to the gene, RPKM (reads per kilobase per million mapped reads). Each recurrence
sample was compared to each non-recurrence sample to identify the up-regulated and down-regulated
genes (Figure 1), together with their expression ratios. Using this method, a total of 30 differentially
expressed gene lists were generated, which were then merged. Genes with inconsistent expression
changes were removed. An average expression difference for each gene was calculated.
Figure 1. RNA-Seq data comparison method. RNA-Seq data of liver grafts from recipients with
(n = 6) or without (n = 5) post-transplant hepatocellular carcinoma (HCC) recurrence was individually
compared to identify differentially expressed genes, for which this result was used to map the frequently
altered pathways. Rc, recurrence; NRc, non-recurrence.
2.3. Bioinformatics analyses
Pathway enrichment analyses were performed using Kyoto Encyclopedia of Genes and Genomes
(KEGG) and Gene Ontology (GO). STRING database (http://string-db.org, version 9) was used to
find related molecules for the candidate genes [12]. High confidence level at 0.700 was used.
2.4. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
RT-qPCR was performed, as described [9,10]. Total RNA from liver graft biopsies were extracted
as above. Reverse transcription was performed using High-Capacity cDNA Reverse Transcription
kit (Applied Biosystems, Foster City, CA, USA). qPCR was performed using Power SYBR Green
PCR Master Mix (Applied Biosystems) and gene-specific primers (Supplementary Table S3). β-Actin
expression was used as an internal normalization control. The relative expression level of each gene
in each sample was normalized with the average expression level in healthy donor livers using
2-ΔΔCt method [13].
2.5. Statistical analyses
Continuous variables were compared by t-test or Mann-Whitney U test. The categorical variables
were compared by chi-square Fisher’s test. Gene expression level correlation was analyzed by Pearson
correlation analysis. p < 0.05 was considered statistically significant.
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3. Results
3.1. Cell adhesion molecules-related pathways in acute phase liver graft injury
Eleven sets of RNA-Seq data of liver grafts from recipients with (n = 6) or without (n = 5)
post-transplant HCC recurrence were subjected to pathway enrichment analyses based on the use of
differentially expressed genes between these two recipient groups. The top five pathways frequently
altered in our studied condition are those related to steroid hormone biosynthesis, retinol metabolism,
metabolism of xenobiotics by cytochrome P450, drug metabolism by cytochrome P450, and finally,
cell adhesion molecules (Supplementary Table S4). Among these pathways, we focused on pathways
related to cell adhesion molecules for further study, not only because of their diversified roles in liver
tumorigenesis, but also because of their expression in immune cells important for post-transplant
tumor recurrence [14–16].
3.2. HFE and CD274 are two cell adhesion molecules with differential involvement in acute phase liver graft
injury
Cell adhesion molecules represent a broad class of membrane-associated molecules with
diversified functions in pathophysiological processes, ranging from cell adhesion, inflammation, tissue
injury, to tumorigenesis. In this category, seventy-five genes were differentially expressed in liver grafts
in the recurrence group compared to the non-recurrence group (Supplementary Table S5), implicating
their involvement in post-transplant HCC recurrence. Six genes with more than two-fold expression
level difference between these two groups, i.e., ITGA8, SELE, HFE, CDH26, HLA-DQA2, and CD274
(Figure 2 and highlighted in Supplementary Table S5), were subjected to RT-qPCR validation in a
sample set of seven recurrences and seven non-recurrences. Among the four genes down-regulated
in recurrence samples (ITGA8, SELE, HFE, and CDH26), only HFE maintained its down-regulation
(Figure 3). The CDH26 validation result was not shown due to its nearly undetectable expression level
in our current experimental setting. For the two genes up-regulated in recurrence samples (HLA-DQA2
and CD274), an up-regulation of CD274 was maintained (Figure 4). No validation experiment was
performed on HLA-DQA2 due to its ubiquitous nature.
Figure 2. RNA-Seq result shows cell adhesion molecules that had more than two-fold gene expression
level difference between recurrence and non-recurrence samples in acutely injured liver grafts. Six cell
adhesion molecules with intragraft gene expression level difference of more than two-fold when
recurrence samples were compared to non-recurrence ones. Four molecules (ITGA8, SELE, HFE,
and CDH26) have been down-regulated in recurrence samples, whereas two molecules (HLA-DQA2
and CD274) were found to have been up-regulated.
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Figure 3. HFE down-regulation in liver grafts from recipients with post-transplant HCC recurrence.
RT-qPCR result demonstrated a down-regulation of HFE, but not ITGA8 and SELE, in liver grafts from
recipients with post-transplant HCC recurrence. ** p < 0.01.
Figure 4. CD274 up-regulation in liver grafts from recipients with post-transplant HCC recurrence.
RT-qPCR result demonstrated an up-regulation of CD274 in liver grafts from recipients with
post-transplant HCC recurrence. * p < 0.05.
3.3. HFE- and CD274-related molecules in acutely injured liver grafts
STRING database result revealed four HFE-related molecules (B2M, TF, TFR2, and TFRC)
(Figure 5A and Supplementary Table S6) and two CD274-related molecules (CD80 and PDCD1)
(Figure 6A and Supplementary Table S6). Their gene expression level correlation with HFE and CD274
was performed in liver grafts from 43 transplant recipients (6 recurrence and 37 non-recurrence)
using RT-qPCR. Among the HFE-related molecules, B2M, TF, and TFR2, but not TFRC, demonstrated
positive gene expression level correlation with HFE (Figure 5B). Among the CD274-related molecules,
CD80, but not PDCD1, exhibited positive gene expression level correlation with CD274 (Figure 6B).
Collectively, our results revealed that the involvement of HFE and CD274 and their related molecules
in acute phase liver graft injury and their concurrent involvement in post-transplant tumor recurrence.
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Figure 5. Correlation analysis of HFE and its related molecules in liver grafts from transplant recipients.
(A) Bioinformatics analysis revealed B2M, TF, TFR2 and TFRC as HFE-related molecules; (B) Among
these molecules, B2M, TF and TFR2, but not TFRC, demonstrated a positive gene expression correlation
with HFE in liver grafts from 43 transplant recipients using RT-qPCR.
Figure 6. Correlation analysis of CD274 and its related molecules in liver grafts from transplant
recipients. (A) Bioinformatics analysis revealed that CD80 and PDCD1 were CD274-related molecules;
(B) CD80, but not PDCD1, demonstrated a positive gene expression correlation with CD274 in liver
grafts from 43 transplant recipients using RT-qPCR.
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4. Discussion
Our previous studies have identified that the acute phase liver graft injury is a key event leading
to post-transplant HCC recurrence. In this study, we adopted a more comprehensive and unbiased
approach using RNA sequencing to analyze differentially expressed genes in this acute phase event,
with an aim to identify key players. The sequencing data revealed a subset of cell adhesion molecules
differentially expressed in liver grafts from recipients with or without post-transplant tumor recurrence.
Cell adhesion molecules belong to a class of cell surface molecules with diversified functions from
adhesion, migration, to inflammation [16]. In liver transplantation, inflammation is initiated in the
hallmark event of ischemia and reperfusion injury resulting from hepatic surgery. Massive recruitment
of immune cells, which express various cell adhesion molecules, takes place during acute phase liver
graft injury that can eventually lead to post-transplant tumor recurrence [17]. Certain cell adhesion
molecules, e.g., MHC molecules [18], are involved in ischemia and reperfusion liver injury. In addition,
our previous studies have demonstrated that certain molecules, e.g., aldose reductase and repressor
and activator protein, are capable of regulating hepatic ischemia and reperfusion injury through their
effects on inflammation [19,20]. Collectively, our and other findings have exemplified the key roles
of cell adhesion molecules in inflammation, ischemia, and reperfusion liver graft injury, as well as
post-transplant tumor recurrence. However, due to the small sample size that was used, findings
that were derived from this study should be further validated in a separate cohort of large sample
size. To minimize variations between patients, we tried to analyze specimens from patients that were
selected based on the Milan criteria.
HFE (hemochromatosis) is a cell adhesion molecule that was identified in this study to have
down-regulated gene expression level in liver grafts from recipients with post-transplant HCC
recurrence. It is an atypical MHC class I molecule with diversified cellular functions, such as iron
homeostasis maintenance and immune function regulation [21,22]. Mutation of this gene can lead
to iron overload, which is a predisposing factor for HCC [21,23]. Besides, two studies have reported
the close link between hepatic iron overload and poor survival of liver transplant recipients [24,25].
In this study, we have also established a positive correlation in the intragraft gene expression of HFE
and its related molecules (B2M/β2-microglobulin, TF/transferrin, and TFR2/transferrin receptor 2) in
liver transplant recipients, for which these molecules are known iron metabolism regulators with close
interaction with HFE [21,26]. Taken together, it is convincing to believe that HFE down-regulation
in liver grafts, as observed in this study, can lead to iron overload and eventually post-transplant
tumor recurrence.
In contrary to HFE, we have demonstrated a high intragraft gene expression level of CD274
from recipients with post-transplant tumor recurrence. CD274, also known as PD-L1, is expressed
on immune cells, as well as non-hemopoietic cells [27]. In addition to its general immunoregulatory
functions, CD274 is also involved in tumorigenesis, as reflected by its high expression level in tumor
tissues rather than in adjacent non-tumor tissues of various cancers [27,28]. The tumor-related function
of CD274 can also help to explain for its high intragraft gene expression level in transplant recipients
with tumor recurrence as observed in this study. The tumor-inducing effect of CD274 may also involve
other immunoregulatory molecules, such as CD80, whose intragraft gene expression level correlated
positively with CD274 in transplant recipients as reported here. Like CD274, CD80 is also found on
immune cells and is involved in an array of immune pathways [29]. Indeed, both molecules are known
to participate in transplantation immunity [30]. In view of these interesting observations from this and
other studies, it is plausible that CD274 may work with its related molecule, e.g., CD80, in triggering
acute phase liver graft injury and post-transplant tumor recurrence.
Taken together, we have successfully used RNA sequencing to unravel the molecular landscape
of acute phase liver graft injury that accounts for post-transplant tumor recurrence. Certain cell
adhesion molecules, e.g., HFE and CD274, were found to have differential roles in our studied
condition. These molecules have potential function as a prognostic marker for risk assessment to
identify transplant recipients more prone to tumor recurrence and to guide them for prophylactic
23
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treatment for prevention. Apart from the preventive measure, the identified molecules can also form
a basis for research on new treatment targets.
Supplementary Materials: The following are available online at http://www.mdpi.com/2227-9059/6/2/41/s1.
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Abstract: Biomarkers refer to a plethora of biological characteristics that can be quantified to
facilitate cancer diagnosis, forecast the prognosis of disease, and predict a response to treatment.
The identification of objective biomarkers is among the most crucial steps in the realization of
individualized cancer care. Several tumor biomarkers for gastrointestinal malignancies have
been applied in the clinical setting to help differentiate between cancer and other conditions,
facilitate patient selection for targeted therapies, and to monitor treatment response and recurrence.
With the coming of the immunotherapy age, the need for a new development of biomarkers that are
indicative of the immune response to tumors are unprecedentedly urgent. Biomarkers from the tumor
microenvironment, tumor genome, and signatures from liquid biopsies have been explored, but the
majority have shown a limited prognostic or predictive value as single biomarkers. Nevertheless,
use of multiplex biomarkers has the potential to provide a significantly increased diagnostic accuracy
compared to traditional single biomarker. A comprehensive analysis of immune-biomarkers is
needed to reveal the dynamic and multifaceted anti-tumor immunity and thus imply for the rational
design of assays and combinational strategies.
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1. Introduction
Biomarkers are defined as objective, quantifiable biological indicators of a normal or abnormal
process, a condition or disease, or a response to treatment [1]. Prognostic biomarkers allow a
selection of patients with a high risk for disease recurrence or rapid progression and help regarding
decision making for a treatment regimen. Predictive biomarkers represent an array of indicators
that project the patient’s response to the treatment. Currently, biomarkers are genetic, epigenetic,
proteinic, or cellular alterations that are inherent to cancer cells, and have been an integral part
of individualized cancer care.Glycoproteins, such as carcinoembryonic antigen (CEA) and cancer
antigen 19-9 (CA19-9), are classical proteinic biomarkers for disease monitoring [2–4]. Biomarkers at
the genome level, which are often driver mutations such as KRAS and epidermal growth factor
receptor (EGFR), have been widely used as a guide for a selection of patients that might benefit
from targeted therapies [4–7]. More recent literature has highlighted BRCA, a tumor suppressor gene
involved in the repair of double-stranded DNA breaks, as a viable predictive biomarker for response
to platinum agents and poly(ADP-ribose) polymerase (PARP) inhibitors [8]. Immunotherapy has
revolutionized human cancer treatment by unleashing the potential of the antitumor immune response;
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however, only 15–20% of patients respond to immunotherapy [9,10]. This underpins the importance
of identifying novel biomarkers that can select the patients for immunotherapy. Programmed death
ligand 1 (PD-L1) positivity, T cell-inflamed phenotype, and high tumor mutational burden have been
reported to enrich the patient populations that benefit from the treatment of immune checkpoint
inhibitors (ICIs) [11–15]; however, these makers alone are insufficiently accurate for patient selection
across different cancer types. Microsatellite instability (MSI), a pan-cancer biomarker, predicts the
response of solid tumors to anti-PD-1/PD-L1 (Programmed death-1/Programmed death ligand 1)
blockade, is only found in 1–2% of most of malignancies [12,16]. Preliminary clinical findings showed
that the signatures that reflect the composition and metabolites of the gut microbiota would impact the
antitumor immune response in patients receiving ICIs, including anti-cytotoxic T-lymphocyte antigen 4
[CTLA-4] and anti-PD-1/PD-L1 antibodies, and have the potential to predict durable clinical responses
in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and melanoma; however, the role
of the microbiome in predicting the benefits from the ICIs remains unclear for gastrointestinal (GI)
cancer [17–21]. A few studies have also suggested the association of members of the gut microbiome
with ICI toxicities, but evidence is lacking in the GI setting [21,22]. In addition, biomarkers that can
guide the choice of combination immunotherapy are scarce [23]. Quantitative multiplexed approaches,
which exert unique advantages in revealing the tumor-immune complexity, may represent a new
avenue for biomarker discovery in the tumor microenvironment, especially for combinational therapies
targeting the suppressive myeloid/stromal compartment [24,25]. This review summarizes the advances
of biomarkers in gastrointestinal malignancies, with a focus on the development of new biomarkers
that are of predictive and/or prognostic values in cancer therapies.
2. Current Clinical Application of Biomarkers in Gastrointestinal Malignancies
2.1. Tumor Markers
The tumor markers currently being used in the clinic are all surrogate markers of malignant
diseases (Table 1). CEA is one of the most commonly used tumor markers for gastrointestinal
malignancies and a member of the immunoglobulin superfamily [26]. It acts as a mediator for
cell adhesion on cancer cells. The overexpression of CEA occurs in >90% of colorectal cancers (CRC)
and 60% of other types of cancer, including gastric, lung, and pancreatic cancers [27]; thus, it has been
widely used as a serum tumor marker. Its sensitivity and specificity are not high, particularly for the
early stages of the disease [28]; therefore, it cannot be used as a biomarker for screening gastrointestinal
cancers. However, in the patients with an established disease, the absolute level of the serum CEA
correlates with the disease burden and has a prognostic value [29]. In CRC, CEA is the only laboratory
test routinely recommended for surveillance. High levels of CEA after surgical resection imply the
presence of a persistent disease and the need for further evaluation [30]. The serial measurement of the
CEA levels after surgery in patients with colorectal cancer can detect recurrences earlier; nevertheless,
this information does not lead to an improved treatment outcome [28]. Currently, the American
Society of Clinical Oncology (ASCO) guidelines recommend that the serum CEA levels be obtained in
most patients with CRC, so as to aid surgical treatment planning, posttreatment follow-up, and the
assessment of prognosis [31]. Another common glycoprotein biomarker is CA19-9, which is used
primarily to assess the disease response to therapy or to detect cancer recurrence in patients with gastric
cancer, pancreatic cancer, gallbladder cancer, cholangiocarcinoma, or adenocarcinoma of the ampulla
of Vater. It is the most useful tumor marker for pancreatic cancer, with sensitivity and specificity rates
of 70–92% and 68–92%, respectively [32–34]. In addition, an elevated preoperative CA19-9 level is
strongly associated with the presence of subradiographic unresectable diseases, and can be used for a
selection of patients for staging the laparoscopy [35]. The lack of tumor specificity is the limitation
of the currently used tumor markers. Tumor specific markers, particularly those reflecting the tumor
biology, are highly demanded.
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Table 1. Major molecular markers in clinical application.
Molecule Tumor Type Implication
Tumor markers
CEA Colorectal, gastric, and pancreatic
cancers




Indicating residual disease, progressive, or
recurrent disease
Measuring treatment response
Targets of matched therapies
HER2 Gastric oresophagogastric-junction cancers Selecting for targeted therapy
KRAS Colorectal, gastric, and pancreaticcancers Predicting for treatment unresponsiveness
Mismatch repair Genes
MMR Solid tumors Predicting for treatment responsiveness
Biomarkers in tumor microenvironment
PD-L1 expression Gastric cancer Enriching patient population responding toanti-PD-1/PD-L1 therapies
CEA—carcinoembryonic antigen; MMR—mismatch repair; PD-L1—programmed death ligand 1;
PD-1—programmed death-1.
2.2. Targets of Matched Therapies
HER2, a tyrosine kinase receptor belonging to the epidermal growth factor receptor
(EGFR) family, is an established prognostic factor and a therapeutic target for gastroesophageal
adenocarcinoma [36–39]. Through the activation of downstream signaling pathways, including
RAS/RAF/mitogen-activated protein kinase (RAS/RAF/MAPK) and phosphatidylinositol-3
kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR), aberrant HER2
amplification or overexpression can lead to uncontrolled cell-cycle progression, cell division, motility,
survival, invasion, and adhesion [7]. Approximately 7–38% of gastroesophageal adenocarcinomas have
an amplification and/or overexpression of HER2, with a slightly higher positivity in gastroesophageal
junction (GEJ), intestinal-type, and well-moderately differentiated tumors [6,7,40,41]. The inhibition of
HER2 with the monoclonal antibody trastuzumab in patients with HER2-amplified/overexpressed
advanced-stage gastric or esophagogastric-junction adenocarcinomas, confers an improved response
rate, progression-free survival, and overall survival when trastuzumab is combined with cisplatin and
fluoropyrimidine [5]. Based on the above evidence from the phase III ToGA trial, the current guideline
suggests that patients with advanced gastric cancer who are potential candidates for trastuzumab
should be screened to determine their HER2 status.
Another biomarker for therapeutic target is c-MET, of which the aberrant expression has been
reported in 18–100% of gastrointestinal tumors [42,43]. Activated c-MET signaling results in enhanced
cancer cell proliferation, survival, and invasion, and is an independent prognostic factor for inferior
survival [44–46]. Several monoclonal antibodies and small-molecule inhibitors of c-MET have been
evaluated in clinical trials, however, most of the phase III trials of MET inhibitors showed negative
results for gastric cancer. In hepatocellular carcinoma, although encouraging results were reported
in phase II studies [47–49], the phase III trial failed to show an improvement in the overall survival
compared with the placebo in patients with c-MET-positive advanced hepatocellular cancer (HCC),
casting doubt on the role of MET inhibition as a viable therapeutic strategy [50,51]. Therefore,
the development of biomarkers for therapeutic target is still a challenge.
In metastatic CRC, the KRAS mutation status has been widely reported as a prognostic and
predictive biomarker [52]. KRAS mutations can be identified in 12–75% of colon cancers and are
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independently associated with a worse prognosis in the majority of the studies, albeit not all of the
studies [53,54]. As the RAS oncogene is located at the downstream of the EGFR signaling pathway,
the RAS mutations can lead to an activation of the pathway, even if the EGFR is blocked [55]. Thus,
the KRAS mutation status is a biomarker for unresponsiveness to anti-EGFR therapy. Interestingly,
there is a bias toward the right-sided CRC for the KRAS mutation, this may partially explain an inferior
survival and poor response to targeted therapy with EGFR inhibitors for the right proximal CRC
compared to the left colon CRC [56]. The characteristics of the HER2, c-MET, and KRAS expression in
GI cancers are summarized in Table 2.




Pathways Involved Cancer types Treatment
HER2 Amplification/overexpression
Activation of the MAPK



























(e.g., MEK inhibitors selumetinib
and trametinib)
MAPK—mitogen-activated protein kinase; GRB2—growth factor receptor-bound protein 2; STAT—signal transducer
and activator of transcription; PI3K—the p85 subunit of phosphatidylinositol 3-kinase; SOS—son of sevenless
homologue 1.
2.3. Mismatch Repair Genes
Mismatch repair (MMR) gene products function to repair the nucleotide base mispairings and
small insertions or deletions that occur during DNA replication [57,58]. Thus, the MMR-deficient
tumors could accumulate hundreds to thousands of somatic mutations, regardless of their cell of
origin. It has been implicated in the pathogenesis of the hereditary nonpolyposis colorectal cancer
syndromes, as well as a variety of different sporadic cancers. MMR-deficiency is present in 15–20% of
all colorectal cancers (CRCs), 8.5–20% of gastric cancers, 3–7% in esophageal/GEJ adenocarcinomas,
and 2–3% of pancreatic cancers [12,16,59,60]. MMR-deficiency has been shown to be positively
prognostic for survival in patients with colon, gastric, and pancreatic cancers [57,60,61]. It could
also serve as a potential predictive marker for a lack of efficacy of fluoropyrimidine based adjuvant
chemotherapy in gastric cancer and colon cancer [62–64]. Importantly, MMR deficiency is a pan-cancer
predictor for response to anti-PD-1/PD-L1 blockade therapies [65]. It is hypothesized that tumors
with an MMR deficiency are enriched with missense mutations that are presented as neoepitopes
to T cells, which are subsequently targets of anti-PD-1/PD-L1 therapies. Le et al. reported a phase
II clinical trial of progressive metastatic carcinoma with or without MMR deficiency, and revealed
significantly increased somatic mutations per tumor in the MMR–deficient tumors compared with the
MMR-proficient tumors (mean, 1782 vs. 73). The MMR deficient patients had a remarkably increased
immune-related objective response rate (40% vs. 0%) and prolonged immune-related progression-free
survival rate (78% vs. 11%), compared to their counterparts [16]. In an expanded cohort of 86 patients
with MMR-deficient tumors, the objective radiographic responses were noted in 53% of the patients
(46 of 86 patients; 95% CI, 42–64%), with 21% (n = 18) achieving a complete radiographic response.
Disease control (measured as partial response + complete response + stable disease) was achieved
in 66 (77%) of the 86 patients (95% CI, 66–85%) [12]. This led to the approval from the Food and
Drug Administration (FDA) for testing MMR-deficiency in order to identify the candidate patients
who may benefit from a second-line PD-1 pathway blockade, regardless of the tumor types [66]. Of
note, this is the first and only FDA approved pan-cancer biomarker for immune checkpoints blockade.
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Clinical trials investigating its role as predictive biomarkers in the first-line and (neo)adjuvant settings
are ongoing [67,68].
3. New Development of Biomarkers
3.1. Biomarkers in Tumor Microenvironment
3.1.1. PD-L1 Expression
As above described, PD-1, which is expressed on activated lymphocytes, including T cells, B cells,
and natural killer cells, limits the T cell effector functions within tissues. By upregulating the ligands
for PD-1 (PD-L1), tumor cells induce the apoptosis of the effector T cells [69,70]. The reported incidence
of PD-L1 expression ranges differently in the different tumor types (14–100%), whether or not these
tumors respond to anti PD-1/PD-L1 treatment [71–76]. Early studies have suggested that PD-L1
positivity enriches the patient populations that can benefit from PD-1/PD-L1 axis inhibition [77,78],
with the hypothesis that pre-existing immunity suppressed by PD-1/PD-L1 could be re-invigorated
on antibody treatment with checkpoint blockade. However, more studies questioned the accuracy of
PD-L1 as an effective predictive biomarker. In the recent phase III trials testing the adjuvant anti-PD-1
in resected stage III melanoma, the first-line anti-PD-1 antibody in combination with chemotherapy in
metastatic NSCLC, and the combination of anti-PD-1 and anti-CTLA4 antibodies in NSCLC with a
high mutational burden, the benefit of immunotherapy did not correlate with the PD-L1 expression
level [79–81]. In the Keynote 059 trial, objective responses and complete responses (CRs) were observed
in both the PD-L1-positive and negative gastric and gastroesophageal adenocarcinoma patients who
had previously received at least two lines of treatment [82]. The PD-L1-positivity was defined as
a combined positive score (CPS) ≥1%, where CPS is the number of PD-L1 staining tumor cells,
lymphocytes, and macrophages divided by the total number of viable tumor cells multiplied by 100,
using PD-L1 Immunohistochemistry (IHC) 22C3 pharmDx immunohistochemistry. Although the
objective response rate (ORR) seemed higher in the patients with PD-L1–positive compared with
the PD-L1–negative tumors (23 of 148 [15.5%] vs. 7 of 109 [6.4%], respectively), the patients with
PD-L1–negative tumors also experienced objective responses, including CR in three patients (2.8%) [82].
Nevertheless, this study has gained the FDA approval of using PD-L1 positivity (Table 1) at the 1%
cutoff as a biomarker to select patients with metastatic gastric and gastroesophageal adenocarcinoma
for the treatment of pembrolizumab [83]. In the Asian population, Nivolulab was approved for the
treatment of the unresectable, advanced, or recurrent gastric cancer that has progressed after using
conventional chemotherapy, based on the results from the phase III ATTRACTION-2 trial, regardless
of PD-L1 status. In hepatocellular cancer (HCC), the report from the phase I/II trial suggests that
ICIs elicited a promising response rate of 16–19% (49/255) in advanced HCC, but the response rate
to the ICIs did not differ according to the PD-L1 expression status [82–85]. In PDACs, reports of the
PD-L1 expression vary from 12–90%, however, single agent anti-PD1 treatment has shown no efficacy,
except for MMR deficient patients, regardless of PD-L1 status [86].
Therefore, evolving evidence suggests that PD-L1 testing alone is insufficiently accurate to
predict patient response to immunotherapy, although it may be used in some GI cancers to enrich the
patients that may more likely benefit from anti-PD-1/PD-L1 antibodies (Table 3). Several factors may
explain the heterogeneity of the predictive values for the PD-L1 expression, including differences in
the PD-L1 IHC assay platforms and detection antibodies, differing IHC cutoffs, tissue preparation,
processing variability, primary versus metastatic lesions, oncogenic versus induced PD-L1 expression,
and the staining of tumor versus immune cells [42,47,75,87,88]. It should be noted that the PD-L1
expression measured in the clinical assays may only represent a snapshot of the dynamic and
multifaceted immune cells and their complex interaction with neoplastic cells. A comprehensive
characterization of the tumor microenvironment is necessary to adequately assess the strength of
PD-L1 in predicting the immune response to anti-PD-L1/PD-1 therapies.
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Table 3. New development of biomarkers.
Molecule Tumor Type Implication
Biomarkers in tumor microenvironment
PD-L1 expression Other cancer types, except gastriccancer
Enriching patient population responding
to anti-PD-1/PD-L1 therapies
Tumor infiltrating lymphocyte Colon and gastric cancers Indicating good prognosis
Immunosuppressive myeloid cells Pancreatic, hepatocellular, andgastric cancers Indicating poor prognosis
Intratumoral stroma Gastric, pancreatic, esophageal,and colon cancers Indicating poor prognosis
Biomarkers in tumor genomics
Targeted gene panels Pan-cancer Selecting patients for targeted therapies
Mutational burden Pan-cancer Enriching patient population respondingto anti-PD-1/PD-L1 therapies
Biomarkers in liquid biopsies
ctDNA/CTC/Exosomes Pan-cancer




3.1.2. Tumor Infiltrating Lymphocyte
Tumor infiltrating lymphocytes (TILs) represent a potent machinery of the adaptive immunity
that has the antitumor potential. TILs have been shown to be associated with improved prognoses and
response to immunotherapy in various cancer type (Table 3) [24,44–46,89–91]. In colorectal cancers,
the type, density, and location of the immune cells, specifically the cytotoxic and memory T cells,
has been reported to be a better predictor of survival than (Union for International Cancer Control )
UICC-TNM staging 89]. Among the tumors with similar degrees of T cell infiltration, those with the
greatest proportion of CD103+ memory T cells have the best prognosis [92]. To standardize the method
of evaluating TILs in CRC, a new method that measures the area occupied by mononuclear cells over
the stromal area on hematoxylin and eosin (H-E)-stained sections was proposed. The results from such
a method confirmed the density of TILs as a useful prognostic factor in CRC [93]. In Epstein–Barr virus
(EBV)-associated gastric cancer an association between a high percentage of TILs, low intratumoral
PD-L1 expression, and longer disease-free survival (DFS) was demonstrated [94]. A meta-analysis
on 23 relevant studies of 3173 hepatocellular carcinoma (HCC) patients showed that high levels of
CD8+ and CD3+ TILs had a better prognostic value on the overall survival (OS), yet high levels of
FoxP3+ TILs had a worse prognostic value on OS and DFS/Relapse-free survival (RFS), implicating
that TILs may serve as a prognostic biomarker in HCC [95]. A TIL density of ≥5% was reported to be
associated with a better objective response as well as the progression free survival (PFS) in NSCLC
patients treated with Nivolumab [96]. Recently, a T cell inflamed expression score utilizing 18 gene
signatures was shown to be significantly associated with a Pembrolizumab response in gastric/GEJ
cancer [97,98]. A significant but nonlinear association was found between the T cell-inflamed gene
expression score and PD-L1 expression. These results suggest the potential for a T cell-inflamed
gene expression profiling score in association with the PD-L1 expression as biomarkers for treatment
selection in gastric/GEJ cancers. In pancreatic cancer, variable frequencies of endogenous CD8+
T cells, CD4+Foxp3− T cells, and CD4+Foxp3+ regulatory T cells (Treg) were reported. Notably,
these T cells were enriched within CD20+ lymphoid aggregates, with a trend toward longer survival
in those patients with tumoral Tertiary lymphoid structures [99]. In our cohort of 24 pancreatic ductal
adenocarcinomas receiving neoadjuvant GVAX®vaccination, which is a tumor vaccine composed of
autologous tumor cells genetically modified to secrete granulocyte–macrophage colony-stimulating
factor (GM-CSF), the ratios of CD8+ T cell to CD68+ T cell are favorable predictors of survival,
as reported in other malignancies [100,101]. Nevertheless, the above results need to be confirmed in
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future trials and more studies on whether and how TILs or effector T cells can be used to predict the
response to immunotherapy in gastrointestinal malignancies are warranted.
3.1.3. Immunosuppressive Myeloid Cells
Tumor-associated myeloid cells not only create a suppressive or anergic environment by
blocking T cell functions and proliferation, but also accelerate tumor growth by promoting cancer
stemness, angiogenesis, stroma deposition, epithelial-to-mesenchymal transition, and metastasis [102].
The accumulation of the intratumoral and circulating myeloid derived suppressive cells (MDSCs) has
been shown to be associated with disease progressiveness and prognosis in pancreatic adenocarcinoma,
hepatocellular carcinoma, and gastric cancer (Table 3) [102–106]. In our study evaluating 24 pancreatic
ductal adenocarcinomas from patients who received neoadjuvant GVAX vaccination, although,
essentially all of the tumors have induction of TILs and PD-L1 expression, the survival of patients
is correlated with the infiltration of myeloid cells [76]. Nevertheless, myeloid cells are also critical
for an innate immune response. It is unlikely that a single myeloid marker would be able to predict
the immune response. Multiplex biomarker assays will need to be developed for characterizing
immunosuppressive myeloid cells before a clinical assay can be used for predicting their response
to immunotherapy.
3.1.4. Intratumoral Stroma
The intratumoral stromal (ITS) proportion, composition, and activation status represent another
array of biomarkers for the disease prognosis. Stromal proportion, quantified by histopathological
microscopy analysis of the conventional hematoxylin and eosinstained slides, has been reported
to be independently associated with poor prognosis in several types of cancers, including gastric
cancer, esophageal, and colon cancers (Table 3) [107–111]. Wu et al. showed that the stromal gene
expression signature as well as the ITS proportion quantified by morphometry in tissue sections of
patient samples, correlated with the survival of gastric cancer patients in multiple independent cohorts.
Measuring the relative amount of ITS may enable the identification of subgroups of gastric cancer
patients that benefit from stroma-directed therapies [112]. More recently, transforming growth factor
beta (TGFβ) activated stroma was found to represent a primary mechanism of immune evasion that
engenders T cell exclusion and primary resistance to anti-PD-1–PD-L1 therapy in microsatellite-stable
(MSS) CRC. In murine models, the authors showed that the inhibition of TGFβ signaling in the
stoma with a TGF-β receptor 1 (TGF-βR1) specific inhibitor could lead to a potent anti-tumour
cytotoxic T cell response and prevent metastasis [113]. Admittedly, there are promising applications
in immunotherapies targeting intratumoral stroma and in combination with immune checkpoint
inhibitors, however, the identification of accompanying predictive features from intratumoral stroma
to enrich for populations that can benefit from combinational therapies are crucial. A summary of
biomarkers in the tumor microenvironment is depicted in Figure 1.
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Figure 1. Biomarkers in tumor microenvironment. PD-L1—programmed death-1 ligand-1.
3.2. Biomarkers in Tumor Genomics
3.2.1. Targeted Gene Panels
Targeted gene sequencing is an emerging approach for identifying potentially targetable genomic
biomarkers and matching them for treatments. However, a number of challenges remain. For example,
the Memorial Sloan Kettering Cancer Center has developed an (IMPAC) targeted gene sequencing
panel, which included 341 genes initially, and has expanded to 410 cancer-associated genes [114].
As reported, 10,945 tumors from 10,366 patients with advanced cancer were sequenced. Eleven percent
of the patients were enrolled in a genomically matched clinical trial. Among the 10,366 patients,
338 patients had pancreatic cancer. Five of these pancreatic cancer patients died before the results
were finalized. Potentially actionable findings were noted in 26% of these pancreatic cancer patients.
Nevertheless, only three of the 225 patients (1%) who would need treatments received matched
therapy based on the sequencing results [115]. Two had no benefit and one had an unknown response.
Therefore, the practical application of molecular results to guide individual patient treatment is
currently limited in patients with pancreatic adenocarcinoma.
3.2.2. Mutational Burden
The tumor mutational burden (TMB) has been shown to be significantly associated with a
clinical benefit to immune checkpoint blockade in various cancer types [6,11,13–15,35,116]. However,
most of the GI cancers have low mutation burdens [5], except those with MMR-deficiency. In a
cohort of 1375 patients across various GI tumors, colon cancer was reported to have the highest
TMB (mean: 11.6 and 9.9 mutations [mut]/megabase [MB]), whereas biliary cancers and pancreatic
adenocarcinomas had the lowest TMB (mean: 5.7 and 4.9 mut/MB) [117]. Using a cut-off of 17 mut/MB
to define high vs. low TMB, the high TMB was seen most frequently in right sided colon cancer (12%),
gastric cancer (11%), and anal cancer (8%), and least frequently in pancreatic cancer (1.3%) and
esophageal squamous cell carcinoma (0%). In addition, primary tumors, MSI-H and/or MSS with
POLE mutations were observed to have a higher TMB. Those with a higher frequency of somatic
mutations and tumor-specific neoantigens were found to have more abundant infiltration of CD8+ T
lymphocytes and a higher expression of regulatory molecules (CTLA-4, PD-1, Lymphocyte-activation
gene 3[LAG-3] and indolamine 2,3-dioxygenase 1 [IDO1]) [118].
3.3. Biomarkers in Liquid Biopsies
A tumor tissue biopsy would be necessary to establish the diagnosis; however, it would not be
feasible for monitoring the treatment response [119]. The analysis of biomarkers from peripheral blood,
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including the circulating tumor DNA (ctDNA), circulating tumor cells (CTC), and exosomes, using a
noninvasive approach known as liquid biopsy, has emerged as a way to overcome the restrictions of
tumor tissue biopsies and has exhibited a great potential of being used to detect the recurrence and
measure the treatment response [120].
3.3.1. ctDNA
ctDNAs are predominantly released as a result of the apoptosis or necrosis of actively growing
cancer cell, but can also be secreted directly from the circulating tumor cells [121]. Notably,
ctDNA can maintain tumor-specific genomic aberrations, including point mutations in tumor
suppressors and oncogenes, copy number variants, DNA methylation patterns, and chromosomal
rearrangements, providing a comprehensive genomic profiling for tumor evolution and dynamics
disease monitoring [119]. In CRC, ctDNA has been shown to successfully gather the real-time molecular
evolution in patients treated with EGFR targeted therapy [122,123]. The ctDNA analyses can not only
identify genetic alterations that are likely to be responsible for resistance to EGFR blockade, but also can
guide the selection of rare populations of patients who are likely to respond to targeted agents [124].
Changes of circulating tumor DNA (ctDNA) levels during therapy might also be an indicator of
clinical efficacy with ICIs. In a small prospective pilot study (n = 15), the ctDNA levels at week eight
showed synchronous changes with tumor size and as well as an association with PFS in various cancer
types [125]. In the chemotherapy setting, the RAS/BRAF mutations detected in ctDNA correlated with
a worse PFS in the metastatic CRC patients (n = 27) treated with first-line chemotherapy [126]. However,
the role of ctDNA in predicting the response to treatment needs to be validated in a larger population.
3.3.2. CTC
CTCs are surrogates of tumor cells in the bloodstream. CTC prevalence differs with cancer
type and stage. In patients with metastatic GI malignancies, CTC could be detected in 30–66% of
patients [127], and its presence has been shown to correlate with decreased OS or decreased PFS [128].
The value of CTCs as a therapeutic target to monitor the treatment response and detect relapse has
also been reported [129]. Nevertheless, the prognostic and predictive role of CTC is not established
in a non-metastatic setting, given the scarcity of CTC in this patient population [130,131]. On the
other hand, CTC recently demonstrated its value in monitoring the response to immunotherapy. In a
prospective cohort of 49 metastatic melanoma patients treated with ICI, a decrease in an RNA signature
score of CTC within seven weeks of therapy correlated with a marked improvement in PFS (hazard
ratio [HR], 0.17; p = 0.008) and overall survival (OS) (HR, 0.12; p = 0.04) [132]. The promising results
support the rationale to apply CTCs in monitoring the tumor burden in other cancer types such as
GI cancers.
Thus far, despite the interesting and promising results from small cohorts of studies on liquid
biopsy approaches as predictive or prognostic biomarkers, there is insufficient evidence of clinical
utility of the majority of ctDNA/CTC assays in either advanced cancer or early-stage cancer [133].
Discordance exists between the results of different platforms [134]. Prospective trials in large
populations will be required to establish the clinical utility of ctDNA and CTC.
3.3.3. Exosomes
Exosomes are endosome derived extracellular vesicles (EVs) ranging in 30–120 nm [135].
They carry a cargo of proteins, metabolites, RNAs (mRNA, miRNA, long non coding RNA),
DNAs (mtDNA, ssDNA, and dsDNA), and lipids [136], and represent an important source as a
biomarker from liquid biopsies. In pancreatic cancer, the glypican-1 (GPC1)+ endosomes were reported
as a diagnostic biomarker to distinguish healthy subjects and patients with a benign pancreatic disease
from patients with early- and late-stage pancreatic cancer, with absolute specificity and sensitivity.
The levels of the GPC1(+) endosomes correlated with the tumor burden and the survival of pre-
and post-surgical patients [137]. A rapid, highly sensitive, and widely usable detection method
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based on the amplified luminescent proximity homogeneous assay, using photosensitizer-beads for
cancer cell-derived EVs was proposed, with the utilization of monitoring the circulating EVs with the
antigen CD147 for the detection of colorectal cancer [138]. Although endosomes held great promise for
non-invasive early detection and target for potential therapeutics, it has several limitations. One of
the biggest challenges in exosome biology is how to accurately measure the quantity and purity of
the exosomes. Only a small subset of EVs carry the relevant communication content, thus its actual
efficiency may be difficult to detect. In addition, more knowledge of the specific markers of the EV
subtypes and fundamental roles of each type of EV is required to better inform their utilization in
various disease settings. The advantages and limitations of various liquid biopsy approaches are
summarized in Table 4.
Table 4. Advantages, disadvantages of ctDNA, CTC, and exosome as biomarkers.
Approaches Advantages Disadvantages References
ctDNA
Higher sensitivity; quick renew/short
half-life; maintain tumor-specific
genomic aberrations
Not suitable for functional assay, noises






study; potentials for therapeutic
targets
Low specificity, particularly in early





Higher sensitivity; higher serum
concentration; diverse EV contents;
Potential for therapeutic targets
Isolation and purification of exosomes;
specific exosome marker to identify
subset of EVs; not suitable for





There are only a handful of biomarkers used in clinics for the management of GI malignancies.
Although many new biomarkers have been identified for GI malignancies, their clinical assays have
not been validated. On the other hand, biomarker assays are highly demanded by a selection of
patients for appropriate treatment. Nevertheless, such a biomarker is often not conceived until a
clinical trial of experimental therapeutics fails to meet its endpoint because of a lack of patient selection.
The development of experimental therapeutics will not be advanced until an adequate biomarker
assay is established. Therefore, in the future, biomarker development should be done in parallel with
drug development. Whenever a potential therapeutic target is identified, a companion biomarker
assay should be developed. For immunotherapy, a single biomarker is often not sufficient in predicting
the treatment response. A comprehensive analysis of immune-biomarkers can not only provide the
rational design of combination immunotherapy, but can also identify multiple immune-biomarkers,
and subsequently develop a multiplex assay to co-evaluate multiple immune-biomarkers. In addition,
recent research on ion channels and aquaporins have suggested their function as possible modulators
of important processes in gastrointestinal carcinogenesis, including colorectal, pancreatic, gastric,
and esophageal cancers, as well as their potential as new cancer biomarkers once appropriately
validated [141–143].
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Abstract: It is estimated that early detection of pancreatic ductal adenocarcinoma (PDAC) could
increase long-term patient survival by as much as 30% to 40% (Seufferlein, T. et al., Nat. Rev.
Gastroenterol. Hepatol. 2016, 13, 74–75). There is an unmet need for reagents that can reliably
identify early cancerous or precancerous lesions through various imaging modalities or could be
employed to deliver anticancer treatments specifically to tumor cells. However, to date, many
PDAC tumor-targeting strategies lack selectivity and are unable to discriminate between tumor and
nontumor cells, causing off-target effects or unclear diagnoses. Although a variety of approaches have
been taken to identify tumor-targeting reagents that can effectively direct therapeutics or imaging
agents to cancer cells (Liu, D. et al., J. Controlled Release 2015, 219, 632–643), translating these reagents
into clinical practice has been limited, and it remains an area open to new methodologies and
reagents (O’Connor, J.P. et al., Nat. Rev. Clin. Oncol. 2017, 14, 169–186). G protein–coupled receptors
(GPCRs), which are key target proteins for drug discovery and comprise a large proportion of
currently marketed therapeutics, hold significant promise for tumor imaging and targeted treatment,
particularly for pancreatic cancer.
Keywords: G protein–coupled receptors; cholecystokinin; gastrin; gastrin-releasing peptide;
bombesin; neurokinin; neurotensin; somatostatin
1. Introduction
The utility of reagents to enhance tumor imaging or direct treatment often relies on tumor-targeting
ligands that bind to proteins that are overexpressed on the surface of malignant cells [1–3]. Tumor-directed
targeting can make use of antibodies, peptides, small molecules, or other moieties, and can result in a
higher cargo concentration either within or on the surface of tumor cells than would be attained without
targeting [4]. In pancreatic ductal adenocarcinoma (PDAC), development of targeted therapies has
focused on receptor tyrosine kinases (RTKs) or their downstream pathways, with limited efficacy [5].
G protein-coupled receptors (GPCRs) represent an opportunity to develop new targeted therapeutics
and imaging agents for pancreatic cancer [6] (Figure 1).
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Figure 1. Pancreatic tumor cell surface membrane with G protein–coupled receptors (GPCRs) can be
targeted with a variety of reagents, including antibodies (depicted as dye-conjugated) or antibody
fragments, aptamers, or small peptides. Additionally, novel bi- or multivalent combinations of targeting
agents exhibit promise as tools for imaging and treatment. Targeting agents are not drawn to scale.
2. G Protein-Coupled Receptors
GPCRs are plasma membrane proteins composed of seven transmembrane-spanning α-helices
linked by three intracellular and three extracellular loop regions, an extracellular amino-terminal
domain, and an intracellular carboxyl-terminal domain. Classical GPCR signaling is initiated by a
ligand interacting with extracellular receptor loop/transmembrane domain residues, which form
a ligand-binding pocket. This interaction triggers a conformational change in the receptor that
initiates binding and activation of intracellular heterotrimeric G proteins. The exchange of guanosine
diphosphate (GDP) for guanosine triphosphate (GTP) on the G alpha subunit dissociates G alpha
from the G beta/gamma subunits and activates numerous downstream effector pathways [7,8].
Receptor activation is followed by desensitization and internalization. Once activated, GPCRs are
phosphorylated by G protein kinases (GPKs), and cytosolic β-arrestins can then bind to the GPCRs,
competing with the GPCR-G protein interaction and downregulating G protein-mediated signaling.
The GPCR/β-arrestin complex can follow one of the endocytic pathways [9], in which GPCRs can
either be recycled back to the plasma membrane or sent to the lysosomes for degradation [10].
GPCRs play an important role in cancer progression, and these proteins have been utilized as
therapeutic and imaging targets. Since many chemotherapeutic agents are only active intracellularly,
transmembrane transport of targeted cargos is a key issue. Unlike single transmembrane spanning
proteins, which are often cleaved by proteases such as matrix metalloproteases (MMPs) to release their
ectodomains [11,12], ligand-induced GPCR internalization improves intracellular bioavailability of
the cargo. GPCR recycling also provides cell membrane–associated targets for additional rounds of
internalization. Increased expression and activity of GPCRs is evident at all stages of PDAC tumor
development, and GPCRs contribute to tumor cell proliferation, tumor progression through stimulation
of angiogenic and metastatic cascades, and the creation of a proinflammatory tumor microenvironment
and evasion of immune cell recognition [13].
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Recent evidence suggests that mutations in GPCRs and their associated G proteins are common
in tumors—approximately 20% of all cancers contain mutated GPCRs or G alpha subunits [14].
For example, defects that impact GPCR trafficking can contribute to receptor retention at the cell surface
and altered downstream signaling. Activating mutations in GPCR-associated proteins, particularly
GNAS, which encodes the Gs-alpha subunit, can be present in up to 12% of pancreatic tumors [10,14].
Reduced GTPase activity leads to constitutive signaling that can drive tumor progression. In addition,
crosstalk between GPCR and RTK signaling pathways can stimulate receptor transactivation and has
been linked to oncogenic Kras activation in early-stage PDAC [15,16].
GPCRs mediate a broad range of autocrine and paracrine responses in cancer cells. They bind
to a diverse group of ligands, including small peptides (e.g., gastrointestinal hormones), lipids
(e.g., sphingosine-1-phosphate, prostaglandins), and proteins (e.g., chemokines) [8]. The density
of GPCRs on the cell surface is typically 103–104 receptors/cell, which should be adequate to ensure
ample uptake of the targeted drug cargo or to bind sufficient imaging reagents to achieve quality
images [17,18]. Herein, we focus on the peptide hormone–ligand subfamily of GPCRs and their use in
developing reagents to identify and treat pancreatic cancer.
3. CCKRs
The peptides gastrin and cholecystokinin (CCK) activate two structurally related G protein-coupled
receptors, the CCK1 receptor (CCK1R) and CCK2 receptor (CCK2R), which are expressed by many
PDAC tumors [19]. Although highly homologous, with 50% overall identity, these receptors differ in
their ligand-binding specificities and inhibitor profiles [20]. CCK1R binds with high affinity to CCK-8
amide with a sulfated tyrosine. CCK2R binds gastrin and CCK with similar affinity and does not
discriminate between sulfated and nonsulfated CCK, as binding is directed by the final four amino
acids of these peptides (Trp-Met-Asp-Phe-NH2, although leucine or norleucine can be interchanged for
methionine to improve stability without altering binding affinity) [21]. Functionally, CCK2R expressed
on pancreatic tumors plays a role in tumor cell proliferation and angiogenesis [22].
Beginning in the late 1990s, many groups explored the use of CCK1R and CCK2R for tumor
imaging and treatment. While anti-CCK2R antibodies have been developed [23,24], most targeting
reagents have been peptide analogs of either CCK or gastrin. With a radionuclide chelator attached
to the N-terminus of CCK or gastrin peptide analogs, a variety of reagents have been created for
tumor imaging and radiotherapy, including CCK-8, gastrin 10, mini-gastrin, gastrin dimers, and cyclic
gastrin analogs [25–31]. Although tumor uptake relative to other tissues was good, the ability of the
peptide-targeted constructs to deliver cargo to tumors was limited by high proteolytic turnover in
serum, often with less than 10% of the reagent remaining in circulation 10 minutes post-injection [32].
One approach to extending the half-life of gastrin- or CCK-based reagents has been to inhibit the
activity of the protease responsible for gastrin/CCK degradation, neutral endopeptidase (NEP).
Co-injection of the NEP inhibitor phosphoramidon with gastrin analogs increased their half-life in
circulation and improved tumor uptake [33–35]. Finally, nanoparticles can be bioconjugated with
gastrin peptide to improve tumor-specific uptake. Attaching gastrin 10 to fluorescent dye–loaded
calcium phosphosilicate nanoparticles enhanced particle uptake by orthotopic pancreatic tumors in a
murine model [36].
4. GRP/Bombesin Receptors
This family of peptide receptors contains gastrin-releasing peptide receptor (GRPR), neuromedin
B receptor (NMBR), and bombesin receptor subtype 3 (BRS3), which are overexpressed by a number
of cancers, including PDAC [37]. PDAC cells have previously been targeted with a GRPR ligand
radiolabeled for positron emission tomography (PET) imaging, or conjugated with Gd3+ for magnetic
resonance imaging (MRI) [38,39]. Human gastrin releasing peptide (GRP) as well as mammalian
bombesin (BN), which differ by only 1 out of 10 amino acids, have been utilized for GRP- or BN-drug
conjugates with paclitaxel or docetaxel. Compared to free drug, the peptide-drug conjugates resulted
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in enhanced cytotoxicity in vitro [40–42]. However, the efficacy of these compounds against pancreatic
tumors in vivo remains unclear [43].
5. Neurokinin Receptors
The neurokinin-1 receptor (NK1R) and its peptide ligand, substance P (SP), regulate many
tumor cell processes, including proliferation, angiogenesis, migration, invasion, and metastasis [44].
NK1R is upregulated in human pancreatic tumors, especially in advanced tumors with poor
prognosis, and has recently been implicated in perineural invasion of PDAC tumors [45]. In mice,
a subpopulation of PanIN epithelial cells express NK1R. Evidence suggests that these are acinar
cell–derived neoplastic PanIN epithelial cells, opening the potential for using NK1R-targeted imaging
for detection of early lesions [46]. Tumor imaging using an NK1R-targeted fluorescent dye has been
used during surgery to facilitate identification and resection of NK1R-positive lesions [47,48]. In PET
imaging, 64Cu-NK1R-NOTA is a promising reagent for identifying NK1R-expressing tumors [49], and
NK1R-targeted cytotoxic drugs are also under development [50].
6. Neurotensin Receptors
Neurotensin receptor (NTS1) has been identified on several PDAC cells lines, in human PDAC
tissues, and in late-stage PanINs and PDAC liver metastases, with lower expression in chronic
pancreatitis [51,52]. NTS1 binding of the ligand neurotensin (NT) activates mitogenic signaling,
while a selective NTS1 antagonist, SR 48692, reduces PDAC cell proliferation [53,54]. Because NT
interacts with the NTS1 receptor with high affinity and only the six C-terminal amino acids of NT are
required for receptor binding, bioconjugation of NT peptide to a variety of reagents holds potential for
improving their delivery to NTS1-expressing tumors [17]. Biodistribution studies using NT-targeted
probes in PDAC tumor–bearing mice showed high tumor-specific uptake of 68Ga-labeled NT peptides
in vivo [55]. In addition to NT peptides, NTS1 small-molecule antagonists labeled with 18F and
177Lu also demonstrated tumor cell internalization and retention in vivo with low kidney and liver
uptake [56,57]. Liposomes functionalized with a branched neurotensin peptide, NT4, and loaded with
doxorubicin have been assessed for antitumor cell efficacy in vitro [58].
Interestingly, recent evidence shows that there is crosstalk between the insulin/IGF-1 receptor
and NT/NTS1 signaling pathways, which leads to activation of the oncogenic YAP/TAZ pathway.
Stimulation of PDAC cells with both insulin and neurotensin results in nuclear localization of YAP,
decreased YAP phosphorylation, and increased expression of YAP/TEAD-regulated genes, while
treatment with either insulin or neurotensin alone only modestly induced the expression of these
genes [59]. This suggests that either antagonism of NTS1 or blockade of downstream signaling
pathways connecting to YAP could a be promising therapeutic target for PDAC [60].
7. Somatostatin Receptors
Somatostatin receptor (SSTR) subtypes SSTR2, SSTR3, and SSTR5 are present in human PDAC
tumors based on mRNA expression [61,62]. The short half-life of somatostatin (SST) prompted the
development of several peptide analogs for therapeutic and imaging purposes, the most clinically
relevant of which is octreotide (OCT). This eight-amino-acid peptide binds to SSTR2 with high affinity
and triggers receptor endocytosis [18,63,64]. OCT-drug conjugates, created by direct coupling of
camptothecin or paclitaxel to the N-terminus of the peptide, were cytotoxic to cancer cell lines that
overexpressed SSTR2 [65] and induced regression of subcutaneous CFPAC-1 tumors in athymic
mice [66]. More recently, a reagent that combined MRI/optical imaging capability and a synthetic
peptide (PTR86) with high affinity for somatostatin receptors showed efficient imaging and targeting
of pancreatic tumors [67]. An SST analog dual-labeled with a radionuclide and fluorescent dye has
recently been evaluated in a preclinical colon cancer model system [68].
Interestingly, a PDAC-specific interaction between two GPCRs, the mu opioid receptor (MOR)
and SSTR2, has recently been identified [69]. The presence of this GPCR heterodimer correlated with
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increased oncogenic signaling and tumor progression and antagonists to either receptor triggered
heterodimer internalization. This suggests that the MOR-SSTR2 heterodimer may represent a unique
PDAC-specific target. Investigation of other novel GPCR heterodimers in PDAC may uncover new
opportunities for therapeutic targeting with higher tumor cell specificity.
8. Dual-Targeted Agents
A challenge for the development of tumor-targeted drug delivery or imaging is the level at
which the target protein is expressed. It is well documented that PDAC tumors and metastatic lesions
are heterogeneous with regard to their expression of GPCRs and other cell-surface receptors [70].
Dual-targeted reagents are capable of targeting different GPCRs simultaneously, or a GPCR and
another extracellular protein. These reagents can achieve better specificity than targeting the proteins
individually. Dual-targeting agents also can provide better sensitivity through a greater number of
potential tumor cell binding sites, thus enabling clearer visualization of cancerous lesions or improved
drug delivery [71].
Simultaneous targeting of two independent GPCRs was achieved using a peptide that combined
ligands for the CCK2 receptor and the melanocortin 1 receptor (also known as MC1R) [72]. This bivalent
reagent joins seven amino acids from melanocortin to the CCK-4 tetrapeptide via a synthetic
fluorescently tagged linker. In vitro, the hybrid ligand was able to bind both cell-surface receptors,
demonstrating a 12-fold higher specificity for cells expressing both receptors. The ability of the bivalent
ligand to improve the imaging of tumors in vivo was confirmed using tumor cell lines engineered to
express either the MSH receptor, CCK2 receptor, or both.
Dual targeting can also exploit a target protein on a nonmalignant cell type within the tumor
microenvironment (TME) in addition to a tumor-cell GPCR. Demonstrating this strategy, bombesin
was fused to an RGD peptide motif, thereby targeting both a GPCR and integrin αvβ3 on tumor
endothelial cells [73]. The resulting 68Ga-labeled heterodimeric peptide has been successfully employed
in PET imaging. A second example, while not targeting a GPCR, demonstrates the utility of bivalent
targeting. Pancreatic tumor xenografts were imaged using a heterodimer of antibody fragments
targeting CD105 on the tumor vasculature and tissue factor (TF) on tumor cells [74,75]. Further
explorations of multivalent combinations of a GPCR-targeted ligand with other TME targets would
constitute novel advancements.
9. Nonpeptide Targeting to GPCRs: Aptamers
RNA and DNA aptamers are single-stranded, structured oligonucleotides that have promise for
both targeted tumor imaging and drug delivery while avoiding some of the common disadvantages
of peptide and antibody targeting [76]. Targeting with antibodies can be associated with a risk of
inappropriate immune response, while peptides are typically susceptible to proteolytic degradation
in the systemic circulation, making them unsuitable for many in vivo applications. Small molecules
such as antagonists, while having a well-defined chemical structure and good stability, can have
low target selectivity or rapid clearance in vivo [3]. Aptamers have a reproducible structure and can
be easily modified to resist nucleases, can be synthesized at a lower cost, are stable to changes in
temperature and pH, and can refold spontaneously once conditions normalize. They have fewer
nonspecific interactions in the systemic circulation, are less immunogenic, and display high binding
affinity to targets with dissociation constant (Kd) values in the nanomolar range. Due to their low
molecular weight (25–70 nucleotides is equivalent to 8–20 kDa), aptamers can also penetrate tumor
tissues more efficiently than antibodies or Fab fragments [77,78].
Aptamers can be attached to a variety of payloads, including small interfering RNAs (siRNAs),
cytotoxic drugs, or nanoparticles, which improves the selective delivery and efficacy of the cargo [79–82].
Tumor-targeting aptamers have been selected for cell-adhesion molecules such as EpCAM, tyrosine kinase
receptors, mucins, and other cell-surface proteins [83]. For example, EGFR-targeted aptamers conjugated
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to gold nanospheres have been successfully used to image head and neck tumors [84]. Aptamer-based
imaging agents and aptamer-targeted therapeutics are now moving into clinical trials [85].
Our research team has identified and characterized aptamers against the GPCR CCK2R. Using a
SELEX-based library selection protocol, we selected aptamers that bound to both a synthetic peptide
contained within the extracellular N-terminal domain of the CCK2R and PDAC cells expressing
CCK2R in its native conformation. Negative selection with non–CCK2R-expressing cells ruled
out nonspecific interactors. Overall, we identified a pool of >100 high-affinity DNA aptamers that
specifically recognized the extracellular N terminus of the human CCK2R [86]. Quantitatively, we have
shown that one of the selected CCK2R aptamers (AP1153) has a 300-fold higher affinity for CCK2R
than its native peptide ligand, gastrin. As evidence for its utility as a pancreatic tumor targeting agent,
we demonstrated that AP1153 was internalized by PDAC cells in a receptor-mediated fashion, and that
bioconjugation of AP1153 to the surface of fluorescent nanoparticles enhanced whole-animal optical
detection of PDAC tumors in vivo. Others have identified aptamers that bind to the GPCR NTS1,
although their further development for diagnostic or therapeutic use has not yet been shown [87].
Finally, aptamers can have direct therapeutic benefit as antitumor reagents. A variety of RNA
aptamers that bind to β2-adrenoceptor (β2AR), a non–peptide-liganded GPCR, have been shown to
stabilize this receptor in active, inactive, or ligand-specific conformations [88]. Similar to neutralizing
antibodies, aptamers can block the interaction between ligand and receptor. Although not directed
toward a GPCR, anti–PD-L1 aptamers block the PD-1/PD-L1 signaling axis, reducing tumor growth
and improving immune surveillance [89]. An anti–CTLA-4 aptamer has also shown promise for
delivering siRNA cargo. The lack of therapeutic efficacy of siRNA-mediated gene silencing is due
in part to low siRNA internalization by tumor cells [90]. Conjugation of an anti–CTLA-4 aptamer
to a STAT3 siRNA helped to overcome this limitation and achieved STAT3 gene silencing in both
tumor-associated T cells and tumor cells [91,92]. GPCR-binding aptamers that disrupt ligand-receptor
interactions and abrogate downstream GPCR signaling, or that improve delivery of either siRNAs or
drug-loaded nanoparticles to tumors, could have application as new PDAC therapeutics [76].
10. Conclusions
Earlier detection and targeted therapies for pancreatic cancer will undoubtedly improve patient
survival [93,94]. However, developing reagents capable of specifically targeting tumors for imaging and
drug delivery remains a significant challenge. GPCRs represent a class of tumor cell surface proteins
with well-characterized ligands, well-understood pathways for internalization and recycling, and
well-documented signaling capabilities, including crosstalk with other oncogenic signaling pathways.
Identifying and validating GPCR-specific imaging or therapeutic reagents could provide new tools
to make clinically significant improvements in PDAC patient care and achieve the goal of improving
survival rates for patients battling this disease.
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Abstract: Palliative chemotherapy is the mainstay of treatment of advanced gastric carcinoma (GC).
Monoclonal antibodies including trastuzumab, ramucirumab, and pembrolizumab have been shown
to provide additional benefits. However, the clinical outcomes are often unpredictable and they can
vary widely among patients. Currently, no biomarker is available for predicting treatment response
in the individual patient except human epidermal growth factor receptor 2 (HER2) amplification and
programmed death-ligand 1 (PD-L1) expression for effectiveness of trastuzumab and pembrolizumab,
respectively. Multi-platform molecular analysis of cancer, including GC, may help identify predictive
biomarkers to guide selection of therapeutic agents. Molecular classification of GC by The Cancer
Genome Atlas Research Network and the Asian Cancer Research Group is expected to identify
therapeutic targets and predictive biomarkers. Complementary to molecular characterization of GC
is molecular profiling by expression analysis and genomic sequencing of tumor DNA. Initial analysis
of patients with gastroesophageal carcinoma demonstrates that the ratio of progression-free survival
(PFS) on molecular profile (MP)-based treatment to PFS on treatment prior to molecular profiling
exceeds 1.3, suggesting the potential value of MP in guiding selection of individualized therapy.
Future strategies aiming to integrate molecular classification and profiling of tumors with therapeutic
agents for achieving the goal of personalized treatment of GC are indicated.
Keywords: Asian Cancer Research Group (ACRG); gastric carcinoma; molecular profiling; precision
therapy; pembrolizumab; predictive biomarkers; ramucirumab; The Cancer Genome Atlas (TCGA);
therapeutic targets; trastuzumab
1. Introduction
With about a million diagnosed cases and over 700,000 deaths recorded annually, gastric carcinoma
(GC) is the third most common cause of cancer deaths worldwide [1]. While 80 to 90% of tumors
develop sporadically, hereditary factors also contribute to gastric carcinogenesis [2]. The incidence
is strongly influenced by ethnicity, diet, and infectious agents [3–6]. In particular, Helicobacter pylori
(H. pylori) and human papilloma virus (HPV) are involved in multi-step processes causing chronic
gastritis, intestinal metaplasia, and invasive carcinoma [7–9]. Population-based screening and
treatment of H. pylori and HPV would be a logical strategy for prevention of some types of GC,
but no randomized trial to date has shown a clear benefit of this approach [10]. Until a preventive
intervention is implemented, it is imperative that effective and tolerable therapies are developed in
attempt to attenuate the global burden of GC.
Systemic chemotherapy and targeted therapy play important roles in the multi-disciplinary
management of GC. With the exception of GC diagnosed at T1 stage, chemotherapy is employed in
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the neoadjuvant and adjuvant settings, or concurrent with radiation therapy. Palliative combination
chemotherapy and targeted therapy are the only treatment options for patients with advanced or
metastatic GC. Selection of chemotherapeutic drugs is typically based on performance status, medical
comorbidities, and medical oncologist’s experience or preference. There are no valid biomarkers
predictive of treatment response of GC to therapeutic agents. Exceptions are, amplification of human
epidermal growth factor receptor 2 (HER2) and expression of programmed death-ligand 1 (PD-L1),
for which trastuzumab and pembrolizumab, respectively, have been demonstrated to produce clinical
benefit [11,12]. Preliminary evidence has indicated that variable responses to treatment can be
attributed to tumor heterogeneity with regard to molecular alterations [13]. Recently, two classification
systems of GC using multi-platforms of molecular analyses have been developed, and they provide
new insights into tumor heterogeneity of GC.
The genomic characterization of GC has led to the development of two new classifications of
GC by The Cancer Genome Atlas (TCGA) Research Network [14] and the Asian Cancer Research
Group (ACRG) [15]. These may serve as a valuable diagnostic companion to the conventionally
used classification systems of GC based on histopathology by World Health Organization [16]
and Lauren [17]. Importantly, TCGA and ACRG are expected to facilitate the development of
personalized prognostication and treatment, as well as improved patient stratification for clinical trial
design. Moreover, molecular profiling of GC has been accomplished through immunohistochemistry
(IHC), in situ hybridization (ISH), genomic DNA sequencing, proteomics, and microRNA expression.
The tumor molecular profiles can potentially be developed into predictive biomarkers of treatment
that could help guide selection of cytotoxic drugs and targeted therapeutics.
The goal of this article is to provide a critical review of the molecular characterization of GC,
and elaborate on the molecular features that can be translated into therapeutic biomarkers and targets
for clinical use. First, we provide an overview of the conventionally used systemic chemotherapy and
targeted therapeutics of GC. The data on molecular classification of GC by TCGA and ACRG as well as
molecular profiling of GC are examined. The potential of translating the molecular classification and
profiling of GC into therapeutic targets and predictive biomarkers are discussed. We hope that this
article will help identify the opportunity and challenge of developing strategies towards the goal of
precision medicine in GC by improving therapeutic efficacy and minimizing treatment-related toxicity.
2. Systemic Treatment of Gastric Carcinoma
Systemic chemotherapy is employed for treatment of patients with localized GC as well
as for those with advanced GC. Surgical resection with pre- and post-operative chemotherapy
and/or radiation therapy represents the primary curative treatment of early-stage GC with 5-year
survival rate of less than 30% [18–20]. For patients with advanced unresectable or metastatic
disease, palliative systemic therapy and chemoradiation therapy are the standard treatment options.
The chemotherapeutic regimens used for patients with advanced or metastatic GC are essentially the
same as those for peri-operative treatment of patients with localized GC. In addition, for advanced or
metastatic GC, trastuzumab is indicated to use in combination with HER2 amplified GC as first-line
treatment; ramucirumab either as monotherapy or in combination with paclitaxel is indicated as
second-line treatment; pembrolizumab has recently been approved as 3rd-line treatment for GC
expressing PD-L1. A number of targeted therapeutics is being investigated in clinical studies.
2.1. Chemotherapy
Chemotherapeutic regimens currently being used for GC consist of anthracycline,
fluoropyrimidine, taxane, and platinum-based agents. For advanced or metastatic GC, first-line
combinations such as EOX (epirubicin, oxaliplatin, capecitabine) and DCF (docetaxel, cisplatin,
5-fluorouracil (5-FU) have produced limited survival benefits, with median survival not exceeding
one year (Table 1). Second-line agents such as docetaxel or irinotecan can lead to slight improvement
of survival. For most patients, GC may initially respond to chemotherapy. However, the tumors will
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typically become resistant, such that the prognosis of patients with advanced disease remains poor.
Currently, there is no clinically available predictor of tumor response to the empiric use of these drug
combinations [21].
Table 1. Major phase III clinical trials of first-line cytotoxic agents in metastatic/advanced gastric carcinoma.
Treatment Patients (n) RR (%) PFS (months) OS (months) Reference
CF vs. DCF 224 vs. 221 25 vs. 37 3.7 vs. 5.6 (* p < 0.001) 8.6 vs. 9.2 (* p < 0.02) [22]
ECF vs. ECX vs. EOF
vs. EOX
263 vs. 250 vs. 245
vs. 244
38 vs. 41 vs. 40
vs. 47
6.2 vs. 6.7 vs. 6.5 vs.
7.0 (NS)
9.9 vs. 9.9 vs. 9.3 vs.
11.2 (NS) [23]
5-FU + LV + cisplatin vs.
5-FU + LV + oxaliplatin 112 vs. 106 25 vs. 34 3.9 vs. 5.8 (NS) 8.8 vs. 10.7 (NS) [24]
Cisplatin + 5-FU vs.
Cisplatin + S-1 508 vs. 521 31 vs. 29 5.6 vs. 5.3 (NS) 7.9 vs. 8.6 (NS) [25]
CF, cisplatin/5-fluorouracil (5-FU); DCF, docetaxel/cisplatin/5-FU; ECF, epirubicin/cisplatin/5-FU; ECX,
epirubicin/cisplatin/capecitabine; EOF, epirubicin/oxaliplatin/5-FU; EOX, epirubicin/oxaliplatin/ capecitabine;
LV, leucovorin; NS, not statistically significant; OS, overall survival; * p < 0.05, statistically significant; PFS,
progression-free survival; RR, response rate.
2.2. Targeted Therapy
Despite the clinical heterogeneity and molecular complexity of GC, targeted therapeutics directed
against the genetic mutations and signaling pathways that drive tumor growth and invasion have been
developed and clinically investigated. Targeted therapies currently in clinical use include trastuzumab,
ramucirumab, and pembrolizumab. Other targeted therapeutics directed against the signaling
pathways of mitogenesis, angiogenesis, and immune checkpoints are under clinical investigation
for treatment of GC.
2.2.1. Mitogenic Signaling Pathways as Therapeutic Targets
Human epidermal growth factor receptor (HER2, also known as ErbB2) is a transmembrane
tyrosine kinase receptor of the ErbB family. The ErbB members play important roles in regulation of
cellular functions including proliferation, growth, survival, adhesion, migration, and differentiation.
HER2 acts by heterodimerization with other ErbB family receptors leading to activation of the
RAS-MAPK (mitogen-activated protein kinase) and PI3K-AKT (phosphatidylinositol 3-kinase—AKT)
pathways. HER2 has been found to be over-expressed in 20% to 30% of GC depending on the tumor
subtype and location.
Several HER2-targeting agents have been developed and evaluated in phase III trials for patients
with advanced HER2-positive gastroesophageal junction carcinoma (GEJC)/GC. Trastuzumab is
a humanized IgG1 monoclonal antibody (mAb) directed against the extracellular domain of HER2,
and it prevents dimerization of the HER2 receptors. This triggers receptor internalization and mediates
antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in inhibition of tumor growth [26].
In the phase III ToGA trial, the combination of trastuzumab and cisplatin/fluoropyrimidine-based
chemotherapy was compared to chemotherapy alone as first-line therapy for advanced HER2-positive
GEJC/GC. Results of this study indicated a significant improvement in the overall response rate (ORR;
47% vs. 35%; p < 0.01) as well as prolonged progression-free survival (PFS; 6.7 months vs. 5.5 months,
p < 0.01) and overall survival (OS; 13.8 months vs. 11.1 months; p < 0.01) [11]. Based on the results
of this study, the combination of trastuzumab with platinum/fluoropyrimidine-based chemotherapy
has become the standard of care for advanced HER2-positive GEJC/GC. However, the treatment
response was not durable, as the benefit from trastuzumab was noted to have diminished considerably
in an updated survival analysis, with an increased hazard ratio (HR) from 0.73 to 0.80, and narrowed
OS difference to 1.4 months. These data suggest considerable heterogeneity among patients with
HER2-positive GEJC/GC, possible treatment resistance, and need to refine and optimize biomarker
selection criteria for future clinical trials. A recent report shows that trastuzumab conjugated with
nanoparticle albumin-bound paclitaxel produced enhanced anti-tumor effect in a mouse xenograft of
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HER2-positive gastric cancer cells [27]. Further investigation of this antibody-nanoparticle conjugate
in patients may raise hope for a novel form of targeted therapy in HER2-positive GC.
2.2.2. Signaling Pathways in Angiogenesis as Therapeutic Targets
Several signaling pathways are involved in tumor-associated angiogenesis, such as those activated
by vascular endothelial growth factor (VEGF) [28], angiopoietins and angiopoietin-like proteins [29,30],
platelet-derived growth factor (PDGF) [31], basic fibroblast growth factor (FGF) [32], fibroblast
activation protein and hepatocyte growth factor [33], and Wingless-related integration site (WNT) [34].
These growth factors and their receptors have been investigated for therapeutic targeting in various
types of malignant tumors. Antibodies directed against VEGF and VEGF receptor (VEGFR) have been
shown to produce anti-tumor efficacy and they are used in combination with cytotoxic chemotherapy
as standard first- or second-line treatment of certain solid tumors.
VEGF is a growth factor secreted by the tumor to stimulate formation of new blood vessels in
response to hypoxia and nutrient depletion. When it binds to VEGFR, a complex cascade of downstream
signaling pathways is activated, resulting in neovascularization, vasodilation, and increased vascular
permeability [28]. Blockade of VEGF and/or VEGFR impedes these pathways and thereby inhibits tumor
survival, migration, and invasion. VEGF and its receptors are over-expressed in approximately 30%
to 40% of all GEJC/GC [35,36], and anti-angiogenic agents targeting VEGF and VEGFR have shown
therapeutic efficacy in GEJC/GC.
Ramucirumab is a recombinant humanized monoclonal antibody (mAb) that binds to VEGF-R2
and prevents its activation by VEGF. In contrast to bevacizumab (anti-VEGFA mAb), it has shown
clinical efficacy as a single agent (REGARD trial) and in combination with paclitaxel (RAINBOW trial).
Based on the results of these studies, ramucirumab either alone or in combination with paclitaxel has
become standard second-line treatments for advanced GEJC/GC. In the REGARD trial, ramucirumab
was associated with a significant improvement in OS (5.2 months vs. 3.8 months, p = 0.0473) and
PFS (2.1 months vs. 1.3 months, p < 0.0001) in patients previously treated with first-line platinum-
or fluoro-pyrimidine-based therapy [37]. In the RAINBOW study, the combination of ramucirumab
and paclitaxel produced significant improvement in OS (9.6 months vs. 7.4 months, p = 0.0169),
PFS (4.4 months vs. 2.9 months, p < 0.0001), and ORR (28% vs. 16%, p = 0.0001) compared with
those treated with paclitaxel alone [38]. However, the clinical benefit of ramucirumab with or without
paclitaxel is limited, and there is no biomarker available to predict tumor response to these treatments.
2.2.3. Immune Checkpoint Molecules as Targets for Therapy
The programmed death-ligand 1 (PD-L1) and 2 (PD-L2) are normally expressed on antigen-presenting
cells (APC) and also on tumor cells. Binding of PD-L1 and PD-L2 to their receptors (PD-1) on activated
T cells leads to downregulation of cytotoxic T-cell activity and causing immunosuppression. PD-L1 is
expressed in 15% to 70% of GCs, and they are associated with poor prognosis [39]. Pembrolizumab and
nivolumab are humanized mAbs directed against PD-1, and they enhance the ability of the immune
system to detect and destroy cancer cells. By blocking the interaction between PD-1 and PD-L1/L2,
pembrolizumab or nivolumab counters the tumor’s immune-escaping tactic.
In the phase Ib KEYNOTE-012 trial, the activity and safety of pembrolizumab were evaluated in
a cohort of 39 patients with advanced GEJC/GC. Pembrolizumab produced an ORR of 22.2%, 6-month
PFS rate 24%, and OS rate 69% [40,41]. An association between higher levels of PD-L1 expression and
ORR (p = 0.102), PFS (p = 0.162), and OS (p = 0.124) was observed. In a phase II study (KEYNOTE-059)
of 259 patients, pembrolizumab monotherapy showed clinical efficacy in previously treated advanced
GEJC/GC [12]. For patients with PD-L1 positive tumors, pembrolizumab produced an ORR of 15.5%,
whereas in patients with PD-L1 negative tumors, 6.4%. In patients with microsatellite-high (MSI-H),
ORR was 57.1%; in those with non-MSI-H tumors, ORR 9.0%. These data demonstrate the value of
PD-L1 and MSI-H as predictive biomarkers for efficacy of pembrolizumab. In the cohort 2 of this study,
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the efficacy and safety of pembrolizumab in combination with cisplatin and 5-fluorouracil (5-FU) will
be assessed.
3. Molecular Classification and Profiling of Gastric Carcinoma
Advances in next-generation sequencing (NGS) technologies and improved understanding of
cancer biology have unlocked opportunities to characterize the genomic landscape of cancer including
GC. Using multi-platform analyses, molecular profiling of GC has enabled The Cancer Genome
Atlas (TCGA) Research Network and the Asian Cancer Research Group (ACRG) to classify GC into
subtypes. The new molecular classification of GC is complementary to the conventionally used
system of subtyping GC based on histopathology. Importantly, molecular classification of GC helps
identify molecular alterations that may be targeted for therapy. Furthermore, molecular profiling of
GC collected from individual patients using a multi-platform approach has offered new opportunity
to identify biomarkers that may be predictive of tumor response to treatment [42–44].
3.1. TCGA Sub-Typing of Gastric Carcinoma: Potential Therapeutic Targets
Molecular classification of GC by the TCGA Research Network utilized six distinct platforms,
including exome sequencing, copy number analysis, methylation, expression of miRNA and mRNA.
Based on TCGA molecular data, GC were divided into four groups: Epstein–Barr virus-positive (EBV;
9%), microsatellite instability (MSI; 22%), chromosomal instability (CIN; 50%), genomically stable (GS;
20%) (Figure 1). Each of these GC subtypes is characterized by distinct features that provide prognostic
information and suggest potential benefit of targeted therapy.
Figure 1. The four molecular subtypes described in the TCGA study, their mutational patterns,
and location. CIN, chromosomal instability; EBV, Epstein–Barr virus; GE, gastroesophageal junction;
GS, genomically stable; MSI, microsatellite instability. This figure is reproduced from reference [14]
with permission from the Nature Publishing Group.
The EBV-positive tumors were found to be mainly located in the gastric fundus or body.
They exhibited higher prevalence of DNA promoter hypermethylation, A to C transversions, PIK3CA
mutation, recurrent JAK2 and ERBB2 amplifications, interleukin-12 (IL-12) mediated signaling,
and PD-L1/2 overexpression. The presence of viral antigens such as EBV (a hallmark of 9% of
GCs) has been shown to result in increased neo-epitope presentation [14], which might contribute to an
anti-tumor immune response. Moreover, the strength of IL-12 mediated signaling signature suggests
a robust immune cell presence, which when coupled with evidence of PD-L1/2 overexpression,
provides support for targeted immunotherapy. PD-L1/2 may therefore represent promising targets in
these tumors and initial promising results have been reported with pembrolizumab [40,41]. In addition,
the strong predilection for mutation in PIK3CA (80%) suggests that inhibition of PI3K warrants further
evaluation in EBV-positive GC.
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The MSI tumors, characterized by genomic instability due to a deficient DNA mismatch repair
system, lacked targetable amplifications. This subtype of tumors was noted to have hypermethylation
in the MLH1 promoter region (leading to MLH1 silencing), and targetable hotspot mutations in PIK3CA,
ERBB3, ERBB2, and EGFR. Of note, the BRAFV600E mutation commonly seen in MSI colorectal cancer
was absent. However, gastric MSI tumors had a high rate of PD-L1 expression. In particular, recent
evidence shows that enhanced anti-PD-1 responsiveness of mismatch repair-deficient tumors is related
to the high number of mutation-associated neoantigens [45].
The CIN tumors were more frequent in the gastro-esophageal junction/cardia. They were noted
to have the highest frequency of TP53 mutations (71%), as well as genomic amplifications of RTKs and
cell cycle mediators. Phosphorylation of EGFR was significantly elevated. Recurrent amplification of
the gene encoding ligand VEGFA was also notable. Additionally, frequent amplifications of cell cycle
mediators (CCNE1, CCND1 and CDK6) were present. Alterations of these genes have been confirmed
in a cohort of 116 advanced/metastatic GC cases [44].
The GS tumors, which lack either chromosomal alteration or microsatellite instability, exhibited
elevated expression of molecules in the cell adhesion and angiogenesis-related pathways. Previous
studies had demonstrated loss of the tumor-suppressor gene CDH1 encoding the cell adhesion molecule
E-cadherin in hereditary diffuse gastric cancer [6]. The TCGA data also revealed recurrent mutations
in RHOA (Ras homolog gene family, member A) and fusion of CLDN18-ARHGAP6 or 26 (30% of
cases). RHOA modulates programmed cell death and actomyosin-dependent cell contractility and
motility [46–48], while CLDN18 and ARHGAP6 are involved in intercellular tight junction structure and
Rho signaling activation, respectively. Thus, alterations in either RHOA or CLDN18-ARHGAP6 might
contribute to lack of cellular cohesion, dispersed growth, and resistance to programmed cell death.
The TCGA data indicate that each of the four defined molecular subtypes displays distinct but
overlapping candidate therapeutic targets. These suggest the potential of targeted therapeutics in each
subtype of GC (Table 2). The discovery of mutations in the RHOA and CLDN18 gene products could
be exploited to develop new therapeutic strategies in the genomically stable subtype.
Table 2. TCGA molecular subtypes of gastric carcinoma and the associated targets and targeted agents.
Subtypes Targets Targeted Agents
EBV
PIK3CA Idelalisib, Taselisib
PD-L1/L2 Pembrolizumab, Nivolumab, Durvalumab, Avelumab, Atezolizumab
MSI













CDK, cyclin-dependent kinase; CCND, cyclin D; CCNE, cyclin E; CIN, chromosomal instability; CLDN,
claudin; EBV, Epstein–Barr virus; EGFR, epidermal growth factor receptor; GS, genomically stable; MLH1,
MutL homolog 1; MSI, microsatellite instability; PD-L1/L2, programmed death ligand 1/ligand 2; PIK3CA,
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; VEGF, vascular endothelial growth factor
3.2. ACRG Sub-Typing of Gastric Carcinoma: Potential Prognostic Biomarkers
Complementary to the TCGA data, the ACRG proposed a classification of GC that correlates four
molecular subtypes with distinct patterns of molecular alterations, disease progression and prognosis.
The molecular analyses include principal component analysis (PCA) [49] of expression data and
compared the association of the first three principal components with a small pre-defined set of gene
expression signatures relevant to biology of GC. These include epithelial-to-mesenchymal transition
(EMT) [50], microsatellite instability (MSI) [51], cytokine signaling [52], cell proliferation [53], DNA
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methylation [54], p53 activity [55], and gastric tissue [56]. Of the 300 specimens of GC being analyzed,
the MSI subtype accounts for 23%, MSS/EMT 20%, MSS/TP53+ (mutated) 26%, and MSS/TP53−
(wild-type) 36% (Figure 2). TP53 is the most frequently mutated gene in GC, and the status of p53
activation is based on a two-gene (CDKN1A and MDM2) p53-activity signature.
Figure 2. Illustration of the Asian Cancer Research Group (ACRG) classification tree. EMT, epithelia-to-
mesenchymal transition; MSI, microsatellite instability; MSS, microsatellite stability. This figure is
reproduced from reference [15] with permission from the Nature Publishing Group.
The MSI tumors, as in the TCGA cohort, were found to be hypermutated [57,58] intestinal-subtype
tumors occurring in the antrum. It is associated with the best overall prognosis and the lowest
frequency of recurrence (22%) of the four subtypes. They exhibited mutations in genes such as KRAS
(23.3%), the PI3K-PTEN-mTOR pathway (42%), ALK (16.3%) and ARID1A (44.2%) [46].
The MSS/TP53+ phenotype is associated with a better prognosis, and a higher prevalence of
mutations in APC, ARID1A, KRAS, PIK3CA and SMAD4, compared to the MSS/TP53− phenotype.
Consistent with these observations, mutations in TP53 (54%), APC (10%), SMAD4 (5.9%), KRAS
(5.9%), and PIK3CA (5.1%) were present at a high rate in a large cohort of 666 specimens of GC [42].
The MSS/TP53− phenotype exhibited the highest prevalence of TP53 and RHOA mutations, as well as
recurrent focal amplifications in ERBB2, CCNE1 and CCND1.
The MSS/EMT phenotype includes tumors of the diffuse-subtype. It is associated with the worst
prognosis, tendency to occur at an earlier age, and the highest recurrence frequency (63%) of the four
subtypes. The MSS/EMT subtype also includes a large set of signet ring cell carcinomas and showed
loss of CDH1 expression.
The ACRG subtyping of GC could be complementary to the TCGA system for molecular
classification of GC. The ACRG data are potentially important for generating prognostic biomarkers in
GC. The validity of these biomarkers for prognosis of patients with GC will need to be investigated in
prospective clinical studies.
3.3. Comparison of TCGA and ACRG Data
TCGA and ACRG integrated the results of a wide scale molecular analysis into two different and
partially overlapping models encompassing four molecular subtypes with distinct salient genomic
features (Table 3). They both identified a MSI subtype characterized by high mutation frequency and
best prognosis. While CIN and GS TCGA subtypes tumors were present across all ACRG subtypes,
TCGA GS, EBV+, and CIN subtypes were enriched in ACRG MSS/EMT, MSS/TP53+, and TP53−
subtypes, respectively. However, CDH1 and RHOA mutations were highly prevalent in the TCGA
GS subtype but infrequent in the ACRG MSS/EMT subtype, these two subtypes were deemed not
equivalent. Similarly, MSS/TP53 did not overlap with the TCGA EBV subtype, as EBV+ tumors
represented a small proportion of samples in the MSS/TP53+ subtype.
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Table 3. Distribution of key genomic alterations across molecular subtypes of gastric carcinoma from
TCGA and ACRG data.
Genetic Alteration
TCGA ACRG
MSI EBV GS CIN MSI MSS/EMT MSS/TP53+ MSS/TP53−
HER2 amp 0 12 3 22 0 0 3.0 17.4
HER2 mut 11 4 3 3 16.3 2.8 0 4.7
MET amp 2 0 0 7 1.6 0 3.0 3.5
PIK3CA amp 3 8 2 7 0 0 0 1.1
PIK3CA mut 42 77 10 3 32.6 8.3 16.9 4.7
KRAS mut 23 4 9 5 23.3 0 8.5 3.5
RHOA mut 5 8 14 2 0 2.8 6.8 3.5
CDH1 mut 8 0 34 3 7.0 2.8 1.7 3.5
FGFR2 amp 0 0 7 7 0 4.9 3.0 1.2
BRAF mut 22 8 0 0 11.6 2.8 1.7 3.5
ALK mut 9 0 5 2 16.3 0 0 2.4
ARID1A mut 84 54 16 9 44.2 13.9 18.6 5.9
TP53 mut 39 4 14 70 25.6 33.3 23.7 60
PTEN mut 25 15 2 1 14 5.6 3.4 3.5
MTOR mut 30 4 3 1 14 0 1.7 3.5
APC mut 36 0 3 12 16.3 2.8 15.3 8.2
FBXW7 mut 34 0 5 1 16.3 2.8 1.7 2.4
SMAD4 mut 8 12 9 7 4.7 2.8 8.5 2.4
MSI, microsatellite instability; EBV, Epstein–Barr virus; GS, genomically stable; CIN, chromosome instability; MSS,
microsatellite stability; EMT, epithelial-mesenchymal transition; amp, amplification; mut, mutation; Numbers refer
to % of samples with the genomic alteration.
Possible reasons for the partial overlap of these two classifications include differences related
to the patient population (Korea in ACRG vs. USA and Western Europe in TCGA), tumor sampling
(predominantly intestinal diffuse type in ACRG), and technological platforms (six distinct molecular
platforms in TCGA including exome sequencing, copy number analysis, methylation, miRNA and
mRNA expression vs. reliance upon mRNA expression in ACRG). Despite these differences, these two
classification schemes not only clarified and simplified the genomic and epigenomic heterogeneity of
GC, but also revealed distinct salient genomic features among gastric cancer subtypes linked to clinical
outcomes. These molecular classification systems of GC lay the groundwork for targeted therapies,
patient stratification for clinical trials and treatment, and improved prognostication.
4. Molecular Profiling of Gastric Carcinoma: Therapeutic Targets and Predictive Biomarkers
Complementary to molecular classification of GC, analysis of molecular profiles of tumors
collected from individual patients using a multi-platform approach has led to identification of targets
for therapy as well as biomarkers that may be predictive of tumor response to treatment.
4.1. Therapeutic Targets
Molecular profiling of tumors including GC has been employed with the hope of identifying
actionable and predictive biomarkers. In one study, 666 specimens of GC were analyzed by
immunohistochemistry, in-situ hybridization, and genomic DNA sequencing [42]. Some of
the analyzed molecules included ribonucleotide reductase regulatory subunit M1 (RRM1), O-6-
methylguanine-DNA-methyltransferase (MGMT), phosphatase and tensin homolog deleted on
chromosome ten (PTEN), topoisomerase (TOP), thymidine synthase (TS), and excision repair
cross-complementing 1 (ERCC1).
Negative expression of three non-NCCN (National Comprehensive Cancer Network)
compendium actionable targets including RRM1 (62%), MGMT (45%), and PTEN (58%) was identified
in more than 40% of the tumor specimens. These data suggest potential sensitivity to gemcitabine,
temozolomide, or PI3K inhibitors, respectively. Negative RRM1 expression is associated with higher
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response rates to gemcitabine-based chemotherapy regimens [59–61]. Therefore, stratifying patients
based on RRM1 expression may increase the likelihood of gemcitabine efficacy.
In the HER2-positive cohort, co-expression of TOP2A occurred most frequently (93%),
suggesting potential sensitivity to a combined anthracycline/trastuzumab approach to treatment.
Furthermore, 50% of patients demonstrated possible benefit from a combination of trastuzumab with
5FU/capecitabine based on concurrent low TS, 53% with irinotecan (high TOPO1), 63% with cisplatin
(low ERCC1) and 55% with gemcitabine (low RRM1).
4.2. Predictive Biomarkers
The potential of these biochemical markers to predict treatment response of tumors to
chemotherapy was examined. Molecular profiling of tumor specimens from 27 patients with
gastroesophageal carcinoma was conducted by the Caris Molecular Intelligence® service (Phoenix,
AZ, USA). These included eleven GC, nine EGJC, and seven esophageal carcinoma (EC) [13].
The frequencies of actionable targets (Table 4) and mutations including TP53 (33%), APC (7.4%),
SMAD4 (7.4%), and PIK3CA (7.4%), were consistent with those in a cohort of 666 specimens of GC [42].
Table 4. Frequency of actionable targets tested by immunohistochemistry along with the associated
therapeutic agents.
Biomarker Number of Specimens (%) Beneficial Agents
TS (−) 19 (70.4) Fluorouracil, Capecitabine
TOPO1 (+) * 16 (59.3) Irinotecan, Topotecan
PTEN (−) 11 (40.7) Trastuzumab, anti-EGFR
ERCC1 (−) * 11 (40.7) Cisplatin, Carboplatin, Oxaliplatin
TOP2A (+) * 11 (40.7) Doxorubicin, Epirubicin
RRM1 (−) 10 (37.0) Gemcitabine
MGMT (−) 9 (33.3) Temozolomide, Dacarbazine
TUBB3 (−) 8 (29.6) Docetaxel, nab-paclitaxel, paclitaxel
cMET (+) 7 (25.9) Anti-MET
TLE3 (+) 6 (22.2) Docetaxel, Paclitaxel
SPARC Mono (+) 5 (18.5) nab-Paclitaxel
SPARC Poly (+) 4 (14.8) nab-Paclitaxel
HER2 (+) * 4 (14.8) Trastuzumab, Lapatinib
PGP (−) * 4 (14.8) Taxane
* Biomarker with associated agent on the National Comprehensive Cancer Network (NCCN) compendium.
ERCC1, excision repair cross-complementation group 1; HER2, human epidermal growth factor receptor 2; cMET,
hepatocyte growth factor receptor; MGMT, O-6-methylguanine-DNA methyltransferase; PGP, p-glycoprotein; PTEN,
phosphatase and tensin homolog; RRM1, ribonucleotide reductase subunit M1; SPARC, secreted protein acidic and
rich in cysteine; TLE3, transducin-like enhancer of split 3; TOPO1, topoisomerase 1; TOP2A, topoisomerase 2A; TS,
thymidylate synthase; TUBB3, tubulin beta 3. The data are modified from [13].
In several cases, the PFS based on tumor molecular profile (MP) was compared to that on
therapy prior to molecular profiling. A ratio of PFS-MP to PFS prior to MP greater than 1.3 is
considered clinically significant. As shown in the three cases in Table 5, the ratio of PFS on MP-based
treatment to PFS on treatment prior to molecular profiling exceeds 1.3, suggesting the potential
value of MP in guiding selection of individualized therapy [13,62]. These results support further
investigation using large sets of data from patients to correlate treatment response with tumor MP,
and testing the hypothesis that tumor MP guides the selection of optimal therapeutic regimen for
individualized treatment.
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Table 5. Progression-free survival on molecular profile-matched therapy vs. on prior therapy.






PFS = 2.2 months
Trastuzumab + Docetaxel + Irinotecan





Epirubicin + Oxaliplatin + Capecitabine
PFS = 2.3 months
Docetaxel + Irinotecan




PFS = 1.9 months
Gemcitabine + nab-Paclitaxel
PFS = 3.6 month 1.9
FISH, fluorescent in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC,
immunohistochemistry; MP, molecular profile; PFS, progression-free survival; PFS ratio, PFS on MP-matched
therapy vs. PFS on prior therapy; SPARC, secreted protein acidic and rich in cysteine.
5. Conclusions and Perspectives
Systemic treatment plays important roles in the multi-disciplinary management of gastric
carcinoma. Cytotoxic drugs, targeted agents, and immunotherapeutics have been shown to provide
clinical benefit though to a limited extent. With the exception of trastuzumab for HER2-amplified and
PD-L1-expressing GC, a clinical tool to predict the treatment response and outcomes of the currently
used systemic therapy is lacking. Moreover, tumor heterogeneity and molecular evolution of tumor
during treatment contribute to therapeutic resistance. Clinically tested and validated biomarkers for
predicting tumor response to systemic treatment will be needed for patients to derive maximal benefit
and avoid unnecessary toxic side effects.
Molecular classification and profiling of GC generate potential targets for therapy as well as
prognostic and predictive biomarkers. The TCGA and ACRG data have not only revealed the molecular
and etiologic differences across the various subtypes of GC, but also yielded many potentially targetable
genomic changes. In addition, molecular profiling of GC by analysis of proteomics [63–65] and
microRNA [66] as well as detection of circulating tumor DNA in plasma and exosomes of patients with
GC [67] have been reported. These platforms may help identify therapeutic biomarkers and targets
that are complementary to tumor molecular profiling by genomic and immunohistochemical analyses
as described above.
Development of therapeutic agents targeting some of those molecular alterations as defined to
the subtyping and profiling of GC are undergoing pre-clinical and clinical investigation. Identification
and validation of prognostic and predictive biomarkers by correlation of molecular profiles of tumors
with clinical outcomes such as tumor response, progression-free survival, and overall survival are
indicated. Future studies aiming to identify and validate predictive tumor biomarkers through
molecular profiling in large data sets are indicated. Results of these studies are expected to facilitate
selection of optimal chemotherapy regimen individualized for the patients, and the development of
novel targeted therapies.
While the molecular data brings the possible hope of developing precision therapies, many
challenges must be overcome to fully understand and realize their clinical impact. First, it is imperative
to design and implement clinical trials that take into account the molecular heterogeneity across the
various subtypes of GC and develop protocols specific for each of these entities. The Personalized
Antibodies from Gastro-Esophageal Adenocarcinoma (PANGEA) “umbrella trial” is one such
innovative trial in which patients are assigned to different treatment arms by matching the molecular
characteristics of a single tumor type to a specific drug [68,69]. Considering that the tumor mutational
profiles can evolve over time and in response to treatment, the adaptive design of this trial, which
allows modifications of some aspects to be made while the trial is ongoing, would be very beneficial
by matching the right drugs to the right patients in a time-sensitive fashion.
Secondly, targeted therapy guided by molecular profiling will need to be tested in patient-derived
tumor xenografts (PDX) and genetically-engineered mouse (GEM) models. The development and
characterization of these realistic model systems represent the complex molecular heterogeneity of
GC. They will be helpful for validating the genomic alterations in the molecular subtypes of GC and
facilitating drug and biomarker development. Finally, development of novel therapies combining
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immunotherapeutics, cytotoxic chemotherapeutic agents, and molecularly-targeted therapeutics is
expected to offer durable clinical benefits and maximize survival in patients with GC.
By integrating the various molecular and clinical data, we hope to develop strategies that will
enable clinicians and scientists to better characterize and classify these tumors, develop targeted
therapies, and identify prognostic and predictive biomarkers for achieving the goal of precision
therapy in patients with this malignant disease.
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Abstract: The role of external beam radiation therapy (EBRT) in the management of upper
gastrointestinal malignancies is constantly evolving. As radiation therapy techniques improve
and are able to deliver more ablative doses of radiotherapy while sparing healthy tissue, radiation
can be applied to a wider range of clinical scenarios. Stereotactic body radiation therapy (SBRT)
allows a high dose of radiation to be delivered to a highly conformal treatment volume in a short
amount of time. Another potential advantage of SBRT is its ability to increase tumor immunogenicity,
while also having less of an immunosuppressive effect on the patient, as compared to conventionally
fractionated radiation therapy. In so doing, SBRT may potentiate the effects of immune therapy when
the two treatments are combined, thus improving therapeutic outcomes. This article provides an
overview of the role of SBRT in the management of upper gastrointestinal GI malignancies and the
emerging data on immune biomarkers and SBRT, with a focus on pancreatic and liver cancer.
Keywords: stereotactic body radiation therapy; immunotherapy; biomarkers
1. Introduction
The role of external beam radiation therapy in the management of upper gastrointestinal (GI)
malignancies is constantly evolving. Surgery has historically been the cornerstone of treatment for a
majority of these cancers, particularly for pancreatic and hepatobiliary malignancies, with radiation
reserved for palliation of symptoms. However, as radiation therapy techniques improve and are able
to deliver more ablative doses of radiotherapy while sparing healthy tissue, radiation can be applied
to a wider range of clinical scenarios.
Stereotactic body radiation therapy (SBRT) is a technique that allows a high dose of radiation
to be delivered to a highly conformal treatment volume in a short amount of time. This results in
a number of advantages. First, it allows for treatment of a higher biologically effective dose (BED),
thus improving local tumor control. Second, it allows for a shorter overall treatment time which is
both more convenient for patients and treating facilities and, more importantly, prevents delays in
systemic treatment and/or surgery. Finally, given the highly conformal nature of SBRT, it allows
for increased sparing of adjacent organs at risk (OARs) [1]. While the role of SBRT in the treatment
of organs organized in series, such as the esophagus, is not well defined, its use in treating those
organized in parallel, such as the liver and pancreas, has been established. This article therefore seeks
to review the role of SBRT in the management of upper GI malignancies with a focus on pancreatic
and liver cancer.
Another potential advantage of SBRT is its ability to increase tumor immunogenicity while
having less of an immunosuppressive effect on the patient, as compared to conventionally fractionated
radiation therapy [2]. In so doing, SBRT may potentiate the effects of immune therapy when the
two treatments are combined, thus improving therapeutic outcomes. While the available data on
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tumor biomarkers and SBRT is in its infancy, it is hypothesis-generating and will also be reviewed in
this article.
2. SBRT for Pancreatic Cancer
Pancreatic cancer is the 4th leading cause of cancer death in the United States [2].
Currently, surgery is considered the only curative treatment; however, less than 20% of patients are
operable at the time of diagnosis [3,4]. Radiation therapy, therefore, plays a role in both the preoperative
and definitive management of pancreatic malignancies. However, because the pancreas is considered
to be radio-resistant, higher radiation doses are required for tumor control [5]. Indeed, studies have
shown that delivering a BED of greater than 70 Gy is associated with improved survival for pancreatic
cancer [6]. This poses a challenge for standard radiotherapy treatment planning due to the close
proximity of highly radiosensitive organs such as the liver, duodenum, and stomach. SBRT in the
management of pancreatic cancer is therefore a highly appealing treatment modality which has been
well studied [7–27].
2.1. The Neoadjuvant Setting
The close proximity of the pancreas to critical vascular structures makes it technically challenging
to achieve microscopically negative (R0) resections. The presence of positive margins following
resection is associated with inferior outcomes [27–31]. Radiation therapy has, therefore, been used in
the preoperative setting to downsize tumors intimately associated with vascular structures so as to
increase the rate of negative margins at the time of surgery. Given the advantages of SBRT outlined
above, there is growing interest in utilizing this technique in the neoadjuvant setting.
In 2015, the Moffitt Center published its experience with SBRT for borderline resectable pancreatic
cancer [32]. This was a retrospective institutional review of all patients treated neoadjuvantly with
SBRT at their institution. It included 159 patients, the majority of which (110) had borderline resectable
disease (BRPC), with the remaining patients (49) having locally advanced unresectable pancreatic
cancer (LAPC). Patients were treated with multi-agent systemic chemotherapy, followed by SBRT to a
median dose of 40 Gy in five fractions and then surgery in patients who were deemed resectable after
neoadjuvant therapy.
Ultimately, 51% of BRPC and 10% of LAPC patients were able to undergo surgery. The R0 resection
rate in these patients was 96% and 100%, respectively. Seven percent of patients had a pathologic
complete response and none of these patients relapsed at a median follow-up of 14 months. The overall
survival and progression free survival rates were 19 months and 12 months, respectively, for those
with BRPC, and 15 months and 13 months, respectively, for those with LAPC. Remarkably, the overall
survival rate for patients who received neoadjuvant treatment and were then able to undergo surgery
was 34 months, versus only 14 months for those who received chemotherapy and radiation but
remained unresectable. Overall survival rates for up-front resectable pancreatic cancer patients,
historically thought to have the best survival outcomes, has not exceeded 30 months in national
randomized controlled trials, including the recently published ESPAC-4 trial [33–40]. Treatment was
well tolerated in only 7% of cases with Grade 3+ acute or late toxicity. The results of this study were
hypothesis-generating and paved the way for prospective trials of neoadjuvant SBRT for borderline
resectable pancreatic cancer, including the ongoing ALLIANCE (NCT01992705) and Pancreatic Cancer
Research Study (NCT01926197).
2.2. The Definitive Setting
There have been a number of studies investigating the role of SBRT in the definitive
setting [10,12–14,16,17,21–26]. Most of these were retrospective series and only two were Phase II
studies. The first of these two Phase II studies was published by Hoyer et al. in 2005 [16]. It included
22 patients with T1-3N0 LAPC deemed unresectable by a surgeon measuring up to 6 cm in size.
The median PTV volume was 136 cm3. Patients were treated with SBRT to a total dose of 45 Gy in
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three fractions. There was no mention of chemotherapy in the trial or a requirement that patients also
undergo systemic chemotherapy. Study results were disappointing with only a 57% local control rate
at one year and a median survival of 5.4 months. The toxicity profile was unfavorable with 36% of
patients experiencing an increase in pain and analgesic use, 23% of patients with severe mucositis or
ulceration, and one gastric perforation requiring emergent surgery. There are a number of reasons why
this early experience with SBRT yielded such poor outcomes. These include a lack of fiducials for daily
set-up and target localization possibly resulting in tumor miss, a lack of OAR constraints, resulting in
high toxicity rates, and no specific requirements for systemic chemotherapy in conjunction with SBRT
either before or after treatment, which we know today is a key component of treatment for patients
with both resectable and especially unresectable disease.
Ten years after the publication of the Hoyer study, Herman et al. published their Phase II
trial of SBRT for unresectable pancreatic cancer [21]. In this study, 49 patients with LAPC were
treated with three weeks of gemcitabine, followed by a one-week break, followed by SBRT to the
tumor to a total dose of 33 Gy in five fractions. The study included 49 patients with a median
PTV volume of 71.4 cm3. Unlike its predecessor study, the results of this trial were encouraging.
The freedom from local progression at one year was 78% at one year as compared to 57% in the Moyer
study. The median progression free survival was 7.8 months and the median overall survival was
13.9 months—a significant improvement from 5.4 months as reported in the Moyer trial. Ten percent of
patients were ultimately able to undergo surgery after completion of SBRT. Overall survival for these
patients ranged from 13.6 to 40.2 months. The primary endpoint of the rate of late (>3 months after
SBRT) gastritis, fistula, enteritis, or ulcers of Grade 2+ was only seen in 11% of patients.
The superior outcomes reported in the Herman et al. trial as compared to the earlier Moyer trial
can be attributed to a number of factors. First, unlike in the Herman trial, and all ongoing protocols,
fiducial markers were not required to ensure accurate tumor positioning, which may have led to tumor
miss. Second, there was no requirement for gemcitabine-based systemic chemotherapy, unlike in
the more recent study, which has been shown to improve survival in patients with locally advanced
disease [41–43]. Furthermore, the Moyer trial did not specify OAR constraints, which likely explains
the poor toxicity profile. Lastly, tumor margins were large (5 mm axially and 1 cm cranio-caudal) and
there was no dose reduction for overlap with the duodenum and stomach as was done in the Herman
trial, which likely explains the 20% rate of severe mucositis and ulceration and the case of gastric
perforation requiring surgery.
As radiation techniques have improved and we have learned more about tissue tolerance for high
dose radiation therapy, SBRT has emerged as an appealing and highly effective treatment modality for
LAPC. A meta-analysis of 19 trials of SBRT for LAPC published in 2017 showed that the median overall
survival was greater than 12 months in the vast majority of studies and was particularly favorable in
the subset of patients who became resectable after receiving SBRT [20]. These studies have paved the
way for randomized Phase III trials (NCT01926197), which will hopefully establish the role of SBRT
for LAPC.
2.3. The Adjuvant Setting
SBRT in the adjuvant setting for resected pancreatic cancer has not been established.
However, there is an ongoing Phase II study examining the role of SBRT in resected T3 and N1
patients, which is currently accruing (NCT02461836).
3. SBRT for Hepatocellular Cancer
Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide [44].
The incidence of HCC is approximately equal to the mortality rate, highlighting the aggressive nature
of this fatal malignancy. While relatively uncommon in the Unites States (US), it is the fastest growing
cause of cancer death in the US [45]. Like with pancreatic cancer, surgery is considered the only
curative treatment but most patients either have unresectable disease due to tumor extent or are
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inoperable due to underlying liver dysfunction. For the latter group of patients, transplant is the
ultimate goal because it can cure both the HCC and the underlying liver disease. However, given
the limited supply of healthy livers available for transplant, most patients are unable to undergo the
procedure right away, thus requiring local treatment as a bridge to liver transplant when an organ
becomes available. SBRT for HCC is, therefore, emerging as a safe and effective treatment modality
both in the definitive setting for unresectable cancers and as a bridge to transplant for those with
underlying liver disease awaiting organ allocation.
Historically, EBRT has been used with caution in the management of hepatic malignancies due
to the low tolerance of the liver for radiation [45]. The challenges facing EBRT for HCC have been
delivering a sufficiently high dose of radiation to achieve tumor control in an organ that is highly
sensitive to radiation and that moves substantially with breathing, making target localization very
difficult. Modern-day SBRT techniques make it possible for external beam radiation to overcome
these road-blocks by delivering high doses of radiation in a very conformal manner while accounting,
and controlling, for tumor motion. Due to a lack of Level I evidence, SBRT is not currently considered
a standard treatment for HCC; however, a number of prospective trials have been completed which
show its safety and efficacy in the management of this disease [46–50].
The most notable of these prospective trials was a combined analysis of sequential Phase I and II
trials conducted at Princess Margaret Hospital published in 2013 [48]. The study included 102 patients
with Child–Turcotte–Pugh Class A disease who were unsuitable for other local liver-directed therapy.
Median gross tumor volume was 117 mL with a range of 1.3–1913.4 mL. Patients were treated with
30–54 Gy in six fractions, delivered every other day. The treatment was relatively well-tolerated with
Grade 3+ toxicity reported in 30% of cases. Local control at one year was 87% and overall survival
was 55%.
SBRT has also been combined with trans-arterial chemo-embolization (TACE) with favorable
outcomes in the literature so far. There are a number of advantages to combining SBRT with TACE.
TACE can shrink tumors, thus creating a smaller treatment volume for SBRT. The combination of
the two treatments allows for ablation of vascular components of the tumor with TACE, while the
poorly vascularized, necrotic portions can be targeted by SBRT. Finally, SBRT can be used to recanalize
tumors with arterial or portal vein thromboses, rendering TACE more effective. A retrospective
study of patients with tumors ≥3 cm compared outcomes among patients who received TACE plus
SBRT compared to TACE alone [51]. The authors found that, after censoring for liver transplantation,
overall survival was significantly better with TACE plus SBRT compared to TACE alone (33 vs.
20 months, respectively).
In conclusion, modern-day SBRT techniques allow for safe and effective delivery of external beam
radiation therapy for hepatocellular carcinoma. While more data is needed, available evidence shows
that there is a role for radiation in the management of this disease. Specifically, radiation plays a role
for lesions unsuitable for other local therapies, for larger lesions in which TACE is less effective, and in
cases with portal vein thrombosis in which other therapies are contra-indicated or ineffective [52].
Indeed, there is a randomized Phase III study underway comparing treatment with Sorafenib with or
without SBRT in patients with HCC (NCT01730937).
4. SBRT and Immunomodulatory Biomarkers in Upper GI Malignancies and
Therapeutic Implications
In addition to allowing for higher doses of radiation to be delivered to a more precise target in
a shorter treatment time, emerging data shows that radiation, specifically SBRT, has advantageous
effects on the immune system, which may have therapeutic implications. The immune-stimulatory
effects of radiation have been known for some time. Indeed, Demaria et al. first introduced the concept
of radiation as an “in situ vaccine” in 2004 [53]. The authors suggest that radiation turns the radiated
tumor into a vaccine by priming the immune system to target cancer cells in other sites in addition to
treating the disease locally, a concept known as the abscopal effect. Since then, Formenti and colleagues
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have been able to site clinical data lending credence to this concept in which radiation delivered
locally results in tumor response at the site of radiation as well as decreased tumor burden outside the
irradiated field, mediated by the patient’s immune system [54–57].
While the dose and fractionation needed to optimally prime the immune system is not yet known,
SBRT appears to be superior to conventional radiation in terms of its effect on tumor immunogenicity.
First, SBRT creates less of an immunosuppressive effect on the host’s immune system as compared
to conventionally fractionated radiation, both due to the absence of the concomitant chemotherapy
and to the relatively smaller volume of irradiated bone marrow [58–60]. In addition, emerging data
shows that SBRT has the potential advantage of directly increasing tumor immunogenicity [2,61].
Indeed, numerous pre-clinical models summarized very nicely by Popp et al. have shown that
SBRT induces complex changes in the tumor microenvironment [53]. The authors review several
preclinical studies showing that SBRT leads to increased recruitment of immune cells, including
antigen-presenting-cells and dendritic cells, as well as cytokines and chemokines, which are all
involved in the immune response [53]. The authors also summarize existing clinical data demonstrating
evidence that SBRT mediates the abscopal effect. However, most of the data they cite involves patients
with either melanoma or lung cancer, for which the benefit of immunotherapeutic agents is already
widely established [62–64].
There is limited clinical data addressing the role of SBRT and its effects on the immune system
for gastrointestinal malignancies; however, studies are emerging. Specifically, studies have shown an
increase in tumor infiltrating lymphocytes and in soluble PD-L1, involved in T-cell regulatory pathways,
following SBRT in pancreatic and hepatic malignancies [61,65]. The immunogenic effect of SBRT on
tumors, coupled with the absence of an immunosuppressive effect on the patient, may allow for novel
therapeutic approaches to treating upper GI malignancies by combining SBRT with immunotherapy.
The combination of these two therapies may be more effective than either treatment alone.
Tumors have varying degrees of immune activity based on their histology. The tumor environment
in pancreatic cancer, for instance, is considered to be immunosuppressive with a low degree of
infiltration by T cells [66]. As a result, immunotherapy with immune check-point inhibitors has been
investigated in this disease, with disappointing results [67,68]. As Foley et al. detail in their paper on
immunotherapy for pancreatic cancer, removing immune suppression without providing a means to
activate the immune system is likely responsible for these disappointing outcomes [66].
Emerging data show that SBRT has more of an immunogenic effect on the tumor environment
when compared to conventionally fractionated radiation therapy delivered concurrently with
chemotherapy for pancreatic cancer. In a recent presentation at the American Society for Radiation
Oncology (ASTRO) annual meeting, Chen et al. presented their data on tumor infiltrating cells in
pancreatic cancer [65]. They showed that there was a statistically significant difference in the ratio
of CD8 T-cells to FOXP3 T-regulatory cells (CD8/FOXP3) detected in tumor cells following SBRT
as compared to conventionally fractionated therapy. They also showed that a higher CD8/FOXP3
ratio was associated with improved progression free survival. The authors thus show that SBRT may
be more effective in terms of local control as compared to conventional fractionation, in addition to
showing that SBRT is more immunogenic than conventional radiation. The combination of SBRT and
immunotherapy may, therefore, provide novel therapeutic strategies for this disease. Indeed, there are
studies underway looking at the efficacy of combining SBRT with immunotherapy in the treatment of
pancreatic cancer (NCT 02648282).
Hepatocellular carcinoma, on the other hand, has been shown to be an immune active malignancy
with a high infiltration of T cells [66]. Kim et al. recently presented their data on the effects of radiation
on soluble PD-L1 in hepatocellular carcinoma and its therapeutic implications [61]. The authors showed
that radiation therapy increases the expression of PD-L1 on tumor cells. This increase was noted both
after conventionally fractionated radiation and after SBRT; however, the levels after SBRT continued
to rise one month following treatment, which was not true following conventionally fractionated
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radiation. The authors conclude that this data may provide evidence for a novel therapeutic strategy
for patients with HCC that combines SBRT with PD-L1 blockade.
5. Conclusions and Future Directions
SBRT has emerged as a highly promising treatment modality in the management of upper GI
malignancies. It allows for more curative doses of radiation to be delivered to a highly conformal
treatment volume, in a short amount of time, allowing for effective and expedited treatment for these
highly aggressive malignancies.
In the case of pancreatic cancer, SBRT has emerged as an effective neoadjuvant treatment to render
tumors which are unresectable upfront, resectable after treatment, thus allowing an increased number
of patients to undergo potentially curative resection. In the case of LAPC, SBRT also has the potential
advantage of rendering some of these initially unresectable tumors resectable, while also providing
reasonable long-term survival rates for patients undergoing definitive treatment. Studies are ongoing
for SBRT in the adjuvant setting. In the case of HCC, SBRT has emerged as an effective treatment for
patients in which other local therapies either cannot be performed or are ineffective as, for example,
for large tumors or those with portal venous invasion.
Finally, the effects of SBRT on the immune system and tumor micro-environment is an area of
active research with heretofore promising results. Emerging data shows that SBRT can increase tumor
immunogenicity, thus providing a rationale for novel therapeutic approaches combining SBRT and
immunotherapeutic agents with the hope that the combination of the two treatments will result in
better outcomes than either treatment alone. More data is needed to confirm these initial findings.
Prospective trials studying the combination of SBRT and immunotherapy in the management of upper
GI malignancies are needed to confirm the therapeutic implications of these retrospective studies,
and some are already underway.
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Abstract: Colorectal cancer (CRC) is one of the world’s most common cancers and is the second
leading cause of cancer deaths, causing more than 50,000 estimated deaths each year. Several risk
factors are highly associated with CRC, including being overweight, eating a diet high in red meat
and over-processed meat, having a history of inflammatory bowel disease, and smoking. Previous
zebrafish studies have demonstrated that multiple oncogenes and tumor suppressor genes can be
regulated through genetic or epigenetic alterations. Zebrafish research has also revealed that the
activation of carcinogenesis-associated signal pathways plays an important role in CRC. The biology
of cancer, intestinal disorders caused by carcinogens, and the morphological patterns of tumors
have been found to be highly similar between zebrafish and humans. Therefore, the zebrafish has
become an important animal model for translational medical research. Several zebrafish models
have been developed to elucidate the characteristics of gastrointestinal diseases. This review article
focuses on zebrafish models that have been used to study human intestinal disorders and tumors,
including models involving mutant and transgenic fish. We also report on xenograft models and
chemically-induced enterocolitis. This review demonstrates that excellent zebrafish models can
provide novel insights into the pathogenesis of gastrointestinal diseases and help facilitate the
evaluation of novel anti-tumor drugs.
Keywords: colorectal cancer; intestinal disorder; intestinal tumors; zebrafish
1. Introduction
Colorectal cancer (CRC) is one of the world’s most common cancers. It is also the second-leading
cause of cancer deaths in the United States, responsible for more than 50,000 estimated deaths in
the world [1]. Although the five-year survival rate for localized CRC is >90%, most CRC patients
are asymptomatic; therefore, only 40% of cases are detected at this stage. At the metastatic stage,
CRC survival rate falls to 8–12%. There are five stages of CRC: aberrant foci, small adenoma/adenomatous
polyps, large adenoma, adenocarcinoma, and invasion/metastasis. Risk factors for CRC include age
(>50 years), being overweight, a diet that is high in red and over-processed meat, a history of inflammatory
bowel disease, and smoking [1]. In addition, 5–10% of familial CRC cases include mutations in the
tumor suppressor gene APC, and environmental risk factors have been linked to somatic mutations
that can cause CRC. Non-familial cases of CRC are often related to overactivity of epidermal growth
factor receptor (EGFR), loss of function at APC, and activating or allele mutations in K-RAS, N-RAS,
BRAF, PIK3CA, WNT, and TP53 genes. It has been hypothesized that the regulation of different
CRC phenotypes could be associated with a balance between anti-proliferation, maintaining genomic
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stability, and oncogenes. For example, microsatellite instability results in the loss of DNA mismatch
repair function, which in turn leads to overactivity of COX-2, EGFR, and/or WNT pathways and
results in small adenomas. K-RAS and/or PIK3CA pathway overactivity results in large adenomas;
and inactivation of the tumor suppressor gene TP53 and downregulation of TGF-β signaling results
in invasive/metastatic carcinomas [2–4]. In non-hereditary sporadic CRC, APC is mutated in 85% of
cases, TP53 is mutated in 40–50% of cases, PIK3CA is mutated in 35% of cases, and TGFBR2 is mutated
in 45–50% of cases [2].
APC mutations activate the WNT pathway by increasing the amount of β-catenin that is
translocated into the nucleus and enhancing the transcription of various oncogenes [5]. Causes of
APC inactivation include hypermethylation of the APC promoter, germline mutations, and somatic
mutations [6]. The APC gene is responsible for approximately 75% of mutations or the loss of
heterozygosity (LOH) in CRC. Most APC mutations are clustered in the mutation cluster region that
is located between codons 1282 and 1581 [7]. Previous studies have demonstrated the effects of APC
restoration in cancerous mice, whereby tumor cells were replaced by normal cells, and some evidence
suggests that APC restoration therapy could have similar benefits for humans [8]. Another study
showed that, in a CRC cell line, β-catenin activates a set of 162 target genes associated with the
WNT pathway; however, no conclusions could be drawn regarding the effect of these genes on
cancer prognosis [9].
The first proposed model of genetic events that led to the development of CRC involved
point mutations in K-RAS [10]. Specifically, point mutations in codons 12, 13, and 61 of K-RAS
activate an enzyme that increases RAS signaling. Indeed, K-RAS has been found to be mutated in
30–40% of CRC cases, and in 60–90% of hyperplastic or non-dysplastic aberrant crypt foci [11,12].
Mutations in codon 12 of K-RAS are associated with more advanced tumor stages [13], and RAS
signaling further activates the Raf-MEK-ERK pathway, the PI3K/AKT/PKB pathway, and Ral
small GTPases [14]. Furthermore, most human CRC cases that involve PI3K gene mutations
also involve K-RAS mutations [15]. AKT1 and AKT2 genes enhance tumor growth by promoting
epithelial-to-mesenchymal transition (EMT) through PI3K activation [16,17], and the tumor suppressor
gene of the PTEN antagonist PI3K/AKT pathway induces AKT-regulated tumor metastasis through
loss-of-function mutations [18]. Finally, the MEK/ERK and PI3K/AKT pathways often converge to
activate a cap-dependent translation, which can inhibit metastasis through the knockdown of survivin [19].
In the majority of human tumors, TP53 is dysfunctional. Several tumors display a gain of function
mutation in TP53, which results in mutated TP53 (mutTP53) proteins [20]. MDM2 can also bind
and inactivate the mutTP53 isoform. In CRC tissues, the overexpression of protein and mRNA was
observed in the spliced isoform MDM2-B. Protein and mRNA overexpression is mainly associated
with the mutTP53 protein as MDM2-B binds to MDM2, which in turn allows mutTP53 to accumulate
in cells [21]. Indeed, a previous report showed that a loss-of-function mutation in TP53 affects 44.9%
of colorectal adenoma cases, 42.22% of single primary CRC cases, and 43.75% of multiple primary
CRC cases [22].
In current clinical practice, the only option to treat unresectable metastatic CRC is conventional
chemotherapy. Although chemotherapy tends to relieve initial symptoms, resistance generally
develops within six months. Life-extending agents, such as conventional cytotoxics and targeted
therapeutics, are frequently used, including 5-fluoracil, capecitabine and topotecan, bevacizumab,
cetuximab, and panitumumab [23,24]. Unfortunately, CRC patients who receive these agents also
develop a resistance to them, and have a final average survival rate of only 13.3 months [25]. So far,
zebrafish has been well used to study several intestinal cancer and disorder. Here we give a broad
view to understand how zebrafish involved in those studies.
2. Development and Anatomy of the Gastrointestinal Tract in Zebrafish
The digestive system plays a critical role in vertebrate physiology and the intestinal anatomy
among amniotes is highly conserved. The zebrafish is a powerful animal model in the study of
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intestinal development. Moreover, genes and organ functions are also well conserved between
zebrafish and higher vertebrates [26–28]. For example, in zebrafish, the internal lining of the intestines
forms a ridge (and not villi). This unique characteristic can be observed in cross-sections of mammalian
intestines as well. Although zebrafish lack a stomach, crypts, Paneth cells, submucosal glands, and the
organization of lymphoid structures, the zebrafish intestine is a simple but unique organ in vertebrate
intestinal biology.
The morphological development of zebrafish intestine has been comparatively well studied in
embryos and larvae [29–32]. However, zebrafish lack a morphologically and functionally distinct
stomach, and do not express genes that encode precise gastric functions. Zebrafish do have an intestinal
bulb with a lumen that is larger than the posterior part of the intestine. This intestinal bulb may function
as a container that is comparable to the stomach. The digestive enzymes and solute transporters are
present in the anterior and mid intestines [33]. A previous report indicated that because the intestinal
bulb of zebrafish lacks gastric glands, the pH in the zebrafish intestines never falls below 7.5 [34].
Early research revealed that the zebrafish digestive tract develops in a segmental fashion, and
that development begins during the mid-somite stages. Gut tube formation begins during mid- to
late-somite stages (~18 somites) in zebrafish; however, in mammals, the gut begins to form during
the early-somite stages (1–2 somites). At the 18-somite stage, a continuous thin layer of endoderm
becomes distinguishable, which will eventually give rise to the primitive gut endoderm. Although gut
formation occurs later in zebrafish, the temporal progression of gut tube formation is similar to that of
mammals: the rostral gut of zebrafish develops first, followed by the hindgut and midgut [29].
Zebrafish gut development begins at almost 20 h post fertilization (hpf) and proceeds as follows.
Firstly, endodermal precursors form the primitive gut: a thin, rod-like cell layer that lengthens from
the future mouth to the future anus of the embryo. Progenitor gut cells then polarize to become
columnar epithelium, and junctional complexes form between cells, which are required for lumen
inflation and the establishment of the epithelial barrier. These developmental progressions occur
in conjunction with cell proliferation along the total length of the intestinal tube. Proliferation is
downregulated at approximately 72 hpf, at which time the intestinal epithelial cells are differentiated
into the three lineages of mature gut epithelium, including absorptive enterocytes, mucus-producing
goblet cells, and hormone-secreting enteroendocrine cells. Around 120 hpf, the yolk is entirely
absorbed, and gut development is almost complete. At this time, the embryo is able to feed and
digest. Previous studies have described the zebrafish intestine as a tapered tube that begins at the
esophageal junction and is folded into three segments: (1), the large diameter rostral intestinal bulb,
which is characterized by an expanded lumen and epithelial folding, and is primarily comprised of
enterocytes and enteroendocrine cells; (2), the mid-intestine, which is demarcated by the presence of
goblet cells and enterocytes with large, supranuclear vacuoles; and (3), the small diameter posterior
intestine, which does not possess endocrine and goblet cells. Even though zebrafish do not have five
intestinal segments like mammals (i.e., jejunum, duodenum, cecum, ileum, and colon), zebrafish and
mammalian intestines do share functional homology. For example, in both zebrafish and mammals,
growth factor gradient combinations of bone morphogenetic protein (Bmp), fibroblast growth factor
(Fgf), and wingless-type MMTV integration site (Wnt) at the posterior end of the endoderm are able to
regulate intestinal development. Additionally, retinoic acid (RA) signaling plays a dose-dependent
role in patterning the anterior–posterior (A-P) body axis, including the endoderm [31,32].
Wang et al. [28] previously performed a microarray analysis of adult zebrafish guts, in which guts
were separated into seven sections of equal lengths (from anterior 1 to posterior 7). Using metabolic
gene data, they were able to confirm the presence of three distinct gut regions. Furthermore, segments
1 to 5 (S1 to S5) showed high expression of intestinal markers that are conserved in humans and mice:
fatty acid binding protein 2 (fabp2), villin 1 (vil1), and apolipoproteins 1 and 4 (apoa1 and apoa4). Fabp2,
Apo1, and Apo4 all participate in lipid metabolism. Wang et al. [28] also reported that the Vil1 gene
plays a role in regulating anti-apoptosis in small intestinal epithelial cells. Additionally, aquaporin
3 (aqp3) and cofilin1 (cfl1) (which are biomarkers of the large intestine in mammals) were found to
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distinguish genes associated with sections S1 to S4 from genes associated with S5 to S7 in zebrafish.
Furthermore, Cfl1 was reported to regulate the dynamic stabilization of actin filaments, and aqp3 was
found to participate in water absorption. Wang et al. [28] also indicated that S1 to S5 share molecular
characteristics with the small intestine of mammals, and that S6 and S7 share similar characteristics
with the large intestine of mammals. Finally, S5 was found to form a transition segment, and was
surmised to be the dorsal fraction of the mid-gut that participates in mucosal immunity [28]. However,
in order to further investigate the correlation of these genes between diseases, to develop the transgenic
zebrafish is quite critical.
3. Developments in Transgenic Zebrafish Technology that Enable the Exploration of Intestinal
Tumors Using a Constitutive or Inducible Expression System
Significant progress has been made in the development of transgenic technology, which is an
essential technique that is used in research and employed in a variety of model organisms [35,36].
A variety of transgenic expression systems exist, including constitutive and inducible systems [37].
Traditionally, establishing a transgenic fish model involved injecting fish embryos with (1) artificial
chromosomes of recombinant bacteria [38], (2) supercoiled [39] or linear DNA [36], and (3) linearized
ISce-I meganuclease [40]. Recently, however, the use of Sleeping Beauty (SB) [41], Ac/Ds [42],
and Tol2 [43] transposon-based systems has effectively increased transgenic efficiency in zebrafish.
The development of SB was based on DNA sequences of Tc1-like elements (TcEs) from teleost fish
species [44,45]. When the SB transposon plasmid and SB transposase mRNA are co-injected into
fertilized eggs, the SB transposon vector is transposed from the plasmid to the zebrafish genome,
and the transposon insertions are transmitted to the next generation of zebrafish germline [46]. The Tol2
transposon element was found in the medaka genome, which can be efficiently excised and integrated
into the zebrafish genome. This enables transgenic lines to be generated by co-injecting fish with Tol2
mRNA and vector plasmid [43]. In a plant transposon system, the maize Dissociation (Ds) element is
capable of effective Activator (Ac) transposase-mediated transposition in the zebrafish, yielding high
transposition frequencies and efficient germline transmission rates [42].
Previous studies noted that the overexpression of oncogenes can lead to serious tumors,
early embryonic developmental abnormalities, and death, which prevents oncogene effects from
being comprehensively characterized. Controlling gene expression through the use of an induction
system can help address this problem. Currently, widely used induction systems include heat shock,
Cre-loxP, GAL4-UAS, Tet-On, Tet-Off, and mifepristone. These systems regulate the duration and
dosage to achieve spatiotemporal control of transgene expression in fish during both the embryonic
and adult stages [37,47].
The important role of intestinal-type fatty acid binding protein (I-FABP; also known as FABP2) has
been observed in vertebrates. Specifically, this role involves the intracellular binding and trafficking
of long chain fatty acids. Mammalian gene promoters and ubiquitous or endogenous tissue-specific
promoters are able to drive the expression of green fluorescent protein (GFP) and red fluorescent
protein (RFP) transgenes in zebrafish [48,49]. Zebrafish 4.5-kb FABP2 gene promoter also drives
intestine-specific GFP/RFP expression in the zebrafish. Indeed, previous research noted the ability
of the FABP2 gene promoter to direct GFP/RFP fluorescent expression in the intestinal tube from
three days post-fertilization (dpf) (when zebrafish were in the larval stage) until the adult stage [49,50].
The first transgenic fish model of an intestinal tumor was developed through the expression of the
H. pylori virulence factor cagA, which was in turn controlled by the 1.6-kb FABP2 promoter in tp53
mutant background zebrafish (tp53M214K) [51]. Heat shock-inducible Cre/Lox expression controlled
by the β-actin promoter of human K-RASG12D has also been induced in intestinal epithelial tumors
alongside several other tumors in zebrafish [52].
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4. Zebrafish Models for Intestinal Tumors and Disorders
The zebrafish is a powerful animal model that can be used for the forward and reverse
genetic analysis of vertebrate embryogenesis, organ development, disease, tumors, and toxicology.
Many zebrafish mutants or transgenic lines have also proven to be excellent animal models for
a variety of human diseases and tumors [53]. Experimental carcinogenesis studies have illustrated
the development of tumors that can occur in the wild in virtually all organs in zebrafish [54,55].
Furthermore, the histopathology of intestinal neoplasia in zebrafish is similar to the histopathology of
intestinal neoplasia in humans [56,57]. One study found that the histological signs of cancer in zebrafish
included preneoplastic intestinal changes, such as hyperplasia, dysplasia, adenocarcinoma, small cell
carcinoma/carcinoid-like, tubular/tubulovillous adenoma, and enteritis [58]. According to histological
diagnosis, the intestinal carcinomas were comprised of neuroendocrine cells. Immunohistochemistry
analysis of cytokeratins (that used human epithelial (cytokeratin wide spectrum screening (WSS),
AE1/AE3) or neuroendocrines (S100, chromogranin A) markers) confirmed that the majority of
intestinal tumors in a cohort of zebrafish were carcinomas [59].
Mutations in the APC gene have been identified as being responsible for human familial
adenomatous polyposis (FAP) syndrome [60,61]. APC gene mutations can also lead to the development
of multiple colorectal adenomas following somatic inactivation of the remaining allele via carriers of
germline truncating mutation [62]. Similarly, results from a mouse model revealed that multiple tumors
developed in the small intestine when the APC gene contained a heterozygous truncating mutation [63].
Finally, APC was also found to be a key inhibitory gene in the WNT/β-catenin pathway [64].
Zebrafish apc-mutants carry a premature stop codon in the putative mutation cluster region (MCR)
of APC, which mimics the mutations found in FAP patients. Homozygous apc-mutant fish embryos
die between 72 and 96 hpf. The unusual features that characterize these fish include an aberrantly
developed gut, liver, and pancreas. [65]. In one study, 17.6% of adult apc-mutant fish (aged >15 months)
developed spontaneous liver tumors, and 11.8% of these fish developed spontaneous intestinal tumors.
The apc-mutant fish appear to have polyps, which is a mammalian resemblance. These intestinal
disturbances were observed in the disorganized large structures with ramifications of the villi,
which are frequently embedded in fibrovascular stroma. The pathologic lesions were classified
as adenomatous polyps. These lesions showed pseudostratification of nuclei, loss of goblet cells,
and a high N/C (nuclear-to-cytoplasmic) ratio that is consistent with dysplastic epithelium. In intestinal
adenoma tissue of apc-mutant fish, high levels of β-catenin accumulated in proliferating cells of
both the cytoplasm and nucleus. In addition, 58.3% of apc-mutant fish (aged 14 months) treated
with 7,12-dimethylbenz[a]anthracene (DMBA) showed intestinal adenomas, whereas only 20.5% of
wild-type fish treated with DMBA showed intestinal adenomas. This well-established apc-mutant
fish is a bona fide tumor suppressor, similar to its mammalian counterpart. Furthermore, the loss
of heterozygous apc-mutant fish resembles the cancer phenotype in mammals [66]. Recent studies
have also used zebrafish to investigate the genetic relationship between mitochondrial pyruvate
carrier 1 (MPC1) and APC. Data from this research has demonstrated that (1) apc controls the levels of
mpc1 and (2) the knockdown of mpc1 recapitulates the phenotypes of impaired apc function, such as
failed intestinal differentiation. Moreover, exogenous human MPC1 RNA rescued failed intestinal
differentiation in apc-deficient zebrafish [67].
In recent years, zebrafish models have been developed to investigate whether the mutations
of human H-RAS, N-RAS, K-RAS or zebrafish k-ras caused tumorigenesis, including models that
illustrate chordoma [68], melanoma [69], rhabdomyosarcoma [70,71], brain tumors [72], gill tumors [73],
liver tumors [74], pancreatic tumors [75], and other tumors that faithfully recapitulate human disease
symptoms. The shock-inducible Cre/Lox-mediated K-RASG12D transgenic fish approach can be
conditionally caused within transgenic fish via heat shock treatment. This heat shock-inducible
recombination approach has enabled the generation of multiple types of K-RASG12D-induced
rhabdomyosarcomas (RMS), myeloproliferative disorders, and intestinal epithelial hyperplasia.
For example, K-RASG12D activation in intestinal epithelial cells triggered intestinal hyperplasia
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in zebrafish. This is consistent with findings that indicated 50% of human CRC cases have RAS
gene mutations [76]. In zebrafish, cases of intestinal epithelial hyperplasia were characterized
by epithelial cells with severely disorganized intestinal epithelial architecture. Specifically, these
cells showed several foci forming large outgrowths in the gastrointestinal cavity of K-RASG12D fish.
The K-RASG12D-induced tumor and hyperplasia transgenic models generated here are similar to their
related human malignancies [52].
Two tp53 mutant (tp53N168K and tp53M214K) fish that harbor missense mutations in the
DNA-binding domain of the tp53 gene have been mutagenized by N-ethyl-N-nitrosourea (ENU).
Both of the mutated tp53 alleles were dominant-negative, which is orthologous to cancerous mutations
in human TP53 cells [77]. Homozygous tp53M214K mutant fish spontaneously formed tumors starting
at the age of 8.5 months, and the tumor incidence rate was 28% when fish were 16.5 months old.
The most common malignant tumors in tp53 mutant zebrafish were peripheral nerve sheath tumors [77].
According to the literature, tp53 zebrafish mutants have been used to study the gastrointestinal
tumorigenesis of liver cancer [78] and intestinal tumors [51], as the synergistic interactions between
target genes and the tp53 mutation encourage the formation of these tumors. The allelic loss of TP53
has also been observed in human CRC, and is thought to be a late event that occurs during the
transition from adenoma to carcinoma [79]. Data from mouse tumor models have also suggested that
TP53 inactivation is an essential event in the progression of pancreatic cancer [80], liver cancer [81],
and colorectal cancer [82]. However, assessing the role played by zebrafish tp53 and tp53-related
pathways in both wild-type and mutant fish could facilitate a better understanding of the role played
by this pleiotropic pathway [79].
Primary risk factors of human gastrointestinal cancer include infection with Helicobacter pylori or
other bacterial strains that carry the virulence factor cagA. To elucidate the mechanism that underlies
the cagA promotion of cancer formation, the expression of cagA by β-actin or FABP2 has been studied
in both wild-type and tp53 mutant zebrafish [77]. The expression of cagA led to significantly increased
rates of intestinal epithelial cell proliferation in zebrafish by expressing either the wild-type or
a phosphorylation-resistant form. Furthermore, the target genes of the WNT pathway, such as cyclinD1,
axin2, and myca, were significantly upregulated. Co-expression of cagA with the loss-of-function allele
axin1 also increased the proliferation of intestinal cells; however, co-expression of cagA with tcf4 (a null
allele of the key β-catenin transcriptional cofactor) restored intestinal proliferation to that of wild-type
fish, which showed normal intestinal architecture, with a single layer of epithelial cells lining the
mucosal folds, at 18 months. Additionally, overexpression of cagA (under the control of ubiquitous
β-actin or the intestine-specific FABP2 promoter) induced mucosal fold epithelial hyperplasia, dysplasia
within mucosal sulci, and mucosal fold fusion in the intestines of 12-month-old wild-type fish.
Intestinal epithelial hyperplasia and definitive neoplasia, such as adenocarcinoma and small cell
carcinoma, were also observed in 12-month-old tp53 and FABP2-cagA/tp53M214K−/− mutant fish.
Finally, a synergistic interaction between cagA and the loss-of-function mutation in the tp53 allele
were found to facilitate the formation of small cell carcinoma and adenocarcinoma in the intestine
of FABP2-cagA/tp53M214K−/− transgenic fish [51]. This model established that the intestinal tumors
transgenic model would be a great advantage in the study of cagA-associated gastrointestinal cancers
(Table 1).
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Table 1. Zebrafish animal models of intestinal disorder and tumors.
Gene Name System or Mutation Site Phenotypes Stage Refs.
mpc1 Knock down of mpc1 Failed intestinal differentiation 96 hpf [67]
apc Stop codon in the MCR Liver and intestine tumors 15 months [65]
apc+DMBA Stop codon in the MCR Intestinal adenomas 14 months [66]
tp53M214 Point mutations in the DBM
Peripheral nerve sheath tumors, intestinal
hyperplasia and adenocarcinoma 12 months [51,77]
K-RASG12D HSP-inducible Cre/Lox
Rhabdomyosarcomas, myeloproliferative




Intestinal hyperplasia, dysplasia and
mucosal fold fusion 12 months [52]
cagAEPISA
B-actin-constitutive
expression Normal 12 months [51]
cagA FABP2-constitutiveexpression
Intestinal hyperplasia, dysplasia and




Intestinal hyperplasia, adenocarcinoma and
small cell carcinoma 12 months [51]
MCR: Mutation cluster region; DMBA: 7,12-dimethylbenz[a]anthracene; DBM: DNA-binding domain; cagAEPISA:
A cagA mutant lacking ELISA motifs; HSP: Heat shock promoter; FABP2: Intestinal fatty acid-binding
protein promoter.
5. The Potential of Zebrafish Xenograft Models to Benefit the Study of CRC Tumor Metastasis
and Drug Screening
Pioneering work conducted by several laboratories has indicated that zebrafish embryos have the
potential to benefit large-scale drug screening applications [83,84]. Zebrafish can be arrayed in a variety
of isolated 12-well, 24-well, and 96-well plates (or even larger plates). For this, fish are bathed in water
that contains the small molecules or chemical compounds of interest, a procedure that is ideally suited
for high-throughput screening [85]. Over the past decade, the study of these zebrafish models is the
most relevant research in clinical relevance [83,84]. Living cells or tissues can be transposed from one
species to another using a xenograft method [86].
Casper zebrafish mutants [87] and vascular fluorescent reporter transgenic zebrafish lines
(fli1a:EGFP) [88] have also previously been generated. Casper zebrafish lack melanocytes and
iridophore cells and are therefore transparent from the embryonic stage through to adulthood;
the fli1a:EGFP reporter line permits the visualization of both blood and lymphatic vessels.
Whole-mount alkaline phosphatase vessel staining assays can be used with fli1a:EGFP transgenic
embryos to investigate angiogenesis, tumor invasion, tumor metastasis, and anti-vascular
endothelial growth factor (VEGF) drugs, as well as to disseminate cancer cells [37,89]. In addition,
the lymphocyte-deficient rag2E450fs (casper) mutant transparent line (ZFIN allele rag2fb101) has
been engrafted into a wide variety of normal and cancerous zebrafish cells to (1) optimize cell
transplantation, (2) improve the visualization of fluorescently-labelled cancer cells at a single-cell
resolution, and (3) analyze interactions between tumor cells and other key players in the tumor
microenvironment. The tumor cells transplantation method using rag2E450fs (casper) mutant also
enables cancer processes to be visualized at a single-cell resolution in vivo [90,91]. Indeed, in conjunction
with advances in imaging technology, these mutant lines have created new opportunities for zebrafish
xenograft models to be employed in the study of tumor cell metastasis and in the screening of
novel drugs [37,92].
In another study, researchers labeled two human colorectal cancer cell lines (SW620 and SW480)
with 1,1′-dioctadecyl-3,3,3′3′-tetramethylindocarbocyanine (DiI), a lipophilic fluorescent tracking
dye. After labeling, cells were collected and injected into the yolk sac or perivitelline space of 2 dpf
zebrafish embryos. The colorectal SW620 cells then proliferated, migrated, and formed compact
cancer cells. Masses were identified seven days later near the intestinal lining [93]. Conversely,
the DiI-labeled non-transfected SW480 cells were irradiated with 0–10 Gy immediately following
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injection. After 24 h, the number of cells that had disseminated into the tail was determined, wherein
a dose-dependent relationship was observed between disseminated cells and radiation intensity
(e.g., the number of cancer cells found in the tail of embryos that had received a radiation dose of 10 Gy
had significant increased). SW480 cells knocked down for AEG-1 were also injected into the zebrafish
perivitelline cavity and irradiated with 0 Gy or 10 Gy. The number of disseminated cells found in
the tail of fish injected with AEG-1 knockdown cells was significantly lower than that of the control
fish. Furthermore, the number of non-transfected SW480 cells (negative control) was significantly
higher in the tail of irradiated embryos than in the control embryos that did not receive radiation
treatment. Yet, there was not a significant increase upon radiation for the SW480 AEG-1 knockdown
cells compared with the unirradiated control. In summary, this study showed (1) that tumor invasion
can be enhanced by radiation, but (2) AEG-1 knockdown can inhibit this process. This was also the
first study to demonstrate that zebrafish comprise an excellent model for the study of early events in
radiation-enhanced tumor invasion [94].
In yet another study, stable fluorescent colorectal carcinoma cells expressing GFP protein
(HCT-116-GFP) were injected into the yolk sac of 2 dpf embryos. These animals were maintained in
96-well plates at 35 ◦C for 24 h to facilitate tumor cell proliferation and embryo recovery. Different
doses of crambescidine-816 (0.5, 1, and 2 μM) or 5′-fluoracile (500 μM) were then administered for
48 h. This was the first study to demonstrate that crambescidin-816 induces colorectal carcinoma in
a zebrafish xenograft model [95]. Recent literature further revealed that CRC zebrafish patient-derived
xenografts (zPDX) derived from surgery resected CRC samples and treated with the same treatment
administered to the patient provide proof of concept experiments that compare responses to
chemotherapy and biological therapies between patients and zPDX [96].
Zebrafish xenograft models can be used for the development and evaluation of anti-cancer drugs.
These models enable the response of human tumors to potential anti-cancer drugs to be observed
directly. Human tumor material is particularly targeted for primary patient-derived biopsy specimens,
and is often hard to maintain in vitro. Therefore, zebrafish models represent an effective way to
reduce the time and expense required to conduct cancer treatment research [92]. Additional future
advances could allow zebrafish to become an excellent in vivo drug testing model, and may provide
an inexpensive and highly scalable platform that can be used in preclinical trials (Figure 1) [97].
Figure 1. Schematic diagram of zebrafish xenograft model. Colorectal cancer (CRC) tumor
cells were labeled with 1,1′-dioctadecyl-3,3,3′3′-tetramethylindocarbocyanine (DiI) dye in vitro,
and approximately 300 tumor cells are injected into the yolk sac of each two days post-fertilization
zebrafish larvae. Tumor invasion, dissemination, metastasis, and angiogenesis can be visualized,
and anti-cancer drug screening can be conducted in vivo in a matter of days.
6. Chemically Induced Enterocolitis in Larvae and Adult Zebrafish
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal
tract. The symptoms of IBD include diarrhea, abdominal pain, weight loss, ulceration, perforation,
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and bowel obstruction. IBD is classified into two major forms, Crohn’s disease (CD) and ulcerative
colitis (UC), both of which can cause high morbidity and mortality. A key feature of CD is the
aggregation of macrophages. CD often forms non-caseating granulomas that affect the whole intestine.
UC is characterized by an increase in neutrophils and a depletion of goblet cell mucin, and usually
affects the mucosal lining of the colon and rectum. Currently, the onset and pathogenic origin of
IBD remain unclear; however, zebrafish provide a platform to investigate IBD (Table 2). Specifically,
chemically-induced enterocolitis is often used to investigate intestinal inflammation. A variety of
zebrafish progeny are suitable for the analysis of chemically induced inflammation [98].
Table 2. The advantages and limitations in the inflammatory bowel disease model of zebrafish.
Items Larvae Adult Zebrafish
Advantages
Many individuals Less skin damage
Live imaging Adaptive immune involved
Germ-free derivation




Chemically-induced skin damage With craft
Less sample number
Example TNBS: immersing larvae in 25–75 ug/mL TNBS from 3 dpf OXO: 0.2% oxazolone by intrarectally injection
DSS: immersing larvae 0.5% (w/v) DSS from 3dpf TNBS: 1 uL per 0.1g of body weight byintrarectally injection
TNBS: 2,4,6-trinitrobenzene sulfonic acid; DSS: Dextran sodium sulfate; OXO: oxazolone.
Chemically-induced enterocolitis models have already been established in both zebrafish larvae
and adult zebrafish, which could cause intestinal epithelium damage and immune cell recruitment.
The first developed an adult fish model for enterocolitis by intrarectally injecting 0.2% oxazolone,
a haptenizing agent. Oxazolone caused the architecture of the intestinal wall to become thick and
disrupted and also caused the intestine to lose goblet cells and undergo an influx of neutrophils
and eosinophils. Furthermore, oxazolone led to an increase in the expression of cytokines, such as
interleukin-1 β, tumor necrosis factor-α, and interleukin-10. That research further showed that
(1) intestinal microbiota contribute to oxazolone-induced enterocolitis, and (2) vancomycin treatment
led to an outgrowth of fusobacteria and reduced the percentage of proteobacteria. Indeed, zebrafish
treated with vancomycin showed a reduction in oxazolone-induced enterocolitis score, decreased
neutrophil infiltration, and diminished cytokine expression [99].
In research that demonstrated how a zebrafish model can be used in high-throughput chemical
screening [100], Fleming et al. established a zebrafish enterocolitis model by immersing 3 dpf larvae in
75 μg/mL of 2,4,6-trinitrobenzene sulfonic acid (TNBS) (which has also been used to induce intestinal
inflammation in mice). Fluorescent dye was then used to image live zebrafish larvae and analyze
intestinal architecture and peristalsis in vivo. TNBS-induced enterocolitis was found to reduce villus
length, enlarge crypts, decrease peristalsis, increase the number of goblet cells, and increase the
expression of tumor necrosis factor-α. Moreover, TNBS was found to cause not only intestinal damage,
but also skin lesions. However, a separate study by Oehlers et al. noted that larvae did not show skin
lesions if they (1) were immersed in lower doses of TNBS or (2) were immersed in the 75 mg/mL dose
for less than three days, to influence the analysis of enterocolitis. However, treatment with prednisolone
or 5-amino salicylic acid slowed the reduction of the progression of enterocolitis. The data also showed
that the number of goblet cells and proliferating cells both increased. Moreover, TNBS induced
leukocytosis and reduced the branches of subintestinal vasculature, and a correlation was found
between microbiota and TNBS-induced mortality. A potential explanation for this correlation is that
microbiota are able to induce the transcription of pro-inflammatory cytokines, such as il-1beta, tnf-alpha,
ccl-20 and il-8, which promote inflammation [101].
TNBS has also been directly injected into the rectum of adult zebrafish to induce enterocolitis.
Histological analysis revealed that this caused intestinal villi to become thicker and shorter, but did not
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affect the number of goblet cells. The survival rate of zebrafish with TNBS-induced enterocolitis
was found to be related to microbiome diversity. In addition, TNBS caused pro-inflammatory
and anti-inflammatory cytokines to be upregulated, and the expression of MCH and its receptor
to increase. These findings suggest another potential therapeutic approach to IBD [102]. He et al.
posited that TNBS may reduce the diversity of intestinal microbiota, which induces enterocolitis
in larvae. Those researchers further showed that the reduction in microbiome diversity was due
to an increase in Proteobacteria and a decrease in Firmicutes. It is possible that those chemicals
influenced the composition of intestinal microbiota, which may have activated the TLR signaling
pathways to initiate mucosal immune-mediated inflammation. However, intestinal damage and
TNF-α overexpression was observed before the occurrence of microbiota dysbiosis, which suggests
that a feedback loop exists between the interactions of the host and microbiota that perpetuated the
inflammatory response [103]. He et al. also conducted additional experiments using germ-free fish,
and found that TNBS-induced enterocolitis was not severe, even though toll-like receptor 3, MyD88,
TRIF, NF-κB, and TNF-α were expressed. When microbial bacteria colonize, the characters revert to
TNBS-treated conventionally-reared zebrafish. In summary, the zebrafish larvae model revealed that
gut microbiota play a key role in TNBS-induced enterocolitis [104].
Dextran sodium sulfate (DSS) is a detergent that is also commonly used in animal models of
IBD [105]. The highest tolerated dose (i.e., that did not induce significant mortality) had a concentration
of 0.5%. Similar to enterocolitis induced by TNBS, DSS-induced enterocolitis caused liver discoloration
and increased the number of neutrophils that migrated to the intestine. Moreover, DSS was found
to upregulate the transcription of ccl20, il1b, il23, il8, mmp9, and tnfa. However, unlike enterocolitis
induced by TNBS, DSS-induced enterocolitis led to the overgrowth of bacteria and reduced the
proliferation of cells. Those researchers further observed that DSS induced the accumulation of
acidic mucins in the intestinal bulb. This phenotype was associated with microbiota, but was
not related to neutrophilic inflammation. Another previous study indicated that increased mucin
secretion could prevent TNBS-induced enterocolitis. The mucosecretory phenotype of DSS was used
to assess protection against TNBS-induced enterocolitis. DSS was found to reduce mortality and
neutrophilic inflammation. In addition, retinoic acid (RA) was a conserved modulator of intestinal
epithelial cell differentiation. Other evidence has also suggested that RA is able to suppress mucin
secretion, and that co-treatment with RA and TNBS increases the mortality rate associated with
TNBS-induced enterocolitis. Furthermore, pre-treatment with DSS in conjunction with RA may
reduce the protective ability of DSS. Results of that study emphasized the importance of mucin
secretion during enterocolitis progression [106]. In addition, Oehlers et al. wrote an additional technical
report that focused on enterocolitis induced by TNBS and DSS that introduced several methods to
assess intestinal damage and inflammatory processes. Those researchers reported that, if the proper
genetic and imaging tools are employed, a zebrafish model could be useful for (1) high-throughput
drug screening and (2) investigations that seek to elucidate the mechanisms that underlie drug
efficacy [107]. They also found that most of the anti-inflammatory drugs they studied were able to
protect against chemically-induced enterocolitis. For example, cholecystokinin (CCK) and dopamine
receptor agonists were found to reduce enterocolitis-associated inflammation, thus providing
a new therapeutic target [108]. TNBS and DSS were also used to establish an inflammatory
lymphangiogenesis model, because they induced intestinal vascular endothelial growth factor (VEGF)
receptor-dependent lymphangiogenesis in zebrafish larvae. This evidence suggests that macrophage
recruitment and macrophage expression of intestinal VEGFs are correlated with intestinal inflammatory
lymphangiogenesis. Therefore, this study helped to elucidate the mechanism underlying inflammatory
lymphangiogenesis during IBD [109].
7. Concluding Comments
In this review paper, we provided an overview of the latest research that employed zebrafish
models of intestinal disorders and tumors. Zebrafish have been found to share a substantial number
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of conserved genes with humans, and zebrafish tissue morphology is also similar to that of humans.
Recent reports have used cells or mouse models to elucidate the disease and its pivotal role in cancer
initiation. The zebrafish model offers unique advantages and can greatly contribute to the field of
cancer research. Therefore, the development of zebrafish models for intestinal disorders and tumors
should greatly benefit studies that seek to investigate potential cancer treatments or the mechanisms
that underlie tumorigenesis. At present, zebrafish models have been established for several bowel
diseases and intestinal tumors, including apc-mutant, K-RASG12D, cagA, and cagA/tp53M214K−/−.
Zebrafish models have also been used to investigate preclinical and primary tumors, tumor metastasis,
cancer biomarkers, targets and small molecule drugs in human digestive organs. Although some
understanding of the molecular mechanisms and biological functions associated with intestinal
diseases and intestinal neoplasms exists, current knowledge is limited. With the ability to facilitate
high-throughput screening for the discovery of novel therapeutic agents, zebrafish could become
increasingly important as an in vivo model (Figure 2). Finally, as the utility of zebrafish models in the
study of cancer becomes more widely accepted it may promote further drug discovery in the future,
thus one day ahead of treatment and prognosis in human patients.
Figure 2. Roles of zebrafish intestinal disorder and tumor models in present and future research.
Zebrafish is an ideal genetic and disease model system which is accessible for rapid screening and
experimental manipulation for preclinical studies. In the future, zebrafish models could be used for
patient selection in clinical trials.
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Abstract: Cancers of the digestive system remain highly lethal; therefore, the care of patients
with malignant diseases of the digestive tract requires the expertise of providers from multiple
health disciplines. Progress has been made to advance the understanding of epidemiology and
genetics, diagnostic and screening evaluation, treatment modalities, and supportive care for patients
with gastrointestinal cancers. At the Multi-Disciplinary Patient Care in Gastrointestinal Oncology
conference at the Hershey Country Club in Hershey, Pennsylvania on 29 September 2017, the faculty
members of the Penn State Health Milton S. Hershey Medical Center presented a variety of
topics that focused on this oncological specialty. In this continuing medical education-certified
conference, updates on the population sciences including health disparities and resistance training
were presented. Progress made in various diagnostic evaluation and screening procedures was
outlined. New developments in therapeutic modalities in surgical, radiation, and medical oncology
were discussed. Cancer genetic testing and counseling and the supportive roles of music and arts
in health and cancer were demonstrated. In summary, this disease-focused medical conference
highlighted the new frontiers in gastrointestinal oncology, and showcase the multi-disciplinary care
provided at the Penn State Cancer Institute.
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1. Introduction
The Multi-Disciplinary Patient Care in Gastrointestinal Oncology conference was held on
September 29, 2017 at the Hershey Country Club in Hershey, Pennsylvania, U.S. This conference’s
target audience included primary care physicians, gastroenterologists, medical oncologists, surgical
oncologists, radiation oncologists, nurse practitioners, physician assistants, and nurses. The faculty
members of the Penn State Cancer Institute and Penn State Health Milton S. Hershey Medical
Center presented a variety of topics that focused on the frontiers in caring for patients with various
gastrointestinal cancers. The purpose of this conference was to provide updates on new developments
and emerging trends in caring for patients with various malignant diseases of the digestive system.
The objectives of this program were to (1) recognize the risk factors and genetic mutations of cancers
in the digestive system for prevention and early detection, (2) discuss diagnostic modalities and
multi-disciplinary treatment of patients with digestive organ cancers, and (3) explore supportive
interventions for patients with malignant diseases of the digestive system.
2. Population Sciences in Cancers of the Digestive System
2.1. Epidemiology of Cancers in the Digestive System
In 2018, the estimated number of new cases of cancer of the digestive system was the highest
among all cancer sites in the United States [1]. Among the cancers of the digestive organs, colon cancer
was the most prevalent. From 2007 to 2013, the five-year relative survival rates by all tumor stages
at diagnosis for pancreatic cancer was the lowest among all cancer sites. The next lowest five-year
relative survival rate was attributed to cancers in the liver, intrahepatic bile duct, esophagus, stomach,
and lung. Lengerich, V.M.D., M.S., Associate Director of Health Disparities and Engagement, provided
an overview of the epidemiology of digestive system cancer in the United States.
2.1.1. Health Disparities in Appalachia
Lengerich presented public health data on various cancers of the digestive system in Appalachia,
in which certain counties of central Pennsylvania are located. Compared with the general population
in the United States, the Appalachian residents tend to have less contact with physicians, lower levels
of preventive care, and less health insurance coverage for non-elderly people. Lengerich reported
epidemiological data on health disparities in the Appalachian communities. In particular, the incidence
and mortality rates of colon cancer and rectal cancer in the Appalachia were greater than of the U.S.
population [2–4]. These data suggest relatively little use of screening interventions for colorectal
cancer in rural Appalachia. This may be related to the low level of awareness of regular screening
for colorectal cancer among the general population in Appalachia. Other contributing factors may
include low availability of screening centers, long distances to health care facilities, high rates of
unemployment and poverty, and inability to afford travel to screening facilities [5].
Various strategies attempted to reduce health disparities in cancer in the Appalachian communities
were presented. An active area of investigation is the use of screening interventions for prevention
and early detection of colorectal cancer, including a national, multimedia campaign called Screen for
Life, which aims to educate people aged 50 or older about the importance of regular screening tests for
colorectal cancer [6]. The effectiveness and methods for dissemination of Screen for Life materials in
rural Appalachia were examined by a network of investigators working in medically under-served
regions. These reports indicated a substantial potential for the Screen for Life materials and campaign,
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though limited at the local level, in rural Appalachia [7–9]. However, these observations led to the
hypothesis that the number of individuals in rural Appalachia seeking colorectal cancer screening
could be increased by disseminating Screen for Life materials at state, regional, and community levels
through health care practices and organizations [5]. Additionally, primary care physicians may help
engage patients in screening for colorectal cancer by encouraging the use of fecal occult blood testing
when colonoscopy is not possible and systems-based reminders that provide electronic resources that
are not visit-dependent [10].
Limited access to healthcare services is challenging for those who live in rural communities,
and strategies to involve Appalachian populations as participants in research and overcome that
disparity were discussed. These include community-based participatory research in rural communities
with the goals of increasing awareness of community assets and enhancing treatment-related care and
psychosocial care [11]. Through collaboration with community physicians, these initiatives may help
improve patients’ access to tertiary care and clinical studies at academic cancer centers, and facilitate
education of patients and the general population. Other strategies include raising funding support for
research on health disparities, increasing availability of screening interventions for early detection of
cancer, and development of community plans to enhance survivorship by improving the long-term
health and well-being of cancer survivors in rural locations.
2.1.2. Key Points and Recommendations
Despite advances in screening, early detection, diagnosis, and treatment of various malignant
diseases, digestive system cancer incidence and mortality rates remain among the highest.
The disparity in cancer care for people in Appalachia is a longstanding problem, which is partly
a socioeconomic issue. Malignant diseases in the digestive organs besides colorectal cancer are largely
unexplored in the Appalachian population. Special emphasis of research efforts, judicial allocation of
funding support for research, and prudent distribution of resources will hopefully make a meaningful
impact on health by lessening the burden of cancers of the digestive system.
2.2. Exercise in Cancer Patients and Survivors
Growing evidence suggests the roles of exercise in improving treatment response and reducing
treatment-related toxicities in cancer patients, as well as preventing disease recurrence in cancer
survivors. The report of a recent survey demonstrates that oncologists have little knowledge regarding
exercise counseling, and they are not routinely discussing exercise with their patients [12]. Schmitz,
Associate Director of Population Sciences, described the benefits of exercise in patients diagnosed with
various malignant diseases with an emphasis on colon cancer.
2.2.1. Clinical Studies of Exercise in Cancer Patients and Survivors
Schmitz provided the existing and emerging evidence for the safety and efficacy of exercise
training during and following systemic treatment of cancer. A large number of studies demonstrated
that exercise is safe in patients with breast cancer, including those who had exercise training during
chemotherapy or radiation therapy, as well as those who had exercise training following completion
of chemotherapy or radiation therapy [13]. The adverse events reported in those studies, such as
plantar fasciitis and other musculoskeletal injuries, were mild and rare. Notably, for women who have
had surgical resection of their axillary lymph nodes and/or radiation therapy to the axilla, aerobic,
and/or resistance training did not cause or worsen lymphedema. Additionally, studies of exercise
interventions in survivors of prostate cancer showed that exercise is safe in this population [13].
Importantly, a significant association between high levels of exercise and low risks of cancer-specific
mortality and cancer recurrence were observed in patients with breast cancer or prostate cancer as
well as other malignant diseases [14].
Colon cancer is the third most common cancer, which is associated with a fairly good
prognosis. Yet, few clinical studies have evaluated the potential benefits of exercise for reducing
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chemotherapy-related toxicities and improving treatment efficacy. None of the trials addressed
safety or adverse events except one report, which indicated that there was no significant abnormality
in electrocardiograms during maximal aerobic fitness testing [15]. However, one study reported
a statistically significant association between high exercise levels and a low risk of recurrence and
all-cause mortality of colorectal cancer [16]. A clinical study to investigate the effects of aerobic exercise
on tumor recurrence and as the molecular and cellular pathways associated with physical activity
among patients with stage II and III colon cancer was completed (www.clinicaltrials.govNCT02250053).
Analysis of the results of this important study pends.
2.2.2. Clinical Studies of Exercise in Cancer Patients at Penn State Cancer Institute
Currently, a clinical study is ongoing at the Penn State Cancer Institute and regional facilities to
further investigate the safety and efficacy of resistance training in patients receiving chemotherapy for
treatment of colorectal cancer (www.clinicaltrials.govNCT03291951). This is a randomized, open-label,
controlled trial of resistance training intervention in patients with newly-diagnosed stage II or III colon
cancer receiving chemotherapy. The primary goal of this study is to examine the effects of resistance
training on chemotherapy-related outcomes, including dose delays, dose reductions, early stoppage,
and grade 3 and 4 toxicities. This clinical trial consists of two aspects: an in-person and telephone-based
intervention to promote home-based resistance training, and a wait-list, control group. In the resistance
training group, the subjects will work with an exercise professional on the same day as a chemotherapy
infusion session, and the subjects will complete a series of exercises at home twice weekly throughout
the intervention. For the control group, the subjects will be told to continue whatever exercise
program they have been undertaking up to enrolling in the study, but to not increase exercise or begin
weight-lifting over the period of study participation.
Another study is currently open for enrollment at Penn State Cancer Institute for patients who
receive chemotherapy for treatment of any solid tumor including cancers in the digestive system
(www.clinicaltrials.govNCT03461471). The primary objective of this study is to assess the safety,
feasibility, and acceptability of an exercise program within the course of chemotherapy. This is an
open-label, single group study for patients diagnosed with a solid tumor malignancy at stages I to IV.
Feasibility will be accomplished if one-third of the patients receiving chemotherapy actually perform
the prescribed exercise (one exercise session per week for four weeks). Other outcome measures
include changes in pain, physical function, nausea, emesis, and arthralgia as well as alterations of
chemotherapy (dose delays and changes).
2.2.3. Key Points and Recommendations
Numerous clinical studies have demonstrated the benefits of exercise training in terms of physical
functions and quality of life for patients with cancer. Significant association has been reported between
high exercise levels and reduced risks of cancer recurrence and cancer-specific mortality. The evidence
to date supports the recommendation of regular exercise for people with cancer as well as those
who have completed cancer treatment. Ongoing studies are being designed and conducted to test
the hypothesis that exercise is safe and improves treatment response, quality of life, and survival in
patients, and reduces toxicities for various malignant diseases including those in the digestive system.
3. Diagnostic Evaluation of Esophageal, Pancreatic, Biliary Tract, and Hepatocellular Carcinoma
Technological advances have been made in the diagnostic evaluation of cancers of the digestive
system. Improved accuracy of diagnosis and staging of malignant diseases in the upper gastrointestinal
organs has been enabled by endoscopy along with various imaging modalities. Surveillance of
hepatocellular carcinoma (HCC) and liver transplantation have become increasingly important for
early detection and treatment of this disease.
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3.1. Diagnostic Evaluation and Staging for Cancers of Esophagus, Pancreas, and Biliary System
Endoscopy plays a central role in the diagnosis of cancer in both the upper and lower
gastrointestinal tracts. Maranki, Medical Director of Endoscopy, discussed the diagnostic evaluation
and staging for cancers of the esophagus, pancreas, and biliary system. In particular, endoscopic
ultrasonography (EUS) is an important diagnostic modality for patients with esophageal and pancreatic
carcinoma by evaluating the extent of tumor invasion and any involvement of the regional lymph
nodes, and by enabling tumor biopsy through fine needle aspiration. The use of a new technique
via SpyGlassTM cholangioscopy has improved the diagnostic yield of biliary tract carcinoma through
high-resolution direct visualization with biopsy of the bile ducts.
3.1.1. Diagnosis and Staging of Esophageal Cancer
Esophageal carcinoma, either squamous cell carcinoma or adenocarcinoma, is typically diagnosed
by esophagogastroduodenoscopy with tissue biopsy. Computed tomography (CT) of the chest and
abdomen and positron emission tomography (PET) in combination with CT scans are indicated to
evaluate any metastatic disease. EUS plays an important role in staging the disease based on depth of
invasion of the esophageal wall and involvement of any regional lymph nodes if there is no evidence
of metastatic disease. Endoscopic mucosal resection of early stage tumors (T1a, T1b) can be therapeutic
and curative.
3.1.2. Diagnosis and Staging of Pancreatic Cancer
Imaging studies for diagnosis of pancreatic carcinoma include dual-phase helical CT scans,
transabdominal ultrasonography (US), EUS-guided fine needle aspiration (FNA), endoscopic
retrograde cholangiopancreatography (ERCP), magnetic resonance cholangiopancreatography (MRCP),
and PET scans. The accuracy of these imaging studies for diagnosis of pancreatic carcinoma (PC) was
compared [17]. In particular, the sensitivity and specificity of EUS-guided FNA are 92% and 100%,
respectively; those of ERCP are 70% and 94%, respectively. Moreover, the performance of EUS for
pancreatic adenocarcinoma was compared to CT and MRI scans with regard to nodal staging, vascular
invasion, and resectability.
As shown in Table 1, EUS appears less sensitive but more specific than CT scans for staging
of lymph node involvement, detecting vascular invasion, and determining resectability of tumors.
For nodal staging, EUS is more sensitive and less specific than MRI scans; for detecting vascular
invasion, EUS is less sensitive and more specific than MRI scans. Notably, the performance of EUS is
dependent on the operator, and EUS should be considered complementary to either CT or MRI scans
for the staging of pancreatic adenocarcinoma.
Table 1. Comparison of endoscopic ultrasonography (EUS) and either computed tomography (CT) or
magnetic resonance imaging (MRI) scans for pancreatic adenocarcinoma.
EUS vs. CT EUS vs. MRI
Sensitivity Specificity Sensitivity Specificity
Nodal staging 24% vs. 58% 88% vs. 85% 36% vs. 15% 87% vs. 97%
Vascular invasion 58% vs. 86% 95% vs. 93% 42% vs. 59% 97% vs. 84%
Resectability 87% vs. 90% 89% vs. 69% NA NA
NA: not available. This table is modified from reference [17].
3.1.3. Diagnosis and Staging of Cholangiocarcinoma
If a lesion in the biliary tract is identified on imaging studies, such as US, CT, MRI, or MRCP,
EUS-guided FNA or ERCP with biliary brushings are indicated for establishing the diagnosis.
CT-guided biopsy of the tissue is considered if necessary. All lesions suspicious of cholangiocarcinoma
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should be further evaluated with MRI or MRCP. However, diagnosis of cholangiocarcinoma by tissue
biopsy can be challenging, and tissue may be obtained via several techniques. Of note, EUS-guided
FNA is not advisable for hilar and intrahepatic lesions if the tumor is considered resectable. This is
due to concerns of tumor seeding the needle tract. A new technique via SpyGlassTM cholangioscopy
has been shown to improve diagnostic yield for cholangiocarcinoma.
SpyGlassTM cholangioscopy uses fiberoptic technology for high-resolution direct visualization
of the bile ducts. Since the launch of the SpyglassTM Direct Visualization System, the sensitivity for
detecting cholangiocarcinoma has been improved [18,19]. ERCP with SpyglassTM Direct Visualization
System enables the direct visualization of the bile ducts, thus facilitating tissue biopsy and therapeutic
intervention. With the implementation of a new digital system, the SpyGlassTM cholangioscopy
provides a sensitivity and specificity of 90% and 95.8%, respectively, for diagnosis of malignant disease
in the bile ducts [20].
3.1.4. Key Points and Recommendations
For diagnostic and staging evaluation of esophageal carcinoma, PET and CT scans and EUS are the
standard of care. Besides CT scans, the role of EUS is particularly valuable for evaluating patients with
localized pancreatic carcinoma that appears resectable on the initial imaging study. A new technique
using ERCP with SpyglassTM Direct Visualization System has improved the sensitivity and specificity
for the diagnosis of cholangiocarcinoma.
3.2. Hepatocellular Carcinoma
HCC is a major cause of cancer-related mortality worldwide. The incidence, disease burden,
and mortality of HCC have been rising in the United States. Krok, Medical Director of Liver
Transplantation, provided a hepatologist’s perspective on HCC. Krok’s presentation focused on the risk
factors of HCC, screening modalities of HCC, and liver transplant for treatment of selected patients.
3.2.1. Risk Factors for HCC
An update on the risk factors for HCC in the United States was provided. For persons above
65 years old, diabetes and obesity represent the major risk factors for HCC, and they are followed by
hepatitis C virus (HCV), alcoholism, smoking, hepatitis B virus (HBV), and rare genetic disorders [21].
In obese men, liver cancer is associated with the highest relative risk of death among all types of
cancer [22]. For patients with hepatitis C viral (HCV) infection, HCC is generally developed in the
setting of advanced hepatic cirrhosis [23]. HBV DNA is considered a key risk for the development of
HCC, and the baseline serum level of HBV DNA is correlated with the incidence of HCC over time.
3.2.2. Screening of HCC
Surveillance of HCC has been shown to improve outcomes by early tumor detection, reduction
of total mortality, and improved survival [24]. Surveillance guidelines for high-risk patients by
ultrasonography (US), with or without serum alpha-fetoprotein (AFP) or prothrombin induced by
vitamin K absence-II (PIVKA-II), have been recommended by various cancer organizations in the
United States, Europe, Japan, and other Asian-Pacific countries. These screening tests are indicated at
various time intervals, from every 3 months or 6 months to 12 months. Besides the U.S., other imaging
modalities for surveillance of HCC, including CT and MRI scans, were described. Their advantages and
disadvantages were compared, with MRI scans showing the highest sensitivity of detecting HCC [25].
Special emphasis was placed on contrast-enhanced ultrasonography (CEUS), which demonstrates
higher sensitivity, negative predictive value, and overall accuracy that standard US [26]. Furthermore,
a meta-analysis indicated that CEUS and gadoxetate-enhanced MRI scans show the highest sensitivity
and positive predictive value for detecting HCC [27].
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3.2.3. Liver Transplantation for Treatment of HCC
Liver transplant is a viable treatment option for many patients with HCC. Liver transplant can
be a curative intervention of choice for HCC, especially for patients with cirrhosis that cannot easily
have a surgical resection. The five-year survival rate is about 75%, which is comparable to patients
without HCC who undergo liver transplant. Both cadaverous and living donor liver transplant
can be offered. In the United States, there have been more than 1,000 liver transplants per year for
patients with HCC since 2008. A total of 15,045 liver transplants have been performed for patients
with HCC. Currently, there are 14,104 patients waiting for a liver transplant with a diagnosis of
HCC. Currently, the Milan criteria are the most commonly used for evaluating candidates for liver
transplant [28]. Once a patient is considered to be within the Milan criteria and meets all criteria for
listing for liver transplant, they will be listed for transplant. Various modalities, including transcatheter
arterial chemoembolization (TACE), radiofrequency ablation, and Yttrium-90, may be used for bridge
treatment prior to liver transplantation. For HCC with vascular invasion, tumor recurrence following
liver transplant progressively increases with time [29].
3.2.4. Key Points and Recommendations
The major risk factors for HCC in the United States include obesity, hepatitis C viral infection,
and alcoholism. Interventions and research efforts should be focused on developing strategies,
especially behavioral modification for preventing HCC. Imaging studies using US, CT, and MRI
scans along with serum tumor markers, including AFP and PIVKA-II, facilitate early detection of HCC.
For individuals at risk of developing HCC, active surveillance is indicated with the hope of detecting
small tumors at a localized stage, so that they can be cured by liver transplantation or surgical resection.
Whereas liver transplantation is a curative intervention for both HCC and the underlying hepatic
cirrhosis, organ donation remains a limiting factor and requires continued public support.
4. Therapeutic Interventions by Surgical Resection, Radiation Therapy, and Systemic Treatment
A number of advances have been made in the localized, systemic, and targeted treatment of
cancers of the digestive organs. New developments in surgical management as well as pre-operative
and post-operative interventions have been applied for improved clinical outcomes. Refinement
of criteria for radiation therapy continues, and new technologies for precise radiotherapy while
minimizing toxicity has been investigated. Constant new developments have occurred in systemic
therapies for improving the treatment response for patients with advanced or metastatic diseases.
4.1. Surgical Gastrointestinal Oncology
Surgical interventions have been playing a crucial role in the treatment of various malignant
diseases in the digestive system. Gusani, Group Leader of Liver, Pancreas, and Foregut Program and
Surgical Oncologist, presented new paradigms in the surgical management of gastrointestinal cancer.
Gusani discussed the importance of treatment of the whole patient involving prehabilitation and
survivorship, and treatment of advanced tumors by considering the whole range of treatment options.
These include multi-visceral and extended resections and the use of neoadjuvant therapy. Improved
surgical outcomes through better understanding of anatomy, surgical techniques, and peri-operative
medicine, and minimally invasive surgery were also discussed.
Gusani presented a surgeon’s perspective on various aspects of gastrointestinal oncology.
The surgical techniques for resection of gastric and gastroesophageal junction adenocarcinoma,
hepatocellular carcinoma, metastatic colon adenocarcinoma in liver, and pancreatic tumors
(adenocarcinoma, cysts, and neuroendocrine tumor) were described. Highlights of their presentation
include the role and goal of physical activity in survivorship of patients who have undergone
surgical resection of gastrointestinal carcinoma, and minimally invasive surgery that offers benefits in
peri-operative outcomes while preserving oncologic outcomes.
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4.2. Radiation Gastrointestinal Oncology
Technological advances have been made and applied in radiation oncology, and increasing
evidence has indicated the clinical efficacy of stereotactic body radiation therapy (SBRT) in cancers
of the digestive system. Mackley, Attending and Consultant Radiation Oncologist, provided an
update on the general indications of radiation therapy for upper gastrointestinal malignancies based
on the National Cancer Consortium Network (NCCN) treatment guidelines. This included current
recommendations that support SBRT as an option in the treatment of unresectable PC and HCC.
Tchelebi, Attending and Consultant Radiation Oncologist, further discussed the technical delivery of
SBRT and the clinical evidence that supports this emerging treatment modality.
4.2.1. SBRT in Pancreatic Carcinoma
SBRT involves very high dose radiation delivered to a highly conformal treatment volume
over a short treatment course (about one to five fractions over one to two weeks). As compared to
three-dimensional conformal radiation therapy, SBRT may achieve superior tumor control by delivering
a higher biological effective dose over a shorter overall treatment time with increased sparing of
adjacent of critical organs. Moreover, Tchelebi presented data from recent clinical studies about using
SBRT in the neoadjuvant setting for patients with borderline resectable pancreatic carcinoma (BRPC)
and unresectable locally advanced pancreatic carcinoma (LAPC) [30]. Clinical data from an earlier
study and recent studies on the use of SBRT as definitive treatment of locally advanced unresectable
pancreatic carcinoma were also presented. Tchelebi concluded that SBRT improves resectability of
BRPC and enables 5–10% of patients with unresectable LAPC to undergo resection. Additionally,
clinical trials are ongoing to investigate chemotherapy (modified FOLFIRINOX) with or without
SBRT in LAPC (www.clinicaltrials.govNCT01926197), and using adjuvant SBRT for patients following
radical resection of pancreatic carcinoma with advanced tumor stages or lymph node involvement
(www.clinicaltrials.govNCT02461836).
4.2.2. SBRT in Hepatocellular Carcinoma
External beam radiation therapy (EBRT) has been used for treatment of patients with HCC in
various settings. EBRT may be considered for definitive treatment of HCC unsuitable for resection,
liver transplant, or radiofrequency ablation; as a bridge to liver transplant; as definitive therapy for
HCC unsuitable/refractory to TACE; or when there is tumor invasion of the portal vein. EBRT may be
used at low doses for symptomatic HCC. Tchelebi reviewed the data from multiple clinical studies
that investigated SBRT for HCC [30]. They discussed the advantages of SBRT for HCC including
the effectiveness for large tumors (>10 cm), HCC with thrombosis in the portal vein, or when other
local therapeutic modalities are contraindicated or less effective; sparing of adjacent un-involved liver;
and producing complete pathological responses in patients who undergo liver transplant. Tchelebi
concluded that SBRT can be used in HCC when other local therapies are not feasible (such as for large
tumors or thrombosis in the portal vein), or in conjunction with TACE, or as a bridge to liver transplant.
4.3. Medical Gastrointestinal Oncology
Systemic therapies play important roles in various gastrointestinal malignancies at different
tumor stages. Progressive advances have been made in improving the therapeutic efficacy of systemic
treatment using chemotherapy, targeted therapy, and immunotherapy [31–41]. Results of recent
clinical studies suggested new treatment options for patients with various malignant disease in the
digestive system. Yee, Team Leader of Gastrointestinal Oncology and Attending and Consultant
Medical Oncologist, provided an overview of the standard treatment of pancreatic, gastroesophageal,
hepatobiliary, and colorectal carcinoma. Yee presented and discussed the most recent evidence
from international medical conferences and medical literature on chemotherapy, targeted therapy,
and immunotherapy in gastrointestinal oncology.
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4.3.1. Systemic Treatment of Pancreatic Carcinoma
Systemic chemotherapy is an essential component of standard treatment for patients with PC
diagnosed at all stages. New developments have been focusing on targeted agents directed against the
tumor microenvironment and cancer stem cells. In a phase II clinical study of 246 patients, PEGylated
hyaluronidase (PEGPH20), that degrades hyaluronan in the tumor-associated stroma, in combination
with nab-paclitaxel and gemcitabine, significantly prolonged progression-free survival (PFS) and
overall survival (OS), as compared to nab-paclitaxel and gemcitabine [42]. Moreover, this study
suggested that hyaluronic acid is a potential predictive biomarker of tumor response to PEGPH20.
Results of a first-in-human clinical trial using napabucasin that targets cancer stem cells by
inhibiting the activation of the signaling molecule STAT3 have been reported. In a phase 1b/II study
of 66 patients with metastatic PC, the STAT3 inhibitor napabucasin that targets cancer stem cells,
in combination with nab-paclitaxel and gemcitabine, produced anti-tumor response, with an overall
response rate of 55%, disease control rate 93%, and progression-free survival 7.1 months [43]. A phase
III study to investigate napabucasin in combination with nab-paclitaxel and gemcitabine versus
nab-paclitaxel and gemcitabine is currently recruiting worldwide including at the Penn State Cancer
Institute (www.clinicaltrials.govNCT02993731).
4.3.2. Systemic Treatment of Gastric and Gastroesophageal Carcinoma
For localized gastric carcinoma (GC) and gastroesophageal junction carcinoma (GEJC),
peri-operative systemic chemotherapy using a combination regimen consisting of cisplatin and
5-fluorouracil is the standard of care. In a phase III study of 716 patients, a group of patients
received peri-operative FLOT (docetaxel, oxaliplatin, 5-fluorouracil), and another group received
peri-operative ECF (epirubicin, cisplatin, 5-fluorouracil) or ECX (epirubicin, cisplatin, capecitabine) [44].
Peri-operative FLOT improved clinical outcomes with a significant prolongation of progression-free
and overall survival, reduction in the progression of disease during or following pre-operative
chemotherapy, and an increase in pT0, pT1, and R0 resection. Results of this study support
peri-operative FLOT as the new standard of systemic treatment for patients with resectable GC
or GEJC.
The anti-PD-1 antibodies pembrolizumab significantly improved the response rate and overall
survival beyond second line treatment of patients with advanced GC or GEJC expressing PD-L1.
Results of this study led to approval of pembrolizumab by the Food and Drug Administration (FDA)
in this patient population [45].
4.3.3. Systemic Treatment of Hepatocellular and Biliary Tract Carcinoma
The anti-PD-1 antibody nivolumab was investigated in a study of 262 sorafenib naïve or
sorafenib-treated patients with advanced HCC. Nivolumab produced tumor responses regardless
of etiology of HCC or tumor expression of PD-L1 [46]. Results of this study led to FDA approval of
nivolumab for treatment of patients with HCC following prior sorafenib regardless of PD-L1 status.
In a phase III trial, the clinical efficacy of adjuvant capecitabine was evaluated in resected
biliary tract carcinoma (BTC). In this study, 447 patients were randomized to receive adjuvant
capecitabine versus observation. Intrahepatic (19%), hilar (28%), extra-hepatic (35%), gallbladder
(18%). Capecitabine 1250 mg/m2 on day 1 through day 14 of every 21-day cycle for a total of 8 cycles.
The results of this study indicated that adjuvant capecitabine significantly prolonged overall survival
in resected biliary tract carcinoma [47].
4.3.4. Systemic Treatment of Colorectal Carcinoma
Nivolumab, an anti-PD-1 antibody, has been recently FDA-approved for treatment of patients
with metastatic colorectal carcinoma (CRC) with microsatellite instability-high (MSI-H) or mismatch
repair-deficiency (dMMR) that has progressed following fluoropyrimidime, oxaliplatin, and irinotecan.
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This indication is based on the data from a multicenter, open-label, single-arm, phase 2 clinical trial
(CheckMate 142) [48].
The benefits of three months vs. six months of adjuvant chemotherapy using FOLFOX
(5-fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) in stage III
or high-risk stage II CRC were investigated [49,50]. Results of these studies indicated that three months
of adjuvant chemotherapy is not inferior to six months of treatment. As a result, three months of
adjuvant chemotherapy is recommended for low-risk disease (T1-3, N1). However, the use of three
months of adjuvant chemotherapy for high-risk disease (T4 or N2 tumors) should be tailored to the
individual patient.
4.4. Key Points and Recommendations
Surgical interventions continue to play crucial roles in the treatment of various malignant
diseases in the digestive system. Besides the importance of surgical techniques for resection,
treatment of the whole patient involving prehabilitation, survivorship, and physical activity, as well
as minimally invasive surgery, offer benefits in both peri-operative and oncological outcomes.
While three-dimensional conformal radiation remains the conventional therapeutic modality in
gastrointestinal oncology, SBRT that involves a highly conformal treatment volume over a short
treatment course has emerged as a treatment option that provides benefits in efficacy and safety,
particularly in PC and HCC. Results of the recent clinical trials that investigated chemotherapy,
targeted therapy, and immunotherapy have led to U.S. FDA approval of nivolumab in HCC and
CRC with dMMR or MSI-H, and pembrolizumab in GC or GEJC expressing PD-L1, as well as solid
tumors that display dMMR. Peri-operative FLOT for resectable GC and GEJC, adjuvant capecitabine
for resected (R0) BTC, and three months of adjuvant FOLFOX or CAPOX for low-risk CRC are expected
to become the new standard of care.
5. Gastrointestinal Cancer Genetics
Convincing evidence indicated that the development of cancer typically involves genetic
disposition and behavioral and environmental factors. Although certain risk factors are potentially
modifiable [51], genetic testing of hereditary gastrointestinal cancer syndromes has become an integral
part of patient care in oncology [52]. Technological advances in the next generation sequencing
of human genomes have improved genetic testing for the screening of various malignant diseases,
particularly cancers of the digestive system. Baker, Director of Cancer Genetics, provided an overview
of the genetic syndromes that predispose a person to GC, CRC, and PC. They discussed the
practical aspects and clinical application of next generation sequencing (NGS) panels for hereditary
gastrointestinal cancer.
5.1. Cancer Genetic Testing and Counseling
The genetics of gastric, colorectal, and pancreatic carcinoma were presented. For GC,
approximately 3–5% of patients have a hereditary risk, and three heritable syndromes are known
to predispose primarily to GC: hereditary diffuse gastric cancer (HDGC), familial intestinal gastric
cancer (FIGC), and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS). Specific
genes and types of mutations were identified in HDGC (E-cadherin and α-E-catenin genes), and GAPPS
(promoter 1B mutations the APC gene), whereas no known genetic variants have been identified in
FIGC. The diagnostic criteria for both FIGC, and GAPPS were described, as was the testing criteria for
HDGC [53]. Other cancer syndromes and the associated genes that predispose a person to GC were also
presented. These include familial adenomatous polyposis (APC), hereditary breast and ovarian cancer
syndrome (BRCA1, BRCA2), juvenile polyposis syndrome (SMAD4, BMPR1A), Li-Fraumeni syndrome
(TP53), Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), and Peutz-Jeghers syndrome (STK11).
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In addition to GC, the genetic syndromes associated with hereditary CRC [52] and PC [52,54]
were presented. Other hereditary cancer syndromes with gastrointestinal involvement [55] and the
standards for informed consent for genetic testing in gastrointestinal practice [52] were also described.
5.2. Next-Generation Sequencing Panels
The traditional approach to cancer genetic testing that entails analysis of one gene per condition
at a time using Sanger sequencing was compared to the contemporary approach using NGS panels.
Given the increased number of genes analyzed with NGS panels, the process of informed consent,
out of necessity, had to change dramatically. No longer was each gene discussed independently,
but rather genes were categorized into groups of high, moderate, or low susceptibility regarding their
impact on cancer risk. Risks, benefits, and limitations of NGS panels were also discussed, using case
examples for illustration. Potential benefits include the ability to simultaneously analyze multiple
cancer susceptibility genes in a more cost-efficient manner, thus increasing the likelihood of identifying
one or more cancer predisposition syndromes within a family. Potential risks and limitations, though,
include the higher likelihood of identifying one or more variants of uncertain significance and the
likelihood that a mutation may be identified in a gene for which our knowledge base is still evolving
with regards to the spectrum of associated cancers, the estimated lifetime risks of these cancers, as well
as appropriate management guidelines. In addition, unexpected findings may be identified such as
a gene mutation that is not consistent with the family history of cancer or a mutation in a recessive
gene that has reproductive implications.
Lastly, choosing a laboratory for NGS panels is a practical aspect of cancer genetic testing and
a number of questions will need to be considered and addressed [56]. Evaluation of the technology
being used involves consideration of the testing platform, depth of coverage, and presence of
a deletion/duplication assay. Analysis of the genes involves considering the number of genes examined,
whether a cancer site-specific panel or a pan-cancer panel would be more appropriate, looking at
the proportion of genes that are “medically actionable”, and whether the option exists to modify the
panel or create a custom panel. Other pertinent factors for consideration include the cost of testing
and insurance coverage, the turn-around time, the rate of variants of uncertain significance (VUS),
the reliability of the laboratory, and the ease of laboratory use.
5.3. Key Points and Recommendations
The genetic syndromes and the associated genetic mutations for GC, CRC, and PC have been
identified. Clinicians should be vigilant about individuals with cancer and their family history of
cancer, and should be prompt to refer patients to cancer geneticists for genetic testing and counseling.
Patients with germline mutations that predispose to various malignant diseases will likely benefit
from screening tests for early detection of tumors and taking appropriate measures for preventive and
therapeutic interventions. Cancer genetic testing using NGS panels is expected to produce potential
benefits by concurrent analysis of multiple cancer susceptibility genes in a cost-efficient manner,
thus increasing the likelihood of identifying cancer predisposition syndromes within a family.
6. Supportive Care in Oncology
Complementary to the treatment of cancer, emotional, psychological, and social support are
essential for the well-being of patients, particularly those with gastrointestinal cancers. In clinical
practice, patients with advanced cancer are recommended to receive palliative care early in the disease
course and concurrent with anti-cancer treatment [57]. At the Penn State Cancer Institute, supportive
care services are provided by healthcare providers from multiple disciplines to patients with malignant
diseases. They include palliative care physicians and nurses, clinical psychologists, kinesiologists,
nutritionists, physical therapists, artists and music therapists, acupuncturists, and population scientists
for smoking cessation. A support group that focuses on gastrointestinal cancer patients and survivors
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is underway at the Penn State Cancer Institute. The goals include improving the quality of life for
cancer patients and survivors as well as the well-being of their caretakers.
6.1. Music and Arts in Health and Oncology
A program that integrates music, arts, and creative writing has been established at the Milton S.
Hershey Medical Center through the Center for Humanistic Medicine and Center Stage Arts in Health.
The goal of this program is to provide supportive care by psychological and cognitive improvement.
This program is particularly needed for patients with gastrointestinal malignancies that are associated
with high levels of psychosocial distress, disease burden, and mortality rate. de Boer, Director of
Center Stage Arts in Health, provided an overview of the music and arts programs at Penn State
Health including the Cancer Institute.
6.2. Center Stage Arts in Health
Center Stage Arts in Health is a multi-faceted program that aims to nourish well-being through
the arts. At Center Stage, professional musicians play cheerful and reflective music with a variety
of genres and instruments in the lobby and numerous clinical and family areas. The staff of Center
Stage visit patients upon their admission to the hospital, and patients have the opportunity to choose
artwork created by regional artists to hang in their room during their hospital stay [58]. Murals
are created in the clinical and family waiting areas (https://sites.psu.edu/centerstage/murals/),
and original art is commissioned for display throughout the hospital. A summer lunchtime concert
series is conducted in the outdoor courtyard, featuring local professional ensembles including jazz,
classical, and soft rock music. At Center Stage and the Penn State Cancer Institute, a set of arts
workshops of multiple modalities, including an expressive workshop program, is offered to cancer
patients and their caregivers. A brief video introduction of the Center Stage program can be watched
at https://www.youtube.com/watch?time_continue=8&v=HT3wJn8OoF4.
Faculty-led investigations are ongoing to observe, explore, and quantify the impact of the arts on
the experience of patients and caregivers. During the summer of 2017, a Pennsylvania State University
undergraduate student, Julian Yee, who majors in psychology, participated in research as a Center
Stage Intern. During the internship, Yee assisted the Center Stage Team to promote music and arts in
health. First of all, Yee observed the pertinence of the social interactions between musical artists and
visitors, staff, and patients. From there, Yee recorded the data of musical acts against the audience’s
reactions. Then, they transported art supplies to guide cancer survivors and their families to make art
crafts on Survivorship Day. Finally, they helped paint a mural in a hallway so when children pass by,
they are reminded that the hospital can be a colorful environment.
6.3. Key Points and Recommendations
Emotional, psychological, and social support is an essential component of the multi-disciplinary
care of patients, and particularly those with cancers in the digestive system. For patients with advanced
gastrointestinal cancer, palliative care is recommended concurrent with anti-cancer treatment early in
the disease course. The Center Stage Arts in Health integrates music, arts, and creative writing with
the aim to nurture the well-being of patients through psychological and cognitive improvement.
7. Conclusions
Cancers of the digestive system continue to represent a major cause of physical and psychosocial
burden. Healthcare practitioners and scientists with expertise in multiple disciplines play critical
roles in providing optimal care for patients with these malignant diseases. Recent advances have
been made in gastrointestinal cancer epidemiology and genetics, diagnostic evaluation, treatment
modalities, and supportive care. This conference paper summarizes the presentations by the faculty
members of the Penn State Health Milton S. Hershey Medical Center with a focus on gastrointestinal
oncology. These specialists provided updates on new developments in (1) health disparities and
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resistance training, (2) diagnostic evaluation and screening procedures, (3) conventional and novel
therapeutic modalities, (4) cancer genetic testing and counseling, and (5) music and arts in health and
cancer. In summary, this medical conference highlighted the new frontiers in the multi-disciplinary
care for patients with gastrointestinal cancers.
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Abstract: Hepatocellular carcinoma (HCC) is increasing in incidence, and the associated mortality
rate remains among the highest. For advanced HCC, sorafenib has been shown to slightly prolong
survival, and regorafenib and nivolumab, both recently approved by the United States Food and Drug
Administration (FDA), may produce clinical benefits to a limited extent. Systemic chemotherapy has
been shown to produce a modest response, but there is no clinically valid biomarker that can be used
to predict which patients may benefit. In this case study, we present two patients with metastatic
HCC, they received systemic treatment using capecitabine, oxaliplatin, and either bevacizumab or
sorafenib. The tumor response to treatment was determined by the progression-free survival (PFS).
Molecular profiling of the tumors showed differential expression of biochemical markers and different
mutational status of the TP53 and β-catenin (CTNNB1) genes. We hypothesize that the PFS correlates
with the tumor molecular profiles, which may be predictive of the therapeutic response to systemic
chemotherapy. Further investigation is indicated to correlate tumor biomarkers and treatment
responses, with the objective of personalizing the therapies for patients with advanced HCC.
Keywords: hepatocellular carcinoma; immunohistochemistry; molecular profiling; next-generation
sequencing; precision medicine; predictive biomarkers
1. Introduction
Hepatocellular carcinoma (HCC) is increasing in incidence, and the associated mortality rate remains
among the highest [1]. For patients with localized HCC, surgical resection and liver transplantation may
be offered with curative intent. Palliative local therapy, such as chemoembolization, radiofrequency
ablation, and stereotactic body radiation therapy, are options for treatment [2]. However, for patients
with advanced or metastatic HCC, palliative systemic treatment is the only option, and the associated
survival benefit is limited [3].
For select patients with advanced HCC, sorafenib is the standard first-line systemic treatment [4].
In the second-line setting, regorafenib (a small molecule inhibitor targeting tyrosine kinases and
angiogenesis receptors) and nivolumab (an anti-PD-1 monoclonal antibody) have been recently
approved by the United States Food and Drug Administration (FDA) for patients with advanced HCC,
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which have failed to respond to sorafenib [5,6]. According to the National Comprehensive Cancer
Network (NCCN), patients with unresectable HCC should receive systemic chemotherapy preferably
in a clinical trial setting [7]. HCC is resistant to conventional chemotherapeutic agents possibly related
to pathogenic mutations in certain genes such as TP53 and CTNNB1 (coding for β-catenin), which
are commonly mutated in HCC [3]. This is supported by evidence that mutated TP53 and CTNNB1
contribute to increased cell proliferation and reduced apoptosis in HCC [8,9]. Multiple studies have
indicated that patients with HCC that carry mutations in TP53 have a relatively poor prognosis [10].
Molecular profiling of HCC has been performed to characterize this type of malignancy with the hope
of identifying predictive biomarkers and therapeutic targets.
A retrospective study showed considerable molecular heterogeneity among 350 specimens of
HCC [11]. An immunohistochemical analysis indicated various frequencies of change in the expression
of protein biomarkers and the associated potential therapeutic agents. For instance, a decreased
expression of thymidine synthetase (TS) and excision repair cross-complementation group 1 (ERCC1)
was found in 79.8% and 66.1% of specimens, respectively. Reduced expression of these biochemical
markers suggests potential benefits from fluoropyrimidines and platinum agents, respectively [12,13].
Furthermore, genetic mutations were most frequently identified in the TP53 and CTNNB1 genes in 30%
and 20% of the tested specimens, respectively. While there was no standard effective chemotherapy for
advanced HCC, early phase studies suggested capecitabine and oxaliplatin (CAPOX) to be effective
in patients with HCC. This was demonstrated in a phase II study that showed modest anti-tumor
activity when using CAPOX as a first-line therapy, with a median progression-free survival (PFS) of
4.1 months [14]. Furthermore, a clinical trial to investigate a combination of capecitabine, oxaliplatin,
and bevacizumab (CAPOX-B) as a first-line regimen in patients with advanced/metastatic HCC
showed a median PFS of 6.8 months [15].
In this case study, we present two patients who were diagnosed with metastatic HCC, analyzed
for tumor molecular profiles, and treated with CAPOX in combination with either bevacizumab
or sorafenib. These two patients had different clinical features regarding the etiology of HCC and
treatment responses, and the molecular profiles of their tumors were distinct in the expression of
biochemical markers and genomic DNA mutations. The correlation of the therapeutic response with
the tumor molecular profiling suggests the potential for developing predictive biomarkers using




This is a 65-year-old Caucasian man who presented with progressive weakness and paresthesia
in the bilateral lower extremities. He also complained about urinary retention lasting two days.
His past medical problems included hypertension, psoriatic arthritis, lymphedema in the right lower
extremity, a cardiac murmur, and osteoarthritis in bilateral knees status post left knee replacement.
He had no history of hepatic cirrhosis, diabetes mellitus, steatohepatitis, viral hepatitis, alcoholism,
hemochromatosis, or Wilson’s disease. His family history showed significant “liver cancer” and
hemochromatosis in his father and “cancer in a digestive organ” in his paternal grandmother. He had
worked in the navy as a maintenance supervisor and a shuttle bus driver. He had previously smoked
one pack of cigarettes per day for 20 years and quit smoking 20 years ago; he had previously consumed
alcohol and he last drank in December 2015. The physical examination was remarkable for chronic
edema in the bilateral lower extremities, the spine was non-tender, and no peritoneal ascites was noted.
Laboratory tests showed elevated serum alpha-fetoprotein (AFP) level in the liver, corresponding to
60.9 ng/mL (reference range: 0–15 ng/mL), and normal AFP-L3 (3.6%, reference range: 0–9.9%), while
his carbohydrate antigen 19–9, carcinoembryonic antigen, prostate-specific antigen, and β-human
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chorionic gonadotropin were all within normal limits. Viral hepatitis serology was non-reactive for
both the hepatitis B viral envelope antigen and the hepatitis C virus.
The initial evaluation conducted using computed tomography (CT) scans (December 2015) revealed
multiple lesions in the liver and bones (T6 spine, sacrum, bilateral ribs) (Figure 1). He underwent a T5–T7
laminectomy, an open biopsy of the thoracic intraspinal (extradural) lesion, and excision of the thoracic
epidural neoplasm. The pathology of the biopsied T6 epidural mass showed metastatic carcinoma, and
the histopathology and immunohistochemical staining for Hep-Par-1 were consistent with a hepatic
primary tumor (Figure 2). Thus, this patient had stage IV B (T3a N0 M1) HCC. Starting in February 2016,
he was started on sorafenib (200 mg orally every 12 h daily) as a first-line therapy. Two months later,
CT scans showed enlarged tumors in the liver, with omental and mesenteric carcinomatosis, stable osseous
metastases, and the serum AFP-liver level increased to 71 ng/mL, consistent with tumor progression.
Figure 1. Computed tomography (CT) scans and magnetic resonance imaging (MRI) scans at initial
diagnosis showed metastatic lesions in the liver, left 11th rib, 6th thoracic spine (T6), and sacrum.
(A) Coronal and (B) axial contrast-enhanced CT scans demonstrate multifocal heterogeneous irregular
hepatic tumors of varying sizes throughout the liver (solid circles) primarily in the right hepatic lobe.
(C) Coronal CT scans in bone window demonstrate a lytic bone metastasis involving the left eleventh rib
(arrow) and a large, destructive upper sacral metastasis (dashed circle). (D) Sagittal contrast-enhanced
MRI scans demonstrate an enhancing mid-thoracic spine epidural metastasis (curved arrow) with
an adjacent bone metastasis involving the T6 spinous process (arrow).
Figure 2. Histopathological and immunohistochemical analysis of the biopsied T6 epidural mass.
(A) The hematoxylin- and eosin-stained section shows infiltration by nests of polygonal cells with
enlarged atypical nuclei and abundant eosinophilic cytoplasm. Nuclear pseudo-inclusion and mitotic
figures are apparent. (B) Immunohistochemical analysis for Hep-Par-1 shows granular cytoplasmic
staining, supporting a diagnosis of metastatic hepatocellular carcinoma (original magnification ×200).
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In May 2016, he started immunotherapy on a clinical trial using an investigative anti-PD-1
monoclonal antibody. The patient received four cycles of this treatment (a total of eight weeks), and
then the tumor progressed. This was evidenced by CT scans (July 2016) showing an increase in both
size and number of omental, peritoneal, mesenteric metastases, a stable disease in liver, bones, and
lymph nodes, and the serum AFP-liver level increased further to 102.3 ng/mL.
Molecular profiling of the epidural metastatic tumor was performed by the Caris® Life
Sciences (https://www.carislifesciences.com/cmi-overview/). The materials and methods for the
tumor molecular profiling were previously described in detail [11]. Briefly, using formalin-fixed
paraffin-embedded tumor tissues, successive 4 μm sections were generated until sufficient material
for testing was obtained. For the molecular analysis, tumor cells were excised by microdissection,
until a total area of at least 50 mm2 was obtained. The expression of a panel of protein and RNA
biomarkers predictive of the response to cytotoxic chemotherapy and molecularly targeted agents
was determined by immunohistochemistry (IHC), chromogenic in-situ hybridization (CISH), and
RNA sequencing (RNA-Seq). The expression levels of various biochemical markers and the associated
therapeutic agents with potential benefits are listed in Table 1. Notably, the immunohistochemical
analysis of tumor tissues showed a lack of expression for thymidine synthetase (TS) and a diminished
expression of excision repair cross-complementation group 1 (ERCC1), suggesting a potential benefit
from capecitabine and oxaliplatin, respectively. Moreover, next-generation sequencing (NGS) of tumor
genomic DNA showed no pathogenic mutation in the tested genes. In particular, no pathogenic
mutation was detected in the genes TP53, CTNNB1, BRCA1, BRCA2, BRAF, KRAS, EGFR, and PIK3CA
(Table 2).
Table 1. Biomarker analysis and associated therapies.











































ALK RNA-Seq Fusion notdetected No ceritinib, crizotinib
ROS1 RNA-Seq Fusion notdetected No crizotinib
The immunohistochemical analyses were developed by Caris MPI, Inc. d/b/a Caris Life Sciences®, which also
determine their performance characteristics. The therapies with potential benefits are based on the body of
evidence, overall clinical utility, competing biomarker interactions, and tumor type from which the evidence
was gathered, as listed in www.carislifesciences.com. The value represents the staining intensity and the
percent of cells showing staining. ALK: anaplastic lymphoma kinase. CISH: chromogenic in-situ hybridization.
ERCC1: excision repair cross-complementation group 1. HER2/Neu: human epidermal growth factor receptor 2.
IHC: immunohistochemistry. RNA-Seq: RNA sequencing. ROS1: avian UR2 sarcoma virus oncogene. TOP2A: DNA
topoisomerase II alpha. TOPO1: DNA topoisomerase I. TS: thymidine synthetase. TUBB3: tubulin beta 3 class III.
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Table 2. Tumor genomic DNA analysis by next-generation sequencing for genetic mutations.
ABL1 BRCA2 EGFR HRAS NF1 RET
AKT1 c-KIT HER2/Neu (ERBB2) IDH1 NOTCH1 ROS1
ALK CDK4 ERBB3 IDH2 NRAS SMO
Androgen Receptor CDKN2A FGFR1 JAK2 NTRK1 SRC
APC CHEK1 FGFR2 KDR (VEGFR2) PDGFRA TP53
ARAF CHEK2 FGFR3 KRAS PDGFRB VHL
ATM cMET FLT3 MEK1 PIK3CA WT1
BAP1 CSF1R GNA11 MEK2 PTCH1
BRAF CTNNB1 GNAQ MLH1 PTEN
BRCA1 DDR2 GNAS MPL RAF1
Using the Illumina NextSeq platform, a direct sequence analysis was performed on the genomic DNA isolated from
a formalin-fixed paraffin-embedded tumor sample. This analysis can detect all variants with >99% confidence based
on the mutational frequency present as well as the amplicon coverage. This test is sensitive enough to detect as little
as a 10% population of cells containing a genomic mutation. The details can be found at www.carislifesciences.com.
On the basis of the tumor molecular profile, treatment with capecitabine, oxaliplatin, and
bevacizumab (CAPOX-B) was initiated. The selection of this regimen (CAPOX-B) was based on
results of the phase II study in patients with advanced HCC. The combination appeared efficacious
and tolerable. This study demonstrated a median PFS of 6.8 months, a median overall survival (OS) of
9.8 months, a partial response rate of 20%, and a disease control rate of 77.5% [15]. For every 21-day
cycle of the CAPOX-B regimen, capecitabine (825 mg/m2) was administered orally twice daily on day 1
through to day 14, oxaliplatin (130 mg/m2) was administered intravenously on day 1, and bevacizumab
(5 mg/kg) was administered intravenously on day 1. Following treatment with three cycles of CAPOX-B,
CT scans revealed a decrease in the size of the hepatic and omental lesions with stable osseous and
peri-portal lymphadenopathy (Figure 3A). After another three cycles of therapy, CT scans showed
a continued decrease in the size of the hepatic, lymph nodal, and omental lesions (Figure 3B).
Figure 3. Following cycle 3 and cycle 6 with capecitabine, oxaliplatin, and bevacizumab (CAPOX-B),
the CT scans showed tumor response. (A) Following cycle 3 with CAPOX-B, the coronal contrast-
enhanced CT scans demonstrate innumerable left sub-diaphragmatic and peri-hepatic omental nodules
(dashed circles) along with peri-gastric nodules (several annotated by arrows) consistent with omental
carcinomatosis and mesenteric metastases. Peri-portal lymphadenopathy can be observed in the solid
circle. (B) Following cycle 6 with CAPOX-B, the coronal contrast-enhanced CT scans demonstrate
a decrease in omental metastases (dashed circle) and peri-portal lymphadenopathy (solid circle), and
a small amount of peri-hepatic ascites.
Following cycle 9 with CAPOX-B, the CT scans showed stable hepatic and metastatic lesions
(Figure 4A). The hepatic and metastatic lesions remained unchanged following cycle 15 with CAPOX-B,
as shown in the CT scans (Figure 4B). The patient went on to receive a total of 18 cycles of CAPOX-B;
the disease eventually progressed as evidenced by new and enlarged hepatic masses in the CT scans
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based on Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1 (Figure 5).
Clinically, the patient experienced fatigue, ascites, and edema in the bilateral lower extremities,
all grade 3 according to the Common Terminology Criteria for Adverse Events (CTCAE Version 4.0).
At that time, the patient decided to pursue the option of home hospice and he subsequently expired
at home.
Figure 4. The tumors remained stable following cycle 9 and cycle 15 with CAPOX-B. (A) Following
cycle 9 with CAPOX-B, the axial contrast-enhanced CT scans demonstrate stable heterogeneous hepatic
tumors (arrows) compatible with a diagnosis of hepatocellular carcinoma. The right hepatic lobe
tumor is subcapsular in location. There are small peri-hepatic and peri-gastric ascites. (B) Following
cycle 15 with CAPOX-B, the axial contrast-enhanced CT scans demonstrate persistent heterogeneously
enhanced hepatic tumors of a stable size (arrows). Progressive peri-hepatic and peri-gastric ascites
with recanalized para-umbilical vein (circle) and splenomegaly can be seen.
Figure 5. Following cycle 18 with CAPOX-B, there was evidence of tumor progression in the CT scans
on the basis of the Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1. Axial
contrast-enhanced CT scans demonstrate enlarging heterogeneous hepatic tumors (arrows). The larger
right hepatic tumor now measures 6.3 cm with an exophytic component. There is a large-volume
abdominal ascites that has progressively increased in size, with gastrohepatic varices (circle).
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2.2. Patient #2
In contrast to patient #1, another patient with recurrent metastatic HCC was treated using
a similar regimen of chemotherapy; he had a relatively short PFS and a distinct tumor molecular
profile. Patient #2 is a 57-year-old Caucasian man who underwent an orthotopic liver transplantation
(in April 2015) because of HCC, in the setting of a hepatitis C viral infection and hepatic cirrhosis.
A pathological examination of the native liver revealed multiple foci of moderately differentiated
HCC, stage pT3b, pN1, and the portal vein margin was also affected by invasive carcinoma. The past
medical history was significant for hepatitis C viral infection (genotype 1; previously treated with
sofosbuvir and ribavirin), hepatic cirrhosis, hypertension, aortic stenosis, and insulin-dependent
diabetes mellitus. The family history was significant for “liver cancer” in his brother, colon cancer
in his brother, thyroid cancer in his sister, and “cancer of type unknown to patient” in his brother.
He had worked as a machine operator. He had previously smoked one pack of cigarettes daily for
30 years and he admitted to previous consumption of alcohol and intravenous drug use. At clinical
presentation, he complained of fatigue and incisional pain, but denied suffering from nausea, vomiting,
and diarrhea. The physical examination was remarkable for a mildly distended abdomen and chronic
1+ pitting edema in the bilateral lower extremities; there was no scleral icterus or jaundice. The serum
AFP-liver level was normal at 2.1 ng/mL, and AFP-L3 was elevated at 39.1%. Surveillance CT scans
(in January 2015) showed a new small thrombus within the right portal vein.
Between May and December 2015, this patient received eight cycles of adjuvant doxorubicin
and sorafenib. For every 21-day cycle, doxorubicin (60 mg/m2) was administered intravenously on
day 1, and two tablets of sorafenib (200 mg) were administered orally every 12 h continuously [16].
In December 2015, surveillance CT scans showed a new 2 cm × 1.4 cm mass in the lower lobe of
the left lung and an enlarged and enhanced (tumor) thrombus within the portal vein. The biopsy of
the pulmonary mass revealed metastatic carcinoma. He received stereotactic body radiation therapy
(SBRT) to the tumor thrombus in the portal vein (in February 2016) and to the tumor in the left lung
lobe (in March 2016). CT scans in April 2016 showed an enlarged left lower lung mass and new
bilateral adrenal nodules corresponding to metastases. The serum AFP-liver level and AFP-L3 were
both elevated at 20.4 ng/mL and 67.4%, respectively.
A tumor molecular profiling of the metastatic carcinoma biopsied from the left lower lobe of the
lung was performed using formalin-fixed paraffin-embedded tumor tissues by Caris® Life Sciences
(https://www.carislifesciences.com/cmi-overview/). The results of the analyses by IHC, CISH, and
RNA-Seq revealed the expression levels of biomarkers and the associated chemotherapy agents with
potential benefits (Table 3). There was a decreased expression of ERCC1, suggesting the potential
benefits of oxaliplatin. However, TS levels were increased, predicting a potential lack of benefits
of capecitabine. The mutational analysis of genomic DNA by NGS was significant for pathogenic
mutations in both TP53 (exon 6, Y220C) and CTNNB1 (exon 3, S37Y); there was no detected pathogenic
mutation in the other genes tested.
In April 2016, the patient was started on a treatment plan using a combination of sorafenib,
oxaliplatin, and capecitabine (SECOX) [17]. This regimen was previously shown to produce anti-tumor
activity and was tolerable, with no treatment-related death being reported. In this single-arm,
multi-center, phase II study, 51 patients with advanced HCC were enrolled and treated with the SECOX
regimen. The best response rate was 16% (all partial response), the median PFS was 5.26 months, and
the median OS was 11.73 months [18]. For every 14-day cycle of the SECOX regimen, two tablets
of sorafenib (200 mg) were administered orally every 12 h continuously, two tablets of capecitabine
(500 mg) were administered orally every 12 h on day 1 through to day 7, and 85 mg/m2 of oxaliplatin
was administered intravenously on day 1.
Following cycle 4 of SECOX, the patient tolerated the treatment well without specific complaints.
CT scans in June 2016 showed a mixed response including an interval progression of the infiltrative
disease within the liver, slightly enlarged bilateral adrenals nodules, an enlarged small right upper
lung lobe, and a reduction in size of the left lower lung lobe. The serum AFP-liver level and AFP-L3
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were both increased, being 55 ng/mL and 55.2%, respectively. The patient received a further four
cycles of SECOX with a slightly increased dosage of oxaliplatin (having been previously reduced
because of thrombocytopenia). In August 2016, CT scans showed progression of the disease in the
right upper lung lobe, liver, adrenals, and peritoneum on the basis of the RECIST guideline v1.1.
The serum AFP-liver level and AFP-L3 both rose further to 78.3 ng/mL and 60.9%, respectively.
SECOX was subsequently discontinued. PFS was 3.7 months. At that time, the patient experienced
grade 1 nausea/emesis/diarrhea and transient grade 1 oxaliplatin-induced cold hypersensitivity
(CTCAE v4.0). Prior to starting regorafenib for treatment, he expired at home.
Table 3. Biomarker analysis and associated therapies.




























TOPO1 IHC Positive 2 + 80% Yes irinotecan,topotecan
Value represents staining intensity and percent of cells showing staining. ERCC1: excision repair cross-
complementation group 1. IHC: immunohistochemistry. TOPO1: DNA topoisomerase I. TOP2A: DNA
topoisomerase II alpha. TS: thymidine synthase. TUBB3: tubulin beta class III.
2.3. Timeline
The clinical data of both patients #1 and #2, including diagnosis, treatment, the key result of tumor
molecular profiles, and responses to treatment, are summarized as a timeline as illustrated in Figure 6.
Figure 6. Cont.
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Figure 6. Timeline to illustrate the chronology of treatment and responses to treatment for patients #1
and #2 and the key data of their tumor molecular profiles.
3. Discussion
In this case study, we present two patients who had different clinical features regarding the
etiology of HCC and treatment responses. The molecular profiling of their tumors were distinct in
the expression of biochemical markers and genomic DNA mutations. In particular, patient #1 showed
an unusually good tumor response with CAPOX-B, and his tumor molecular profiling indicated
a negative expression of TS and ERCC1, as well as a lack of pathogenic mutations in the TP53 and
CTNNB1 genes. In contrast, patient #2 received eight cycles of SECOX with a PFS of 3.7 months, and
his tumor molecular profiling showed negative expression of ERCC1, but increased expression of TS,
and also pathogenic mutations in both the TP53 and the CTNNB1 genes. It is known that TP53 and
CTNNB1 are the two most common mutations in HCC and they contribute to tumor resistance to
chemotherapeutic agents. These data suggest that the tumor molecular profile of HCC may correlate
with the treatment efficacy as determined by PFS.
HCC is generally considered resistant to cytotoxic chemotherapeutic drugs, but treatment
responses of tumors are variable among patients. Currently, there is no predictive biomarker of
treatment response for patients with HCC. These cases highlight the value of molecular profiling in
HCC, especially in patients with advanced and/or metastatic HCC that has progressed following
standard therapies. Patient #1 had a PFS of 12.3 months; this is well beyond the median PFS of
6.8 months as reported in the phase II trials using CAPOX or nivolumab [6,14], and almost twice as
long as the median PFS in the study evaluating CAPOX-B as a first-line treatment [15]. Given the
patient’s negative IHC analysis for TS and ERCC1 and the lack of pathogenic mutations in the tested
genes, we hypothesize that his robust response to CAPOX-B was related to a favorable molecular
profile. His response to CAPOX-B was particularly impressive, considering his PFS in response to
CAPOX-B as a third-line treatment. On the other hand, patient #2 had a relatively short PFS of
3.7 months, less than the median PFS of 5.26 months as reported in the phase II study evaluating the
efficacy of SECOX in advanced HCC [18]. Similarly, we hypothesize that patient #2’s low response to
SECOX was related to his molecular profile which showed a potential lack of benefit from capecitabine
and exhibited pathogenic mutations in two key genes, TP53 and CTNNB1. No data on tumor molecular
profiling were available from the previous phase II studies that investigated CAPOX-B and SECOX.
How the etiology of HCC contributes to therapeutic responsiveness or resistance is unclear, though
the various modalities of treatment for patients with HCC have been the same in clinical practice
regardless of their etiology. While the etiology of patient #1’s HCC is unclear, patient #2 undoubtedly
had developed HCC as a consequence of a hepatitis C viral infection and hepatic cirrhosis. It is
noteworthy that the tumor profile of patient #1 showed negative TS expression and no pathogenic
mutation in TP53, and that of patient #2 showed positive TS expression with pathogenic mutation in
TP53; such an association is consistent with the data of a previous study [11]. Nevertheless, it will be
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important to determine any association between the etiology of HCC and the tumor molecular profiles,
as well as the clinical efficacy of systemic treatments including chemotherapy.
4. Conclusions and Future Perspectives
This case study sheds new light on the potential value of molecular profiling of advanced/
metastatic HCC in terms of guiding treatment. However, definitive conclusions on the clinical utility
of the tumor molecular profiles of HCC as predictive biomarkers cannot be drawn based on the
limited scope of the data from these case reports. Retrospective studies using data from a large patient
population are indicated to correlate biomarkers with treatment responses. Ultimately, a prospective
clinical study will be needed to test the hypothesis that molecular profile-based biomarkers can predict
clinical outcomes. Our goal is to identify and develop predictive biomarkers for treatment response in
order to help guide the selection of personalized therapy for patients with HCC.
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Abstract: Progress has been made in the treatment of gastrointestinal cancers through advances
in systemic therapies, surgical interventions, and radiation therapy. At the Multi-Disciplinary
Patient Care in Gastrointestinal Oncology conference, the faculty members of the Penn State
Health Milton S. Hershey Medical Center presented a variety of topics that focused on this
sub-specialty. This conference paper highlights the new development in systemic treatment
of various malignant diseases in the digestive system. Results of the recent clinical trials that
investigated the clinical efficacy of pegylated hyaluronidase, napabucasin, and L-asparaginase
in pancreatic carcinoma are presented. The use of peri-operative chemotherapy comprised of
5-fluorouracil or capecitabine, leucovorin, oxaliplatin, and docetaxel (FLOT), and immunotherapy
including pembrolizumab, nivolumab, and ipilimumab in gastroesophageal carcinoma are discussed.
Data from clinical trials that investigated the targeted therapeutics including nivolumab,
ramucirumab, lenvatinib, and BLU-554 are reported. The role of adjuvant capecitabine in resected
biliary tract carcinoma (BTC) and nab-paclitaxel in combination with gemcitabine and cisplatin in
advanced BTC are presented. In colorectal carcinoma, the efficacy of nivolumab, adjuvant FOLFOX or
CAPOX, irinotecan/cetuximab/vemurafenib, and trifluridine/tipiracil/bevacizumab, is examined.
In summary, some of the above systemic therapies have become or are expected to become new
standard of care, while the others demonstrate the potential of becoming new treatment options.
Keywords: biliary tract carcinoma; chemotherapy; clinical trial; colorectal carcinoma; gastric
carcinoma; gastrointestinal oncology; hepatocellular carcinoma; immunotherapy; pancreatic
carcinoma; targeted therapy
1. Introduction
Cancers in the digestive system are among the most common malignant diseases worldwide,
and are associated with relatively high mortality rates. Optimal caring of patients with malignant
diseases of digestive organs requires the expertise of providers from multiple health disciplines.
At the Multi-Disciplinary Patient Care in Gastrointestinal Oncology conference held on 29 September
2017 in Hershey, Pennsylvania, the faculty members of the Penn State Cancer Institute and Penn
State Health Milton S. Hershey Medical Center presented a variety of topics that focused on this
sub-specialty. These included presentations regarding the new frontiers in diagnostic and staging
evaluation, surgical interventions, and radiation therapy. In particular, important advances in systemic
chemotherapy, as well as the discovery of molecular biomarkers and therapeutic targets in those
cancers, were discussed. This article focuses on the presentations about new development of systemic
and targeted therapies in various malignancies of the digestive system.
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2. Update of Systemic and Targeted Therapies
A number of advances have been made in the systemic and targeted treatment of cancers of the
digestive organs. These include cancers in the pancreas, stomach and gastroesophageal junction, liver,
biliary tract, colon, and rectum. Here is a summary of the most recent evidence on chemotherapy and
targeted therapy in gastrointestinal oncology as presented at the international medical conferences and
in the published medical literature. Those conferences were held in 2017, including Annual Conference
of the American Society of Clinical Oncology, Annual Conference of the European Society of Medical
Oncology World Gastrointestinal Congress, and the Annual Conference of the International Liver
Cancer Association in Seoul, South Korea.
3. Pancreatic Carcinoma
Systemic chemotherapy plays important roles in the treatment of pancreatic carcinoma diagnosed
at all stages [1]. New development has been focusing on targeted agents directed against the tumor
microenvironment, cancer stem cells, and cellular metabolism [2]. In this section, highlights of
the recent clinical trials investigating the clinical efficacy of (i) hyaluronidase that degrades
tumor-associated stroma, (ii) napabucasin that targets cancer stem cells, and (iii) L-asparaginase
that inhibits cellular metabolism, are reported.
3.1. Targeting Tumor-Associated Stroma Using Pegylated Hyaluronidase
A unique feature of pancreatic carcinoma is desmoplastic reaction, resulting in formation of a
dense stroma that hinders delivery of therapeutic agents to the cancer cells. Hyaluronan is a component
of the tumor-associated stroma, and pegylated hyaluronidase (PEGPH20) has been developed to
degrade hyaluronan in order to facilitate delivery of chemotherapeutic agents to the cancer cells.
In a phase II, open-label clinical study of 246 patients with metastatic pancreatic adenocarcinoma,
nab-paclitaxel (125 mg/m2 iv weekly for 3 weeks) + gemcitabine (1000 mg/m2 iv weekly for 3 weeks)
with or without PEGPH20 (3 μg/kg iv twice a week for cycle 1 and weekly for cycle 2 and beyond)
were administered for every 4-weeks cycle (ClinicalTrials.gov identifier: NCT01839487). PEGPH20 in
combination with nab-paclitaxel and gemcitabine significantly prolongs progression-free survival
(PFS), as compared to nab-paclitaxel and gemcitabine (Table 1). The improvement of PFS is even
greater for patients with tumors expressing high levels of HA, and this is also seen with overall
survival (OS). Moreover, this study suggested that hyaluronic acid is a potential predictive biomarker
of tumor response to PEGPH20 [3]. A phase III, randomized, double-blind, placebo-controlled,
multicenter clinical study is ongoing to confirm the clinical efficacy of PEGPH20 in combination with
nab-paclitaxel and gemcitabine (NCT02715804).
Table 1. Results of a phase II clinical study to investigate pegylated hyaluronidase in combination with
nab-paclitaxel and gemcitabine in metastatic pancreatic carcinoma.








HR 0.51, * P < 0.048 5.2
OS (months)
HA-High (35%) 11.5 8.5
HA: hyaluronan. HR: hazard ratio. OS: overall survival. PEGPH20: pegylated hyaluronidase. PFS: progression-free
survival. * P indicates statistical significance.
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3.2. Targeting Cancer Stem Cells by a STAT3 Inhibitor
Tumor metastasis and therapeutic resistance have been attributed to cancer stem cells.
Targeting the cancer stem cells is expected to improve survival through improving anti-tumor
response to treatment. A first-in-human clinical trial was conducted to investigate the clinical efficacy
of napabucasin that targets cancer stem cells by inhibiting the activation of signal transducer and
activator of transcription 3 (STAT3). In a phase 1b/II study of 66 patients (55 evaluable) with metastatic
pancreatic adenocarcinoma, napabucasin 240 mg orally twice daily in combination with nab-paclitaxel
(125 mg/m2 iv) and gemcitabine (1000 mg/m2 iv) was administered weekly for 3 weeks of every 4-week
cycle until disease progression (NCT02231723). Results of this study indicate that the combination of
napabucasin with nab-paclitaxel and gemcitabine produced anti-tumor response (Table 2) [4]. A phase
III, open-label clinical study to confirm the efficacy of napabucasin in combination with nab-paclitaxel
and gemcitabine in patients with metastatic pancreatic adenocarcinoma is ongoing (NCT02993731).
Table 2. Results of a phase I/II clinical study to investigate napabucasin in combination with
nab-paclitaxel and gemcitabine in metastatic pancreatic adenocarcinoma.
Efficacy Endpoints Outcome
Complete Response 1 (1.8%)
Partial Response 26 (47.3%)
Stable Disease 24 (43.6%)
Overall Response Rate 55%
Disease Control Rate 93%
Disease Progression 3 (on treatment), 1 after off treatment due to toxicity
Progression-Free Survival 7.1 months
1-Year Overall Survival Rate 56%
3.3. Targeting Asparagine by Enzymatic Degradation
Asparagine is an essential amino acid required for survival of pancreatic cancer cells, which have
no or little asparagine synthetase to produce endogenous asparagine. Asparagine promotes
proliferation of cancer cells through regulating serine uptake, influencing serine metabolism and
thus synthesis of protein and nucleotides [5]. Eryaspase consists of L-asparaginase encapsulated
within erythrocytes, and it hydrolyzes and depletes asparagine from the circulating blood plasma
(http://erytech.com/ery-asp.html). In a phase IIb study, 140 patients with metastatic pancreatic
carcinoma were randomized to receive eryaspase (100 IU/kg on day 3 and day 17 of every 4-weeks
cycle) in combination with either gemcitabine or FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin);
versus chemotherapy alone (NCT02195180). Expression of asparagine synthetase was either none (0)
or low (1) as determined by immunohistochemistry. Eryaspase in combination with either gemcitabine
or FOLFOX significantly prolonged overall survival as compared to either gemcitabine or FOLFOX
(26.1 weeks vs 19 weeks, HR 0.57, * P = 0.03) [6].
While some of the above clinical trials are ongoing, the evidence suggests that subsets of patients
whose tumors with expression of certain molecular biomarkers likely benefit from the targeted
therapeutic agents. Conceivably, patients with pancreatic carcinoma with high expression level
of HA may benefit from addition of PEGPH20 to either nab-paclitaxel/gemcitabine or FOLFIRINOX.
Those with pancreatic cancer cells with constitutively activated STAT3 may benefit from addition of
napabucasin to nab-paclitaxel/gemcitabine. Pancreatic carcinoma with no or low level of expression of
asparagine synthetase will likely be sensitive to treatment with eryaspase in combination with either
gemcitabine or FOLFOX.
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4. Gastric, Gastroesophageal Junction, and Esophageal Carcinoma
Systemic chemotherapy is the standard of care for patients with advanced or metastatic gastric
carcinoma (GC), gastroesophageal junction carcinoma (GEJC), and esophageal carcinoma (EC).
Monoclonal antibodies including trastuzumab directed against human epidermal growth factor
receptor 2 (HER2) and ramucirumab that targets vascular endothelial growth receptor 2 (VEGFR2),
either as single agents or in combination with chemotherapy, have become part of the standard of
care for treatment of advanced GC and GEJC. For resectable GC or GEJC, chemotherapy improves the
surgical outcome; whereas chemotherapy concurrent with radiation therapy with or without surgery
can be potentially curable for localized EC. Immunotherapy has emerged as a new treatment option
for patients with gastroesophageal carcinoma [7]. In this section, highlights of the clinical studies that
investigated peri-operative chemotherapy and immunotherapy are discussed.
4.1. Peri-Operative FLOT in Resectable Tumors
For resectable GC or GEJC, peri-operative chemotherapy using epirubicin, cisplatin and
either 5-fluorouracil or capecitabine (ECF and ECX, respectively) has been the standard of care.
However, the survival benefit of this regimen remains limited. The combination of docetaxel,
oxaliplatin, and either 5-fluorouracil or capecitabine (FLOT) produced survival benefit in advanced
gastroesophageal carcinoma, but its clinical efficacy in resectable tumors had not been determined. In a
phase III trial (FLOT4) of 716 patients with resectable GC or GEJC, peri-operative FLOT was compared
with ECF or ECX. In the treatment group receiving FLOT, 4 pre-operative and 4 post-operative 2-week
cycles of docetaxel 50 mg/m2 iv, oxaliplatin 85 mg/m2 iv, leucovorin 200 mg/m2 iv, and 5-fluorouracil
2600 mg/m2 as 24h iv infusion, all were administrated on day 1. For the ECF or ECX treatment group,
the patients received 3 pre-operative and 3 post-operative 3-week cycles of epirubicin 50 mg/m2 iv
and cisplatin 60 mg/m2 iv both on day 1, and either 5-fluorouracil 200 mg/m2/24 h continuous iv
infusion or capecitabine 1250 mg/m2 orally on day 1 through day 21 (NCT01216644). Results of this
study showed that, as compared to either ECF or ECX, FLOT significantly prolonged PFS and OS,
associated with lower rate of disease progression, and increased rate of complete resection of tumors
(Table 3). ECF or ECX was associated with more grade 3 or 4 nausea and emesis than FLOT, which was
associated with more grade 3 or 4 neutropenia [8]. This study supports peri-operative FLOT as the
new standard of systemic treatment for patients with resectable GC or GEJC.









* P = 0.004
50
HR 0.77,
* P = 0.012
1%
* P = 0.001
25%
* P = 0.001
84%
* P = 0.001
ECF or ECX 18 35 5% 15% 77%
ECF: epirubicin, cisplatin, 5-fluorouracil. ECX: epirubicin, cisplatin, capecitabine. FLOT: 5-fluorouracil, leucovorin,
oxaliplatin, docetaxel. OS: overall survival. PD: progression of disease. PFS: progression-free survival. * P indicates
statistical significance.
4.2. Pembrolizumab in PD-L1-Expressing Gastric and Gastroesophageal Carcinoma
In a phase I clinical study, the anti-programmed death-1 (anti-PD-1) antibody pembrolizumab
exhibited anti-tumor activity in patients with previously treated advanced GC. In a phase II clinical
study, 259 patients with recurrent or metastatic GC or GCJC that have progressed on 2 or more prior
chemotherapy received pembrolizumab (200 mg iv every 21 days) (KEYNOTE-059, NCT02335411).
Pembrolizumab significantly improved response rate and overall survival beyond 2nd line treatment in
patients with advanced GC or GEJC expressing PD-L1 (≥1% expression of PD-L1). The overall response
rate (ORR) is 16.4% in all patients. Among patients with ≥1% expression of PD-L1, ORR 22.7%, vs. 8.6%
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if PD-L1 negative [9]. Results of this study has led to US FDA approval of pembrolizumab for treatment
of patients with advanced, PD-L1-positive (≥1%) GC or GEJC that have progressed following 2 or
more lines of therapy.
4.3. Nivolumab and Ipilimumab in Gastric, Gastroesophageal Junction, and Esophageal Carcinoma
A combination of immune checkpoint inhibitors was investigated in advanced GC, GEJC, and EC.
In a previous phase III clinical study (ONO-12), the anti-PD-1 antibody nivolumab has been shown
to prolong overall survival (OS), as compared to placebo, as a 3rd-line or beyond treatment in Asian
patients with advanced GC or GEJC [10]. In a phase I/II study, nivolumab in combination with or
without the anti-CTLA4 antibody, ipilimumab, produced anti-tumor activity in Western patients with
advanced GC, GEJC, and EC (CheckMate 032, NCT01928394). The data of a long-term follow-up
of the CheckMate 032 study were reported [11]. In the phase II study, nivolumab either alone or
in combination with ipilimumab showed durable anti-tumor responses in metastatic GC or GEJC,
particularly in tumors expressing PD-L1 (≥1%), and also long-term OS in those Western patients with
previously treated GC, GEJC, and EC (Table 4).
Table 4. Results of a phase II clinical study to investigate nivolumab and ipilimumab in metastatic




Nivolumab (1 mg/kg) +
Ipilimumab (3 mg/kg)
every 3 Weeks
Nivolumab (3 mg/kg) +
Ipilimumab (1 mg/kg)
Every 3 Weeks
ORR (%) 12 24 8
ORR (%)
PD-L1 ≥ 1% 19 40 23
ORR (%)
PD-L1 ≤ 1% 12 22 0
OS (months) 6.2 6.9 4.8
ORR: overall response rate. OS: overall survival.
4.4. Pembrolizumab in PD-L1-Expressing Esophageal Carcinoma
For patients with advanced or metastatic EC, the conventionally used systemic chemotherapy has
been extrapolated from evidence of clinical studies in GC or GEJC. In a phase IB study, pembrolizumab
was investigated in patients with PD-L1-positive advanced esophageal carcinoma (KEYNOTE-028,
NCT02054806). Among the 83 patients being evaluated, 37 (45%) had PD-L1-positive tumors
and 23 patients were enrolled. ORR was 30% (95% CI, 13% to 53%), and median duration of
response 15 months (6 to 26 months). Treatment-related adverse events were reported in 9 patients,
and those most commonly include anorexia, lymphocytopenia, and skin rash. There were no grade
4 pembrolizumab-related adverse events or deaths. Increased tumor response and delayed tumor
progression were associated with relatively high interferon-γ composite scores. It was concluded
that pembrolizumab produced durable anti-tumor activity and manageable toxicity in patients with
pretreated, PD-L1-positive advanced esophageal carcinoma [12].
The promising data of the above mentioned clinical studies are expected to create new
opportunities of effective treatment for patients with GC, GEJC, and EC. While pembrolizumab has
been FDA-approved as a 3rd-line or beyond treatment of advanced GC and GEJC expressing PD-L1,
the potential use of pembrolizumab either alone or in combination with cytotoxic chemotherapy
is being explored as 1st-line treatment. Meanwhile, nivolumab, either as a single agent or in
combination with ipilimumab, may provide additional treatment options for patients with GC,
GEJC, and EC. The use of peri-operative FLOT is expected to be the new standard of care for
patients with resectable GC and GEJC. However, this regimen tends to be associated with severe
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neutropenia, such that precaution will need to be taken for patients with impaired bone marrow
reserve, and granulocyte-colony stimulating factors may need to be routinely administered as part of
this regimen.
5. Hepatocellular Carcinoma
For patients with advanced or metastatic hepatocellular carcinoma (HCC), sorafenib is the
standard first-line treatment. For HCC that has progressed following treatment with sorafenib,
regorafenib as a second-line treatment provides survival benefit. However, treatment using sorafenib
or regorafenib is palliative, and the clinical benefits of these targeted agents are somewhat limited [13].
Results of clinical trials that investigated the clinical efficacy of targeted therapeutic agents including
nivolumab, ramucirumab, lenvatinib, and BLU-554 have recently been reported.
5.1. Nivolumab
The efficacy of nivolumab, an anti-PD-1 antibody, was investigated in sorafenib naïve or
sorafenib-treated patients with advanced HCC. In this clinical study (CheckMate 040), 262 patients
were enrolled and 98% of them had hepatic cirrhosis of Child-Pugh scores 5–6. In both groups of
subjects, those who had never received sorafenib and those who had previously been treated with
sorafenib, nivolumab showed anti-tumor response to varying extent (Table 5). Importantly, nivolumab
produced tumor responses regardless of the etiology of HCC or tumor expression of PD-L1. Based on
results of this study, FDA approved nivolumab for treatment of patients with HCC following prior
sorafenib regardless of PD-L1 status [14].
Table 5. Results of a clinical study to investigate nivolumab in advanced hepatocellular carcinoma.
Outcomes Sorafenib-Naïve (n = 80) Sorafenib-Treated (n = 182)
Overall response rate 24% 19%
Complete response 1% 1%
Partial response 19% 13%
Stable disease 34% 41%
Disease control rate 63% 56%
In the CheckMate-040 study, the efficacy of nivolumab was further evaluated in a subgroup
of 154 patients with HCC who progressed on sorafenib or who were intolerant to sorafenib with
additional eligibility criteria (NCT01658878). By assessment using RECIST v1.1, the overall response
rate (ORR) was 14.3%, complete response (CR) 1.9%, and partial response (PR) 12.3%. Among those
who responded to nivolumab, 91% of the patients had a response duration ≥6 months, and 55% with
duration ≥12 months. Assessment using modified RECIST criteria, the efficacy of nivolumab is even
greater, with ORR 18.2%, CR 3.2%, and PR 14.9%.
However, nivolumab is associated with the risk of various immune-related adverse reactions.
Skin rash is relatively common. Other reactions include pneumonitis, colitis, hepatitis,
endocrinopathies (in hypophysis, adrenal, thyroid, endocrine pancreas), nephritis, encephalitis,
and infusion-related. These reactions may require treatment with corticosteroids. Depending on
the severity of the reactions, nivolumab may need to be withheld or discontinued.
5.2. Ramucirumab
Hepatocellular carcinogenesis is promoted by tumor-associated neo-angiogenesis, and vascular
endothelial growth factor (VEGF) and receptor-induced signaling plays an important role [13].
The anti-VEGF antibody bevacizumab was previously investigated in advanced HCC without proven
clinical benefit. Ramucirumab is a monoclonal antibody directed against VEGFR2 and it produced
anti-tumor response in colon, gastric and gastroesophageal junction, and pulmonary carcinoma.
The anti-tumor effect of ramucirumab in HCC was previously known.
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In a phase III trial (REACH), the clinical efficacy of ramucirumab was investigated in patients
with advanced HCC. In this study, 643 patients with advanced HCC who had previously been treated
with sorafenib, were randomized to receive ramucirumab or placebo. Results of this study showed that
ramucirumab produced statistically significant improvement of the hazard ratio of HCC in patients
with hepatic cirrhosis of Child-Pugh 5. The efficacy is further increased in patients with hepatic cirrhosis
of Child-Pugh 5 and serum AFP ≥ 400 ng/mL (Table 6). Thus, ramucirumab produced survival benefit
in patients with advanced HCC, particularly those with hepatic cirrhosis of Child-Pugh Class A (score
5 or 6) and serum AFP ≥ 400 ng/mL [15].
Table 6. Results of a phase III clinical study to investigate ramucirumab in advanced
hepatocellular carcinoma.
Outcomes Ramucirumab vs. Placebo
Ramucirumab vs. Placebo
(AFP ≥ 400 ng/mL)
HR (Child-Pugh 5) 0.80 (P = 0.06) 0.61 (* P = 0.01)
HR (Child-Pugh 6) 0.96 (P = 0.76) 0.64 (* P = 0.04)
HR (Child-Pugh 7 or 8) 1.00 (P > 0.99) 0.67 (P = 0.28)
AFP: Alpha fetoprotein; HR: Hazard Ratio. * P indicates statistical significance.
5.3. Lenvatinib
Lenvatinib is a small molecule inhibitor of receptor tyrosine kinases (RTKs) involved in
neo-angiogenesis by inhibiting the kinase activities of VEGFR1, 2, and 3. Lenvatinib also inhibits RTKs
implicated in tumor growth and metastasis, including fibroblast growth factor receptors (FGFR1, 2,
3, and 4); platelet-derived growth factor receptor (PDGFRα), KIT, and RET. Currently, lenvatinib is
FDA-approved for treatment of patients with locally recurrent or metastatic, progressive, radioactive
iodine-refractory differentiated thyroid cancer (available online: https://www.accessdata.fda.gov/
drugsatfda_docs/label/2015/206947s000lbl.pdf). In a phase III trial, the clinical efficacy of lenvatinib
versus sorafenib was investigated as 1st-line treatment of unresectable HCC. In this open-label study,
954 subjects with advanced HCC and hepatic cirrhosis of Child-Pugh A were randomized to receive
either lenvatinib or sorafenib as first-line therapy [16]. Results of this study show that lenvatinib
produced significant improvements in PFS, TTP, and ORR (Table 7). The investigators concluded that
lenvatinib is non-inferior to sorafenib in overall survival.
Table 7. Results of a phase III clinical trial to investigate lenvatinib vs sorafenib in unresectable
hepatocellular carcinoma.
Outcomes Lenvatinib Sorafenib
Median OS (months) 13.6HR 0.92; NS 12.3
Median PFS (months) 7.4HR 0.66; * P < 0.00001 3.7
Median TTP (months) 8.9HR 0.63; * P < 0.00001 3.7
ORR (%) 24* P < 0.00001 9
HR: hazard ratio. NS, not statistically significant. ORR: overall response rate. OS: overall survival. PFS:
progression-free survival. TTP: time to tumor progression. * P indicates statistical significance.
5.4. BLU-554
FGF19 stimulates proliferation of hepatocytes and induces hepatocellular carcinoma through
activation of FGFR4 [17]. BLU-554 is a highly selective small molecular inhibitor of FGFR4, and FGF19
has been identified as a potential predictive biomarker of treatment response to BLU-554. A phase I
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clinical trial was conducted to investigate the safety and efficacy of BLU-554 in patients with advanced
HCC that had been pre-treated (Table 8). This trial includes a dose-escalation phase and an expansion
portion. Of the first 77 enrolled subjects being analyzed, 44 of them had FGF19-expressing (at least 1%
expression) HCC. In the dose-escalation phase, the maximum-tolerated dose of 600 mg of BLU-554
daily was established. BLU-554 produced anti-tumor response in FGF19+ HCC. Patients with HCC
without expression of FGF19 did not demonstrate anti-tumor response to BLU-554. [18]. This study
suggests the potential use of BLU-544 as a new treatment of patients with HCC that express FGF19.
Table 8. Results of a phase I clinical trial to investigate BLU-544 in pretreated advanced
hepatocellular carcinoma.
Outcomes Result
Complete Response 1 patient
Partial Response 5 patients
Stable Disease 20 patients
Overall Response Rate 16%
Disease Control Rate 68%
While nivolumab produces efficacy in a subset of patients with advanced HCC previously
treated with sorafenib, future investigation is indicated to improve the response rate conceivably
by combination of nivolumab with other interventions. These may include radiation therapy,
other immune checkpoint inhibitors, or chemotherapy. The clinical data showing the efficacy of
ramucirumab in patients with HCC and elevated serum AFP levels appear promising. It will be
worthy to determine if a combination of ramucirumab with other therapeutics active in HCC such as
sorafenib or nivolumab produces enhanced therapeutic response. Considering the inhibitory activity
of lenvatinib in multiple RTKs including VEGFR2 and FGFR4, it is possible that subsets of patients
may particularly benefit from lenvatinib, such as those with elevated serum AFP and FGF19 + HCC
(as demonstrated in the study using ramucirumab and BLU-554, respectively).
6. Biliary Tract Carcinoma
The prognosis of patients with biliary tract carcinoma (BTC) is generally poor, and effective
treatment is desperately needed to improve treatment response and survival [19]. For patients who
have localized BTC being surgically resected, tumors tend to recur both locally and as distant metastasis.
Even when BTC is completely surgically removed (R0 resection), tumor recurrence may occur and
the current standard of care is observation [20]. However, a meta-analysis indicated that adjuvant
chemotherapy provides a benefit of overall survival in patients with resected BTC [21]. Moreover,
for patients with radically resected extrahepatic cholangiocarcinoma and gallbladder carcinoma,
adjuvant capecitabine and gemcitabine followed by capecitabine concurrent with radiation therapy
was efficacious and well tolerated [22]. Recently, the results of a clinical trial that investigated the role
of adjuvant capecitabine in resected BTC have been reported. Besides, for advanced or metastatic BTC,
gemcitabine and cisplatin are the standard first-line treatment though with limited survival benefit [20].
The potential value of combining nab-paclitaxel with gemcitabine and cisplatin as first-line treatment
of advanced BTC has been examined in a clinical study.
6.1. Adjuvant Capecitabine in Resected BTC
In a phase III clinical trial, the survival benefit of adjuvant capecitabine versus observation in
resected BTC was investigated. In this study, 447 patients with surgical removed BTC (R0 resection)
were enrolled. BTC in these patients include intrahepatic (19%), hilar (28%), extra-hepatic (35%)
cholangiocarcinoma, and gallbladder carcinoma (18%) [23]. In the treatment arm, the subjects
received adjuvant capecitabine 1250 mg/m2 on day 1 through day 14 of every 21-day cycle for a
total of 8 cycles. The subjects in the control arm were observed with no treatment following surgery.
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Adjuvant capecitabine significantly prolonged overall survival and recurrence-free survival in resected
BTC (Table 9). Results of this study suggest adjuvant capecitabine as the new standard of care for
resected (R0) BTC.
Table 9. Results of a phase III clinical trial to investigate adjuvant capecitabine in resected (R0) biliary
tract carcinoma.
Regimen Capecitabine Observation
Overall survival 51 monthsHR 0.75; * P = 0.028 36 months
Recurrence-free survival 25 months 18 months
HR: Hazard ratio. * P indicates statistical significance.
6.2. Combination of nab-Paclitaxel, Gemcitabine, and Cisplatin in Advanced BTC
For patients with locally advanced unresectable or metastatic BTC, palliative systemic
chemotherapy using gemcitabine and cisplatin is the standard of care [20]. The clinical efficacy
of the combination of nab-paclitaxel, gemcitabine, and cisplatin as 1st-line treatment of advanced BTC
was investigated. In a phase II trial, a single arm of 51 patients were enrolled for treatment using
nab-paclitaxel in combination with gemcitabine and cisplatin [24]. Results of this study suggest that
the combination of nab-paclitaxel with gemcitabine and cisplatin may provide additional survival
benefit as compared with historical control using gemcitabine and cisplatin (Table 10). A phase III
clinical trial is indicated to test this hypothesis.
Table 10. Results of a phase II clinical trial to investigate nab-paclitaxel in combination with gemcitabine







nab-Paclitaxel + Gemcitabine + Cisplatin 11.4 months >20 months(estimated) 66.7%
Gemcitabine + Cisplatin 8.0 months(Historical control)
11.7 months
(Historical control) -
While the phase III study results support the use of adjuvant capecitabine as the new standard of
care for resected (R0) BTC, the optimal adjuvant therapy for patients with R1 or R2 resected BTC, as well
as tumors with lymph nodes and/or resection margins involved by invasive carcinoma, remains to
be determined. Whether the combination of nab-paclitaxel with gemcitabine and cisplatin provides
superior survival benefit as compared to gemcitabine/cisplatin will need to be directly compared in a
randomized, placebo-controlled clinical study. While the combination of gemcitabine and cisplatin
is the current standard treatment for advanced or metastatic BTC, the roles of targeted therapy and
immunotherapy in BTC remain to be explored.
7. Colorectal Carcinoma
Systemic chemotherapy and targeted therapy have been used as the standard of care for
patients with colorectal carcinoma (CRC), as neoadjuvant therapy, adjuvant therapy, and palliative
treatment. In this section, results of recent clinical studies investigating (i) immunotherapy (nivolumab),
(ii) duration of adjuvant chemotherapy (oxaliplatin and either 5-fluorouracil or capecitabine),
(iii) targeted therapy (irinotecan and cetuximab ± vemurafinib), and (iv) palliative chemotherapy
(trifluridine/tipiracil and bevacizumab) are presented and discussed.
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7.1. Nivolumab
Metastatic CRC with DNA mismatch repair-deficient (dMMR) or microsatellite instability-high
(MSI-H) displays high levels of tumor-associated neoantigens and tumor-infiltrating lymphocytes.
These pathological features suggest anti-tumor response as observed with anti-PD-1 antibodies in other
types of tumors. In a multicenter, open-label, single-arm, phase II clinical trial, the therapeutic efficacy
of nivolumab was investigated in patients with metastatic CRC who had progressed or been intolerant
of ≥1 line of treatment (CheckMate 142, NCT02060188). Patients received nivolumab 3 mg/kg iv every
2 weeks until tumor progression, intolerable toxicity, death, or withdrawal from study. At a median
follow-up of 12 months, 23 of 74 enrolled patients showed objective tumor response, and 51 patients
had disease control for ≥12 weeks [25]. Results of this clinical study have led to U.S. FDA approval of
nivolumab for treatment of patients with metastatic CRC with MSI-H or dMMR previously treated
with chemotherapy (fluoropyrimidine and either oxaliplatin or irinotecan).
7.2. Adjuvant FOLFOX or CAPOX: 3 Months vs. 6 Months
Adjuvant chemotherapy using oxaliplatin in combination with either 5-fluorouracil or
capecitabine (FOLFOX and CAPOX, respectively) for 6 months has been the standard of care for
patients following surgical resection of stage III or high-risk stage II CRC. A major drawback of
this treatment is that, oxaliplatin-induced neurotoxicity tends to accumulate over time and possibly
become permanent.
To determine if adjuvant chemotherapy (either FOLFOX or CAPOX) for 3 months was as effective
as 6 months, a global prospective study known as the International Duration Evaluation of Adjuvant
therapy (IDEA) was planned. The IDEA study combined data from six concurrent, phase III clinical
trials conducted in twelve countries in North America, Europe, and Asia. More than 12,800 patients
were enrolled and followed for a median time of 39 months [26]. Results of the IDEA study showed
that the rate of disease-free survival with a 3-month course of adjuvant chemotherapy was slightly
lower as compared to the standard 6-month course, 74.6% vs. 75.5%, respectively. Moreover, in
a subset of patients with low-risk colon cancer (60% of patients in the IDEA study, pT1-T3, pN1),
the rates of recurrence-free survival in patients receiving a 3-month course vs a 6-month course were
83.1% and 83.3%, respectively. Besides, patients who received a 6-month course of chemotherapy
experienced more side effects including fatigue, diarrhea, and neuropathy than those receiving a
3-month course. In particular, the rates of grade ≥2 chemotherapy-induced neuropathy for patients
who received 6 months vs. 3 months of chemotherapy were 45% vs. 15% with FOLFOX, and 48% vs.
17% with CAPOX.
One of those trials in the IDEA collaboration is a non-inferiority, randomized (1:1) clinical study
aimed to evaluate if 3 months of adjuvant FOLFOX or CAPOX as effective as 6 months’ adjuvant
chemotherapy in stage III or high-risk stage II CRC (SCOT study). In this phase III, open-label,
multi-center study, 6088 patients with either stage III or high-risk stage II CRC were enrolled, 32.5% of
patients received FOLFOX and 67.5% CAPOX [27]. Results of this study show that 3 months of
adjuvant chemotherapy is not inferior to 6 months of treatment (Table 11).
Table 11. Results of a phase III clinical study to investigate the efficacy of 3 months vs. 6 months of
adjuvant chemotherapy in surgically resected stage III or high-risk stage II colorectal carcinoma.
Outcome 3 Months of CAPOX or FOLFOX 6 Months of CAPOX or FOLFOX
DFS Events 734 735
3-Year DFS Rate (%)
76.8
HR 1.008 (95% CI 0.910–1.117)
Non-inferiority, * P = 0.014
77.4
CAPOX: capecitabine and oxaliplatin. CI: confidence interval. DFS: disease-free survival. FOLFOX: 5-fluorouracil,
leucovorin, and oxaliplatin. HR: hazard ratio. * P indicates statistical significance.
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Based on these data, for low-risk disease (T1-3, N1), the recommendation for the duration of
adjuvant chemotherapy is 3 months; for high-risk disease (T4 or N2 tumors), the use of shorter course
of adjuvant chemotherapy should be tailored to the individual patient.
7.3. Irinotecan and Cetuximab ± Vemurafinib
Patients with metastatic CRC that carry the BRAFV600 mutation tend to respond poorly to standard
chemotherapy and/or the BRAF inhibitor vemurafenib. In vitro blockade of BRAFV600 mutation by
vemurafenib has been shown to up-regulate epidermal growth factor receptor (EGFR); a combination
of the EGFR inhibitor cetuximab and irinotecan can block the EGFR-mediated signaling events.
A randomized clinical study aimed to investigate a combination of irinotecan and cetuximab with or
without vemurafenib in BRAFV600-mutated metastatic CRC (SWOG S1406). In this study, 106 patients
with BRAFV600 mutated and RAS wild-type metastatic CRC were enrolled. The patients had received 1
or 2 prior chemotherapy, 39% of the patients received prior irinotecan, and none had prior anti-EGFR
antibodies [28]. Addition of vemurafenib to irinotecan and cetuximab improved anti-tumor response
and patient survival (Table 12). Results of this study suggest the combination of vemurafenib with
cetuximab and irinotecan as a potential treatment option for patients with BRAFV600 mutated and RAS
wild-type metastatic CRC.
Table 12. Results of a clinical study to investigate the addition of vemurafenib to irinotecan and
cetuximab in metastatic colorectal carcinoma with BRAFV600 mutation and wild-type RAS.
Regimen Vemurafenib + Irinotecan and Cetuximab Irinotecan and Cetuximab
PFS (months) 4.4(5.7 if no prior irinotecan)
2.0
(1.9 if no prior irinotecan)
RR (%) 16# P = 0.08 4
DCR (%) 67% 22
DCR: disease control rate. PFS: progression-free survival. RR: response rate. # P indicates a trend for
statistical significance.
7.4. Trifluridine/Tipiracil and Bevacizumab
Previous study has demonstrated a significant overall survival benefit of TAS-102, a combination
of trifluridine and tipiracil, in patients with refractory metastatic CRC. A phase I/II, open-label,
single-arm, multi-center clinical trial aimed to investigate TAS-102 in combination with bevacizumab
in patients with metastatic CRC that had been refractory or intolerant to chemotherapy, anti-VEGF
therapy, and anti-EGFR therapy, but had not received regorafenib. In this study, 25 patients were
enrolled; 6 patients in phase 1 (dose-escalation) and 19 in phase II. The recommended phase II dose was
determined for TAS-102 (35 mg/m2 orally twice daily on days 1 to 5 and days 8 to 12 of every 28-day
cycle) in combination with bevacizumab (5 mg/kg iv over 30 min every 2 weeks). Results of this study
demonstrate a PFS of 42.9% (80% confidence interval 27.8 to 59.0) at 16 weeks, with myelosuppression
as the most common grade 3 or 4 adverse event. The mutational statuses of RAS, TP53, APC,
and PIK3CA were not associated with survival. These data suggest the combination of TAS-102
with bevacizumab as a new potential treatment option for patients with refractory metastatic CRC [29].
For patients with advanced or metastatic CRC, new therapeutic tools have become available,
and new potential treatment options are underway. Since FDA’s approval of nivolumab for treatment
of patients with previously treated metastatic CRC with MSI-H or dMMR, molecular analysis for
MSI and MMR should be routinely conducted. Any improvement of survival benefit by combination
of nivolumab with other therapeutic agents is under active investigation. A 3-month course of
adjuvant FOLFOX or CAPOX is expected to be the standard of care for low-risk CRC in patients who
will likely benefit from reduced chemotherapy-induced toxicity, particularly peripheral neuropathy.
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The combination of vemurafenib with cetuximab and irinotecan has the potential of becoming a
treatment option for patients with metastatic CRC that carry BRAFV600 mutation and wild-type RAS.
The combination of trifluridine/tipiracil and bevacizumab appears an attractive option for patients
with refractory metastatic CRC. A phase III clinical study to compare the efficacy and safety of this
combination with the current standard treatment, and even addition of oxaliplatin or irinotecan to the
combination may be considered in future investigation.
8. Conclusions and Future Perspectives
In this article, the presentations on the new development in systemic treatment of various
malignant diseases in the digestive system at the Multi-Disciplinary Patient Care in Gastrointestinal
Oncology Conference on 29 September 2017 are summarized. These include highlights of the
recent clinical trials that investigated chemotherapy, targeted therapy, and immunotherapy in the
malignant diseases of various digestive organs. Results of some of the clinical studies have led to
U.S. FDA approval of nivolumab in HCC and CRC with dMMR or MSI-H, and pembrolizumab in
GC/GEJC expressing PD-L1. The recent FDA’s approval of pembrolizumab for treatment of solid
tumors, including those in the digestive organs, that display dMMR also needs to be mentioned [30].
Peri-operative FLOT for resectable GC and GEJC, adjuvant capecitabine for resected (R0) BTC,
and 3 months of adjuvant FOLFOX or CAPOX for low-risk CRC are expected to become new standard
of care. Various targeted therapeutic agents, and new combinations of chemotherapy and targeted
therapy demonstrate the potential of providing new treatment options for patients with cancers of the
digestive system.
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